Methods and treatment involving excess free light

Anti-LIGHT antibodies target and neutralize free LIGHT to treat ALI, ARDS, and Crohn's disease by suppressing inflammation, reducing the risk of disease progression and mortality.

JP2024159821APending Publication Date: 2024-11-08AVALO THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024137709
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-01-04
Filing Date
2024-08-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current therapies are inadequate for treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) associated with COVID-19, as well as Crohn's disease, which are characterized by elevated levels of free LIGHT, a cytokine that drives inflammation and tissue damage.

Method used

Development of anti-LIGHT antibodies that specifically bind to and neutralize free LIGHT, reducing its inflammatory effects and administering them to subjects to treat conditions such as ALI, ARDS, Crohn's disease, and other inflammatory conditions.

Benefits of technology

The anti-LIGHT antibodies effectively suppress T cell activation, reduce cytokine expression, and prevent progression to ARDS, thereby lowering morbidity and mortality in subjects with COVID-19 and Crohn's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159821000001_ABST
    Figure 2024159821000001_ABST
Patent Text Reader

Abstract

To provide methods and treatment involving excess free LIGHT.SOLUTION: The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT and to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. The conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), where the ALI and ARDS are optionally associated with viral infection, including coronavirus infection. The conditions also include Crohn's disease or an inflammatory condition associated with Crohn's disease.SELECTED DRAWING: Figure 10
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 63 / 003,826, filed April 1, 2020, U.S. Provisional Application No. 63 / 027,127, filed May 19, 2020, and U.S. Provisional Application No. 63 / 133,636, filed January 4, 2021, the contents of each of which are incorporated by reference herein for all purposes.

[0002] This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy was created on March 26, 2021, is named 01118-0047-00PCT_US_ST25.txt, and is 27,637 bytes in size.

[0003] The present disclosure relates to methods of diagnosing and treating subjects with conditions associated with elevated free LIGHT levels, including subjects with Crohn's disease (CD) or inflammatory conditions associated with Crohn's disease, subjects with immune dysregulation that can lead to multisystem organ failure, or subjects with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS), including those associated with coronavirus infections, including COVID-19. For example, in some embodiments, subjects can be treated with anti-LIGHT antibodies. The present disclosure also relates to novel assays for detecting free LIGHT. [Background technology]

[0004] In December 2019, the spread of the 2019 novel coronavirus 2019-nCoV (SARS-CoV-2) emerged as a global emergency, causing both high morbidity and mortality. SARS-CoV-2 originated in Wuhan, China (Wu, F. et al. Nature 579, 265-269 (2020)), but has spread rapidly around the world and has been designated a global pandemic by the World Health Organization. The virus is highly infectious, and it is estimated that up to 60% of the world's population may eventually become infected with SARS-CoV-2. This represents more than 180 million people in the United States alone.

[0005] COVID-19 is a disease caused by SARS-CoV-2. Early symptoms of COVID-19 infection include fever with or without respiratory symptoms, including cough, shortness of breath, and pneumonia. In most subjects, the disease is mild and self-limiting, but 15%-20% experience severe respiratory illness, requiring hospitalization and oxygen therapy. (Huang, C. et al. Lancet 395, 497-506 (2020)). Many of these subjects require intensive care and mechanical ventilation due to the emergence of acute respiratory distress syndrome (ARDS) (ibid., Graham, RL, Donaldson, EF & Baric, RS Nature reviews. Microbiology 11, 836-848 (2013)), a well-reported and potentially fatal complication of other viral respiratory syndromes (i.e., SARS, MERS, and H1N1). Other complications of COVID-19 include arrhythmias, shock, acute kidney injury, acute cardiac injury, liver dysfunction, and secondary infections (Huang C, et al., Lancet (2020), Wang, D. et al., JAMA (2020)).

[0006] Accumulating evidence suggests that the primary cause of mortality is an uncontrolled immune response resulting in a cytokine storm, acute lung injury, and acute respiratory distress syndrome (ARDS) leading to fatal respiratory failure. Even subjects who recover may have long-lasting and debilitating sequelae. There is an urgent need for cytokine-neutralizing therapeutics to control COVID-19-associated hyperinflammation and ARDS.

[0007] In COVID-19 and other human corona respiratory virus (hCoV) infections, ARDS appears to result from a dysregulated hyperinflammatory response manifested by the release of excessive proinflammatory cytokines and chemokines, termed the "cytokine storm." (Channappanavar, R. & Perlman, S. Seminars in immunopathology 39, 529-539, (2017); Mehta, P. The Lancet (2020)). Cytokines and chemokines have long been thought to play important roles in immunity and immunopathology during viral infection. A rapid and well-coordinated innate immune response is the first line of defense against viral infection, but a dysregulated and excessive immune response can lead to immunopathology. (Fehr, AR, Channappanavar, R. & Perlman, S. Annual review of medicine 68, 387-399 (2017), Channappanavar, R. et al. Cell hostµbe 19, 181-193 (2016)). Although there is no direct evidence for the involvement of proinflammatory cytokines and chemokines in lung pathology during SARS and MERS, correlative evidence from subjects with severe disease suggests a role for an exaggerated inflammatory response in hCoV pathogenesis. (Channappanavar, Seminars in immunopathology 39, 529-539 (2017), Mehta (2020), Sandoval-Montes, C. & Santos-Argumedo, L. Journal of leukocyte biology 77, 513-521 (2005), Xu et al., Microbiol 6(10):130(2019)).

[0008] The cytokine storm in COVID-19 infection is thought to result from early and rapid viral replication, which may be even higher in immunocompromised subjects. A striking property of pathogenic human coronaviruses such as SARS-CoV and MERS-CoV is that both viruses replicate very quickly to high titers after infection both in vitro and in vivo (Gralinski, LE & Baric, RS The Journal of pathology 235, 185-195 (2015)). This high replication may lead to enhanced cytopathic effects and the production of higher levels of proinflammatory cytokines and chemokines by infected epithelial cells (Xiao, F. et al. Gastroenterology (2020)). These cytokines and chemokines then orchestrate a massive infiltration of inflammatory cells into the lungs (Gralinski, LE & Baric, RS The Journal of pathology 235, 185-195 (2015)). Studies from hCoV infections in humans and experimental animals have demonstrated a strong correlation between high SARS-CoV and MERS-CoV titers and disease severity. Infection also appears to increase secretion of cytokines (e.g., IL4 and IL10), which can then increase T cell activation. (Sandoval-Montes (2005); Xu, Z. et al. The Lancet. Respiratory medicine (2020)). Therefore, the cytokine storm that promotes tissue damage and vascular permeability in the lungs is likely mediated, in part, by T cell activation with increased expression of cytokines.

[0009] In addition, reports indicate that pulmonary fibrosis, known to be a consequence of ARDS, is a known complication of COVID-19 infection. (Huang, C. et al. Lancet 395, 497-506 (2020)).

[0010] Both human and animal studies demonstrate the accumulation of inflammatory monocyte-macrophages and neutrophils in the lungs following hCoV infection. These cells are the main source of cytokines and chemokines associated with the hCoV fatal disease observed in both human and animal models. (Channappanavar, Seminars in immunopathology (2017)).

[0011] Although the main focus of COVID-19 treatment is the development of appropriate antiviral and vaccination approaches, currently there are no established therapies for the treatment of COVID-19-associated ARDS. Agents targeting cytokine storm include cytokine-directed therapies, including IL-1β and IL-6 antagonists, but there is no established monotherapy for the treatment and / or prevention of cytokine storm-associated ALI. The development of safe and effective therapies in COVID-19-associated acute lung injury (ALI) and ARDS could significantly reduce the mortality and post-infection morbidity of this global pandemic and ease the severe burden on healthcare systems.

[0012] Furthermore, the first clinical sign of COVID-19 that allowed case detection was pneumonia (Chan, JF, et al., Lancet (2020)). Complications of COVID-19 pneumonia include acute respiratory distress syndrome (ARDS), arrhythmias, shock, acute kidney injury, acute cardiac injury, liver dysfunction, and secondary infections (Huang C, et al., Lancet (2020), Wang, D. et al., JAMA (2020)). The main cause of mortality in COVID-19 appears to be a dysfunctional hyperimmune response that leads to cytokine storm, acute lung injury, and ARDS. 15-20% of COVID-19 patients experience severe respiratory illness, requiring hospitalization and oxygen therapy (Huang C, et al., Lancet (2020)). There is currently no treatment to prevent the progression of COVID-19 pneumonia to ARDS in patients with COVID-19.

[0013] Crohn's disease (CD) is an idiopathic, chronic, inflammatory condition of the gastrointestinal tract with a high risk of complications and the need for surgical intervention. Crohn's disease is a lifelong disorder that can become clinically evident at almost any time from early childhood to late adulthood. (Freeman, Natural history and long-term clinical course of Crohn's disease, World J.Gastroenterol.,2014:20(1);31-36). The typical age of detection or diagnosis of the disease is usually in the late teens and early twenties, and in the last few decades, more than 80% of patients with Crohn's disease are diagnosed before the age of 40. (Freeman 2014).

[0014] Crohn's disease can affect the entire gastrointestinal tract. (Shi and Ng, The state of the art on treatment of Crohn's disease, J. Gastroenterol., 2018:53;989-998). The majority of patients have a chronic on-and-off course for 10 years after diagnosis. The disease appears to be progressive, but the rate of progression can be altered or slowed by the use of medications or surgical intervention. (Freeman 2014). Common symptoms include diarrhea, abdominal pain, rectal bleeding, fever, weight loss, and fatigue. (Veauthier and Hornecker, Crohn's Disease: Diagnosis and Management, Am. Fam. Physician, 2018:98(11);661-669).

[0015] Corticosteroids and thiopurines remain the mainstay of treatment, but anti-TNF agents are increasingly being prescribed earlier in the disease course (Shi and Ng 2018). Anti-TNF therapy is recommended for patients at high risk for poor prognosis (Shi and Ng 2018). However, primary non-response or secondary lack of response to anti-TNF therapy occurs in a high proportion of patients (Shi and Ng 2018). Therefore, new and improved therapies are needed.

[0016] An important immunoregulatory cytokine, LIGHT ("Lymphotoxin homologous, inducible expression"), also known as TNFSF14 (tumor necrosis factor superfamily member 14), T A receptor expressed on lymphocytes H Competes with HSV glycoprotein D for binding to VEM (herpesvirus entry mediator) to L ymphotoxin,exhibits I nducible expression and competes with HSV G Lycoprotein D for binding to H VEM (herpesvirus entry mediator), a receptor expressed on T Lymphocytes (an acronym for “pro-inflammatory cytokines”) are secreted at high levels during viral infection, supporting ARDS-associated pulmonary fibrosis and cytokine storm (Xu,W.et al.Frontiers in Microbiology 10,130(2019)). Neutrophils and macrophages express high levels of LIGHT and TNF and are the main source of these inflammatory cytokines (Kwon,BSet al.The Journal of Biological Chemistry 272,14272-14276(1997)).

[0017] LIGHT (TNFSF14) belongs to the tumor necrosis factor superfamily and is expressed by activated T cells, monocytes-macrophages, and additional types of antigen-presenting cells. LIGHT is considered one of the "master regulators" of the immune system and plays a key role in the transduction system that controls the immune response. LIGHT has a dual mechanism of action and exerts its effects by activating both T and B cells, as well as upregulating other inflammatory cytokines.

[0018] LIGHT activates two major receptors, herpesvirus entry mediator (HVEM) and lymphotoxin beta receptor (LTβR), both expressed on lung epithelial cells. Early in infection, LIGHT released from neutrophils and macrophages binds to cellular receptors, leading to inflammatory cell infiltration and the release of high levels of TNF and additional proinflammatory cytokines. LIGHT also has a costimulatory role in T cell activation, which drives proinflammatory and tissue damaging effects. (Ware, CF Advances in experimental medicine and biology 647, 146-155 (2009); Ware, CF Immunological reviews 223, 186-201 (2008)). Thus, LIGHT has a role in many immune-mediated pathologies such as Crohn's disease, IBD, rheumatoid arthritis, and fibrosis. An additional receptor for LIGHT is the decoy receptor (called DCR3), which binds to LIGHT and prevents its activity by competing with receptor binding. (Steinberg, MW, et al., M. Seminars in immunopathology 31, 207-221 (2009); Wroblewski, VJ et al. Biochemical pharmacology 65, 657-667 (2003)). In hyperinflammatory and cytokine storm conditions, DcR3 is likely to be overwhelmed, generating high DCR3-free (active) LIGHT.

[0019] LIGHT has been shown to play an important role in viral pneumonia. LIGHT protein has been reported to be elevated in PBMCs of subjects exhibiting severe pneumonia caused by viral infection, as part of the TNF and IL-1 families of genes and cognate proteins that are elevated in these subjects compared to healthy controls (Xu (2019)). LIGHT levels correlated with disease severity - LIGHT levels increased as the disease progressed from mild to severe.

[0020] High LIGHT levels in the lungs may be a driving force for pulmonary fibrosis. Alveolar and interstitial fibrosis are a hallmark of ARDS (Marshall, R., Bellingan, G. & Laurent, G. Thorax 53, 815-817 (1998)) and are responsible for further lung damage and the need for supportive mechanical ventilation. Hyperactivated fibroblasts are the primary cause of pulmonary fibrosis. After infection, fibroblasts proliferate, differentiate into myofibroblasts, and migrate into the alveolar space. Hyperactivated myofibroblasts secrete extracellular matrix and form attachments to the basement membrane. As a result, this process leads to the disappearance of alveolar space by disordered extracellular matrix. (Quesnel, C. et al. The European respiratory journal 35, 1312-1321 (2010)). LIGHT supports pulmonary fibrosis through several mechanisms. Recently, da Silva et al. (da Silva Antunes, R., Mehta, AK, Madge, L., Tocker, J. & Croft, M. Front Immunol 9, 576 (2018)) reported a role for LIGHT, via its receptor LTβR, in promoting fibroblast proliferation in the process of pulmonary fibrosis.

[0021] Genetic deficiency in LIGHT and blocking LIGHT binding to both its receptors strongly reduced tissue remodeling and fibrosis in the lungs of allergen-challenged mice in models of severe asthma and idiopathic pulmonary fibrosis. (Doherty, TA et al. Nature medicine 17, 596-603, (2011)). Neutralization of LIGHT results in a reduced fibrotic phenotype. (Da Silva (2018); Herro, R. & Croft, M. Pharmacol Res 104, 151-155 (2016)). This strategy of neutralizing LIGHT as a treatment for fibrosis should be relevant to fibrosis resulting from ARDS. High LIGHT levels induce high cytokine secretion by bronchial and alveolar epithelial cells in vitro via LTβR and HVEM (TNFRSF14), supporting steroid-resistant lung inflammation. (da Silva Antunes,R.,Madge,L.,Soroosh,P.,Tocker,J.&Croft,M.Journal of immunology(Baltimore,Md.:1950)195,2429-2441(2015),Herro,R.,Da Silva Antunes,R.,Aguilera,AR,Tamada,K.&Croft,M.The Journal of allergy and clinical immunology 136,757-768(2015)).

[0022] LIGHT plays a role as an important mediator in mucosal inflammation and the pathogenesis of inflammatory bowel disease (IBD) (Cohavy et al., LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine, J.Immunol., 2004;173(1):251-8; Ware, CF, Network Communications: Lymphotoxins, LIGHT and TNF, Annual Rev.Immunol., 2005:23:787-819; Cohavy et al., LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling, J.Immunol., 2005:174:646-53; Wang et al., The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease, J.Immunol., 2005:174;8173-82). The human LIGHT gene is located on chromosome 19p13.3, a region implicated in the pathogenesis of CD (Granger et al., Genomic characterization of light reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis, J. Immunol., 2001:167:5122-28; Rioux et al., Genome wide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci, Am. J. Hum. Genet., 2000:66:1863-70). The concept that LIGHT provides an important proinflammatory signal during cellular immune responses is reinforced by studies in IBD patients. LIGHT messenger ribonucleic acid (RNA) is upregulated in biopsies from inflamed areas of the small intestine (Cohavy et al., LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling, J. Immunol., 2005:174:646-53).

[0023] Decoy receptor 3 belongs to the TNF superfamily (TNFRSF6B) (Yu et al., A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis, J. Biol. Chem., 1999:274(20):13733-6). It functions as a decoy receptor that competes with death receptors for ligand binding, and is hypothesized to play a regulatory role in suppressing Fas ligand (FasL)- and LIGHT-mediated cell death and T cell activation, as well as inducing angiogenesis via neutralization of TNF-like ligand 1A (TL1A) (Yu et al. 1999). Decoy receptor 3 is overexpressed in the epithelial layer of ileal specimens in patients with CD, both at sites of active inflammation and at sites of inactivity. Serum levels of decoy receptor 3 are significantly elevated in patients with active and inactive CD compared to healthy controls. Expression of DcR3 in intestinal epithelial cells is induced by TNFα. Increased DcR3 expression is associated with activation of nuclear factor kappa B (NF-κB) and results in protection of intestinal epithelial cells and lamina propria T cells from CD95L-induced apoptosis (Funke et al., Functional characterisation of decoy receptor 3 in Crohn's disease. Gut, 2009: Apr; 58(4): 483-91). Deletion variants of DcR3 have recently been observed in patients with pediatric-onset IBD, further suggesting an important protective role for DcR3, potentially by mitigating the effects of TNF and LIGHT (Cardinale et al., Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease, Genes Immun. 2013: Oct; 14(7): 447-52)).

[0024] The roles of LIGHT and DcR3 in the pathogenesis of IBD, described above, provide a rationale for testing anti-LIGHT monoclonal antibodies in CD patients with or without loss-of-function mutations in DcR3. Most of the currently available assays only measure total LIGHT, including LIGHT bound to its receptor, including DcR3.Total LIGHT cannot provide an accurate depiction of the level of disease-causing LIGHT, which may be free, unbound LIGHT.Therefore, there is a need for an improved LIGHT assay that only measures free LIGHT. [Prior art documents] [Non-patent literature]

[0025] [Non-Patent Document 1] Wu,F.et al.Nature 579,265-269(2020) [Non-Patent Document 2] Huang,C.et al.Lancet 395,497-506(2020) [Non-Patent Document 3] Graham,RL,Donaldson,EF&Baric,RSNature reviews.Microbiology 11,836-848(2013) [Non-Patent Document 4] Channappanavar, R. & Perlman, S. Seminars in immunopathology 39, 529-539, (2017) Summary of the Invention [Means for solving the problem]

[0026] The present disclosure includes, for example, any one or combination of the following embodiments. Embodiment 1. A method for detecting the presence of free LIGHT in a biological sample from a subject, comprising: (a) contacting a biological sample with at least one anti-LIGHT antibody; (b) incubating the biological sample to allow the anti-LIGHT antibody to bind to free LIGHT; (c) detecting the presence of a complex formed between the anti-LIGHT antibody and free LIGHT in the biological sample. Embodiment 2. A method of diagnosing a condition associated with elevated free LIGHT in a subject, comprising: (a) contacting a biological sample with at least one anti-LIGHT antibody; (b) incubating the biological sample to allow the anti-LIGHT antibody to bind to free LIGHT; (c) detecting the presence of a complex formed between the anti-LIGHT antibody and free LIGHT in the biological sample; (d) diagnosing the subject as having a condition associated with elevated free LIGHT if elevated levels of free LIGHT are detected relative to a control. Embodiment 3. A method of treating a condition associated with elevated free LIGHT, comprising administering to a subject in need of such treatment an effective amount of an anti-LIGHT antibody. Embodiment 4. A method of treating a condition associated with elevated free LIGHT in a subject in need thereof, comprising: (a) contacting a biological sample isolated from a subject with a first anti-LIGHT antibody; (b) incubating the biological sample to allow the first anti-LIGHT antibody to bind to free LIGHT; (c) detecting the presence of a complex formed between the first anti-LIGHT antibody and free LIGHT in the biological sample; and (d) administering to the subject an effective amount of a second anti-LIGHT antibody, wherein the first and second antibodies are different, thereby treating a condition associated with elevated free LIGHT. Embodiment 5. The condition associated with elevated free LIGHT is (a) inflammation, optionally wherein the inflammation is hyperinflammation; (b) immune dysregulation leading to multisystem organ failure; (c) acute lung injury (ALI), optionally wherein the ALI is associated with a bacterial or viral infection, including a coronavirus infection; (d) Acute Respiratory Distress Syndrome (ARDS), optionally wherein the ARDS is associated with a bacterial or viral infection, including a coronavirus infection; (e) Cytokine storm driving tissue injury and vascular permeability; (f) post-infectious pulmonary fibrosis; and (g) pneumonia, optionally comprising any one or more of the following: pneumonia associated with a bacterial or viral infection, including a coronavirus infection. Embodiment 6 The method of any one of embodiments 2, 4, and 5, wherein detection of free LIGHT indicates that treatment of a condition associated with elevated free LIGHT with an anti-LIGHT antibody is efficacious. Embodiment 7. The method of any one of embodiments 3-6, wherein the anti-LIGHT antibody administered to the subject inhibits T cell activation. Embodiment 8. The method of any one of embodiments 3-7, wherein the anti-LIGHT antibody administered to the subject inhibits increased expression of a cytokine. Embodiment 9. The method of any one of embodiments 3-8, wherein the anti-LIGHT antibody administered to the subject reduces the subject's risk of mortality or morbidity. Embodiment 10. The method of any one of embodiments 3-9, wherein the anti-LIGHT antibody administered to the subject prevents progression to ARDS. Embodiment 11. The method of any one of embodiments 3-10, wherein the anti-LIGHT antibody administered to the subject prevents the need for mechanical ventilation / intubation in the subject. Embodiment 12. A method of treating severe COVID-19 pneumonia comprising administering to a subject in need thereof an anti-LIGHT antibody. Embodiment 13. A method of treating acute inflammatory disease associated with COVID-19 pneumonia, comprising administering to a subject in need thereof an anti-LIGHT antibody. Embodiment 14. A method of treating respiratory failure associated with COVID-19 pneumonia, comprising administering to a subject in need thereof an anti-LIGHT antibody. Embodiment 15. A method of treating a cytokine storm comprising administering to a subject in need of such treatment an anti-LIGHT antibody. Embodiment 16. A method of treating a dysregulated hyperimmune response (sometimes referred to as a "cytokine storm"), comprising administering to a subject in need of such treatment an anti-LIGHT antibody. Embodiment 17. A method of treating acute respiratory distress syndrome (ARDS), comprising administering to a subject in need thereof an anti-LIGHT antibody. Embodiment 18. The anti-LIGHT antibody comprises the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (b) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (c) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (d) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (e) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (f) SEQ ID NOs: 40, 41, 42, 43, 44, and 45; (g) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (h) the method of any one of embodiments 1 and 2, comprising a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. Embodiment 19. The first anti-LIGHT antibody comprises the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (b) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (c) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (d) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (e) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (f) SEQ ID NOs: 40, 41, 42, 43, 44, and 45; (g) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (h) a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57; The method of embodiment 4, wherein the second anti-LIGHT antibody comprises a heavy chain and a light chain that together comprise any one of the sets of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of (a)-(h) above, or SEQ ID NOs: 2, 3, 4, 5, 6, and 7. Embodiment 20. The anti-LIGHT antibody administered to the subject has the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 2, 3, 4, 5, 6, and 7; (b) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (c) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (d) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (e) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (f) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (g) SEQ ID NOs: 40, 41, 42, 43, 44, and 45, (h) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (i) The method of any one of embodiments 3 and 5 to 17, comprising a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. Embodiment 21. The method of any one of the preceding embodiments, wherein the antibody comprises the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of any one of antibodies 1C02, 13H04, 31A10, 1C06, 98C07, 18E04, 42A02, 29C09, 14B09, 117C06, 114F05, or 62C01 described in WO2015 / 107331. Embodiment 22 The method of any one of embodiments 2-21, wherein the condition associated with elevated free LIGHT is a coronavirus infection. Embodiment 23. The method of embodiment 22, wherein the condition associated with elevated release of LIGHT is a COVID-19 infection. Embodiment 24. The method of embodiment 23, wherein the coronavirus infection is a MERS-CoV or SARS-CoV infection. Embodiment 25 The method of any one of embodiments 2-24, wherein the condition associated with elevated free LIGHT is Crohn's disease or an inflammatory condition associated with Crohn's disease. Embodiment 26. The method of any one of the preceding embodiments, wherein the administered anti-LIGHT antibody comprises heavy and light chains comprising the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively. Embodiment 27 The method of any one of the preceding embodiments, wherein a single dose of about 16 mg / kg of an anti-LIGHT antibody is administered. Embodiment 28. The method of any one of the preceding embodiments, wherein the subject has been receiving or is currently receiving an anti-COVID-19 therapy, and optionally, the therapy is a corticosteroid, hydroxychloroquine, and / or remdesivir. Embodiment 29. The method of embodiment 28, wherein the dose of corticosteroid is considered a high dose. Embodiment 30 The method of any one of the preceding embodiments, wherein the subject is a human. Embodiment 31 The method of any one of the preceding embodiments, wherein the subject has a respiratory disease, optionally caused by a coronavirus infection. Embodiment 32 The method of any one of the preceding embodiments, wherein the subject has pneumonia. Embodiment 33. The method of any one of the preceding embodiments, wherein the subject has acute lung injury (ALI). Embodiment 34. The method of any one of the preceding embodiments, wherein the subject has acute respiratory distress syndrome (ARDS). Embodiment 35 The method of any one of the preceding embodiments, wherein the subject has a mild coronavirus infection. Embodiment 36 The method of any one of the preceding embodiments, wherein the subject has a moderate coronavirus infection. Embodiment 37 The method of any one of the preceding embodiments, wherein the subject has a severe coronavirus infection. Embodiment 38. The method of any one of the preceding embodiments, wherein the subject is in early infection (Stage I) of a coronavirus infection. Embodiment 39. The method of any one of the preceding embodiments, wherein the subject is in the pulmonary stage (stage II) of coronavirus infection. Embodiment 40. The method of any one of the preceding embodiments, wherein the subject is in the hyperinflammatory stage (stage III) of coronavirus infection. Embodiment 41. The method of any one of the preceding embodiments, wherein the subject is a pediatric subject.Embodiment 42. The method of any one of the preceding embodiments, wherein the subject is an adult. Embodiment 43. A kit for use in the method according to any one of embodiments 1 to 3, 5 to 18, and 20 to 42, comprising an anti-LIGHT antibody and reagents for carrying out the method. Embodiment 44. A kit for use in the method of any one of embodiments 4 and 19, comprising a first anti-LIGHT antibody and a second LIGHT antibody, wherein the first and second antibodies are different, and reagents for carrying out the method. Embodiment 45 The kit of embodiment 43, further comprising a solid phase to which the anti-LIGHT antibody is attached. Embodiment 46 The kit of embodiment 44, further comprising a solid phase to which the first anti-LIGHT antibody is attached. Embodiment 47 The kit of embodiment 43 or 44, further comprising a solid phase to which free LIGHT from the biological sample is bound. Embodiment 48. A method for determining the amount of free / unbound tumor necrosis factor superfamily member 14 (TNFSF14 or LIGHT) in a sample suspected of containing free LIGHT from a subject, comprising: (a) contacting the sample with a capture molecule for free LIGHT that specifically binds to free LIGHT but not to bound LIGHT; (b) incubating the sample to allow the capture molecules to bind to free LIGHT; (c) detecting binding of free LIGHT to the capture molecule to determine the amount of free LIGHT in the sample. Embodiment 49. The capture molecule is an antibody, optionally wherein the antibody has the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (b) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (c) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (d) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (e) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (f) SEQ ID NOs: 40, 41, 42, 43, 44, and 45; (g) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (h) the method of embodiment 48, comprising an anti-LIGHT antibody comprising a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. Embodiment 50. The method according to any one of embodiments 48 to 49, wherein the capture molecule specifically binds to free LIGHT but not to the LIGHT / DcR3 complex, the LIGHT / HVEM complex, or the LIGHT / LTβR complex. Embodiment 51 The method of any one of embodiments 48 to 50, wherein the capture molecule specifically binds to free LIGHT at or near the site where LIGHT binds to DcR3. Embodiment 52 The method of embodiment 51, wherein the capture molecule specifically binds to free LIGHT at the site where LIGHT binds to DcR3. Embodiment 53. The method of any one of embodiments 48 to 52, wherein a detection molecule is provided, which binds to LIGHT at a site that is different from the site at which the capture molecule binds. Embodiment 54 The method of any one of embodiments 48-53, further comprising comparing the amount of free LIGHT and total LIGHT in the sample. Embodiment 55. The method of any one of embodiments 48 to 54, wherein the capture molecule is an antibody. Embodiment 56. The method according to any one of embodiments 48 to 55, wherein the capture molecule is an antibody selected from a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a single-chain antibody, a bispecific or bieffective antibody, a simian antibody, a human antibody, and a humanized antibody. Embodiment 57. The method of any one of embodiments 48 to 56, wherein the capture antibody is a monoclonal antibody. Embodiment 58. The method of any one of embodiments 48 to 57, wherein the capture antibody is bound to a support (e.g., a nanoparticle in the Simoa platform). Embodiment 59. The method of any one of embodiments 48 to 58, wherein the capture antibody is Enzo ALX-804-841-C100. Embodiment 60. The method of any one of embodiments 48 to 59, wherein the detection molecule is an antibody. Embodiment 61. The method of any one of embodiments 48 to 60, wherein the detection molecule is a monoclonal antibody. Embodiment 62. The method of any one of embodiments 48 to 61, wherein the capture antibody is Enzo ALX-804-841-C100 and the detection antibody is ProSci RF16062. Embodiment 63. The method of any one of embodiments 48 to 62, wherein the sample is serum, plasma, saliva, or feces. Embodiment 64. The method of any one of embodiments 48 to 63, wherein the sample is a serum sample. Embodiment 65. A method of treating Crohn's disease or an inflammatory condition associated with Crohn's disease, comprising administering to a subject in need of such treatment an anti-LIGHT antibody, wherein the anti-LIGHT antibody has the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 2, 3, 4, 5, 6, and 7; (b) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (c) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (d) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (e) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (f) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (g) SEQ ID NOs: 40, 41, 42, 43, 44, and 45, (h) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (i) the heavy chain and the light chain together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. Embodiment 66. The method of embodiment 25 or 65, wherein a dose of 1.0 mg / kg of anti-LIGHT antibody is administered every 14 days. Embodiment 67. The method of embodiment 25 or 65, wherein a dose of 3.0 mg / kg of the anti-LIGHT antibody is administered every 14 days. Embodiment 68. The method of any one of embodiments 65 to 67, wherein the subject is a human.Embodiment 69. The method of any one of embodiments 65 to 68, wherein the subject is an adult.Embodiment 70. The method of any one of embodiments 65 to 69, wherein the subject has failed treatment with an approved therapeutic dose of an anti-TNFα monoclonal antibody therapy, either by failing to initially respond or by failing to initially respond to induction with a subsequent failure to respond. Embodiment 71 The method of any one of embodiments 65-70, wherein administration of an anti-LIGHT antibody reduces the subject's CDAI score. Embodiment 72 The method of any one of embodiments 65-71, wherein administration of an anti-LIGHT antibody reduces the subject's SES-CD score. Embodiment 73 The method of any one of embodiments 65-72, wherein administration of an anti-LIGHT antibody increases the subject's IBD-Q score. Embodiment 74 The method of any one of embodiments 3-24 and 26-42, wherein administration of the anti-LIGHT antibody reduces serum free LIGHT levels in the subject by 85% or more. Embodiment 75 The method of embodiment 74, wherein the decrease in serum free LIGHT levels occurs less than 5 days after administration of the anti-LIGHT antibody. Embodiment 76 The method of embodiment 74, wherein the decrease in serum free LIGHT levels occurs about 1 day after administration of the anti-LIGHT antibody. Embodiment 77. The method of any one of embodiments 3-24, 26-42, and 74-76, wherein administration of the anti-LIGHT antibody reduces the subject's risk of death by 50% or more 60 days after administration. Embodiment 78. The method of any one of embodiments 3-24, 26-42, and 74-76, wherein administration of the anti-LIGHT antibody reduces the subject's risk of death by 50% or more 28 days after administration. Embodiment 79. The method of any one of embodiments 3-24, 26-42, and 74-78, wherein the subject is 60 years of age or older. Embodiment 80 The method of embodiment 79, wherein administration of the anti-LIGHT antibody reduces the subject's length of hospitalization as compared to subjects receiving standard medical treatment. Embodiment 81 The method of any one of embodiments 3-24, 26-42, and 74-80, wherein administration of an anti-LIGHT antibody reduces the subject's risk of respiratory failure. Embodiment 82 The method of any one of embodiments 3-42, 65-73, and 77-81, wherein administration of an anti-LIGHT antibody reduces serum free LIGHT levels in the subject. Embodiment 83. Use of an anti-LIGHT antibody in the manufacture of a medicament for treating a condition associated with elevated free LIGHT. Embodiment 84. A composition comprising an anti-LIGHT antibody for use as a medicament in the treatment of a condition associated with elevated free LIGHT. Embodiment 85. A composition comprising an anti-LIGHT antibody for use in treating a condition associated with elevated free LIGHT. Embodiment 86. The condition associated with elevated free LIGHT is a. inflammation, optionally wherein the inflammation is hyperinflammation; b. Immune dysregulation leading to multisystem organ failure, c. Acute lung injury (ALI), optionally wherein the ALI is associated with a bacterial or viral infection, including a coronavirus infection; d. Acute respiratory distress syndrome (ARDS), optionally wherein the ARDS is associated with a bacterial or viral infection, including a coronavirus infection; e. Cytokine storm driving tissue damage and vascular permeability; f. post-infectious pulmonary fibrosis, g. pneumonia, optionally wherein the pneumonia is associated with a bacterial or viral infection, including a coronavirus infection; h. Crohn's disease or an inflammatory condition associated with Crohn's disease; or i. COVID-19 infection. Embodiment 87. An anti-LIGHT antibody comprises the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 2, 3, 4, 5, 6, and 7; (b) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (c) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (d) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (e) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (f) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (g) SEQ ID NOs: 40, 41, 42, 43, 44, and 45, (h) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (i) The use or composition for use according to any one of embodiments 83 to 86, comprising a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. [Brief description of the drawings]

[0027] [Figure 1]Capture of free LIGHT (i.e., DCR-free LIGHT, active LIGHT) by a candidate antibody pair (capture antibody: Enzo ALX-804-841-C100, detection antibody: ProSci RF16062; specific epitopes not detailed for these antibodies) is shown, with linearity performed at 1:10, 1:20, and 1:40 dilutions. Free LIGHT was detected and measured with high sensitivity using the Simoa™ ultrasensitive assay (Myriad RBM), using Quanterix's fully automated immunoassay platform: Simoa HD-1 Analyzer and single molecule array (Simoa) technology. All incubations are performed at room temperature inside the Simoa HD-1 Analyzer. Capture antibody-conjugated paramagnetic beads were incubated with standards, samples, or controls, and biotinylated detection antibodies. The beads were then washed and incubated with streptavidin-β-galactosidase (SβG). After a final wash, the beads were added to a Simoa Disc along with the enzyme substrate, resorufin β-galactopyranoside (RGP). The fluorescent signal is compared to a standard curve and the amount of LIGHT released is determined for each sample. After pairwise screening of anti-LIGHT antibodies for sandwich immunoassay-based detection of free LIGHT, assays were performed with one candidate pair to test for linearity and specificity. [Figure 2A] Linearity was performed at 1:10, 1:20, 1:40, and 1:80 dilutions to demonstrate capture of free LIGHT by the candidate pairs, shown in table form in Figure 2A and graph form in Figure 2B. The same assay described in Figure 1 was performed at different dilutions. [Figure 2B] Linearity was performed at 1:10, 1:20, 1:40, and 1:80 dilutions to demonstrate capture of free LIGHT by the candidate pairs, shown in table form in Figure 2A and graph form in Figure 2B. The same assay described in Figure 1 was performed at different dilutions. [Diagram 3]DcR3 interference with the capture of free LIGHT was tested in the free LIGHT detection candidate pair (Enzo ALX-804-841-C100-ProSci RF16062 (capture-detection)). Dilutions containing free LIGHT were used rather than native free LIGHT in serum or plasma samples. DcR3 spike concentrations were 10,000 ng / ml and 11 lower concentrations. Signal inhibition values ​​were calculated as the signal reduction (MFI) in the Enzo / ProSci pair. [Figure 4A]Comparison of DcR3 interference of free LIGHT detection antibody pairs in spiked and unspiked samples. Figure 4A: Spike and recovery experiments were performed to evaluate DcR3 (10 μg / mL) interference in candidate pairs (Enzo ALX-804-841-C100-ProSci RF16062 (capture-detection)). Serum and plasma samples were incubated with (spiked) and without (unspiked) 150 pg / mL free LIGHT (in the form of LIGHT standard recombinant antigen). The spiked and unspiked samples were incubated with DcR3. The % recovered signal was calculated based on MFI compared to the no interference control. The % recovered signal due to interference is divided by the signal of the control. Signal inhibition values ​​were calculated for unspiked serum 1 (had the most significant reduction). Signal inhibition values ​​were calculated for unspiked serum 1 (had the most significant reduction). 78% represents the associated signal reduction (100%-% recovery). Thus, DcR3 recovery for serum 1 is 22%, representing a 78% drop in signal, and anti-LIGHT antibody recovery is 15%, representing an 85% drop in signal. Additionally, in the sample group spiked with LIGHT (150 pg / ml) (lower panel), sample serum 1 shows 92% inhibition (8% recovery). Figure 4B: Another spike and recovery experiment using the same parameters was performed to evaluate DcR3 interference with a different free LIGHT detection candidate pair (ProSci RF16062-LSBio LS-C133566-100 (capture-detection)). Figure 4C: Graph characterizing DcR3 interference by recovery for each candidate pair in native free LIGHT and spiked free LIGHT samples. The relatively low % recovered signal in native free LIGHT samples with the Enzo ALX-804-841-C100-ProSci RF16062 candidate pair indicated that the pair binds to native free LIGHT. In contrast, the relatively little DcR3 interference with the % recovered signal for the ProSci RF16062-LSBio LS-C133566-100 candidate pair indicated that the pair did not bind effectively to native free LIGHT; nevertheless, both candidate pairs bound to the non-native LIGHT standard recombinant antigen to approximately the same extent. [Figure 4B] Same as above. [Figure 4C] Same as above. [Diagram 5] Figure 1 shows free LIGHT levels in serum samples from 89 Crohn's disease (CD) subjects selected and grouped according to disease duration. 89 subjects and 10 healthy controls (gender and age matched) were measured using the free LIGHT assay described herein with candidate antibody pairs. After excluding outliers, 62 samples and 7 controls were analyzed. Crohn's disease subjects showed significantly higher serum free LIGHT levels (527.93 pg / ml, mean in subjects 0-1 month from disease) than healthy controls (40.43 pg / ml, P<0.0021). Free LIGHT serum levels also correlate with disease program. This suggests that free LIGHT represents a potential target for the treatment of CD and that the free LIGHT assay can serve as a companion diagnostic for anti-LIGHT therapy. [Figure 6] Serum free LIGHT levels in hospitalized COVID-19 patients compared to healthy controls. The amount of free LIGHT in serum was analyzed using the Kruskal-Wallis test (non-parametric one-way ANOVA). P-value was <0.0001, indicating higher free LIGHT levels in COVID-19 patients compared to controls. [Figure 7] Serum free LIGHT levels in non-ventilated and intubated COVID-19 patients compared to healthy controls. Serum free LIGHT levels were analyzed using the non-parametric Kruskal-Wallis test. Separate tests were performed for the comparison of non-ventilated and intubated patients to controls. P values ​​for both tests were <0.0001. [Figure 8] Serum free LIGHT levels were compared between healthy controls over 60 years of age (N=14), subjects over 60 years of age who eventually recovered (N=5), and subjects over 60 years of age who eventually died (N=23) using the Kruskal-Wallis test. [Figure 9]Figure 1 shows serum free LIGHT levels compared in subjects in the study described in Examples 2 and 3. Squares are subjects treated with placebo (n=34) and circles are subjects treated with anti-LIGHT monoclonal antibody (n=36). Mean free LIGHT levels were comparable at baseline across cohorts. Mean free LIGHT levels dramatically decreased by day 1 after treatment with anti-LIGHT antibody, but increased in the placebo-treated group. Mean free LIGHT levels were approximately 100 pg / mL higher in patients ≥ 60 years old. Pharmacodynamic effects were at the top of standard of care, with approximately 90% of patients receiving systemic corticosteroids. [Figure 10] 1 shows the primary endpoint of the study described in Examples 2 and 3, the proportion of patients alive and free of respiratory failure at day 28 in the anti-LIGHT monoclonal antibody treatment group compared to the placebo treatment group. [Figure 11] 1 shows a box plot generated from data from a LIGHT study using the free LIGHT assay described herein on samples from ARDS patients compared to healthy donor LIGHT levels. There are 79 healthy control data points. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] The following definitions are provided to facilitate understanding of the invention. They are not intended to limit the invention in any way. In an embodiment of the present invention, for example, the following items are provided: (Item 1) 1. A method for detecting the presence of free LIGHT in a biological sample from a subject, comprising: (a) contacting the biological sample with at least one anti-LIGHT antibody; (b) incubating the biological sample to allow the anti-LIGHT antibody to bind free LIGHT; (c) detecting the presence of a complex formed between said anti-LIGHT antibody and free LIGHT in said biological sample. (Item 2) 1. A method for diagnosing a condition associated with elevated free LIGHT in a subject, comprising: (a) contacting a biological sample with at least one anti-LIGHT antibody; (b) incubating the biological sample to allow the anti-LIGHT antibody to bind free LIGHT; (c) detecting the presence of a complex formed between the anti-LIGHT antibody and free LIGHT in the biological sample; (d) diagnosing the subject as having a condition associated with elevated free LIGHT if elevated levels of free LIGHT are detected relative to a control. (Item 3) A method of treating a condition associated with elevated free LIGHT, comprising administering to a subject in need thereof an effective amount of an anti-LIGHT antibody. (Item 4) 1. A method of treating a condition associated with elevated free LIGHT in a subject in need thereof, comprising: (a) contacting a biological sample isolated from the subject with a first anti-LIGHT antibody; (b) incubating the biological sample to allow the first anti-LIGHT antibody to bind to free LIGHT; (c) detecting the presence of a complex formed between the first anti-LIGHT antibody and free LIGHT in the biological sample; and (d) administering to the subject an effective amount of a second anti-LIGHT antibody, wherein the first antibody and the second antibody are different, thereby treating the condition associated with elevated free LIGHT. (Item 5) the condition associated with elevated free LIGHT being (a) inflammation, optionally wherein the inflammation is hyperinflammation; (b) immune dysregulation leading to multisystem organ failure; (c) acute lung injury (ALI), optionally wherein the ALI is associated with a bacterial or viral infection, including a coronavirus infection; (d) Acute Respiratory Distress Syndrome (ARDS), optionally wherein the ARDS is associated with a bacterial or viral infection, including a coronavirus infection; (e) Cytokine storm driving tissue injury and vascular permeability; (f) post-infectious pulmonary fibrosis; and (g) The method of any one of items 2 to 4, wherein the pneumonia optionally comprises any one or more of the following: pneumonia associated with a bacterial or viral infection, including a coronavirus infection. (Item 6) 6. The method of any one of paragraphs 2, 4, and 5, wherein detection of said free LIGHT indicates that treatment of a condition associated with said elevated free LIGHT with an anti-LIGHT antibody is efficacious. (Item 7) 7. The method of any one of items 3 to 6, wherein the anti-LIGHT antibody administered to the subject inhibits T cell activation. (Item 8) 8. The method of any one of items 3 to 7, wherein the anti-LIGHT antibody administered to the subject inhibits increased expression of a cytokine. (Item 9) 9. The method of any one of items 3 to 8, wherein the anti-LIGHT antibody administered to the subject reduces the risk of mortality or morbidity in the subject. (Item 10) 10. The method of any one of items 3 to 9, wherein the anti-LIGHT antibody administered to the subject prevents progression to ARDS. (Item 11) 11. The method of any one of items 3-10, wherein the anti-LIGHT antibody administered to the subject prevents the need for mechanical ventilation / intubation in the subject. (Item 12) 1. A method of treating severe COVID-19 pneumonia, comprising administering to a subject in need thereof an anti-LIGHT antibody. (Item 13) A method of treating acute inflammatory disease associated with COVID-19 pneumonia, comprising administering to a subject in need thereof an anti-LIGHT antibody. (Item 14) A method of treating respiratory failure associated with COVID-19 pneumonia, comprising administering to a subject in need thereof an anti-LIGHT antibody. (Item 15) A method of treating a cytokine storm, comprising administering to a subject in need of such treatment an anti-LIGHT antibody. (Item 16) A method of treating a dysregulated hyperimmune response (sometimes referred to as a "cytokine storm"), comprising administering to a subject in need of such treatment an anti-LIGHT antibody. (Item 17) A method of treating acute respiratory distress syndrome (ARDS), comprising administering to a subject in need thereof an anti-LIGHT antibody. (Item 18) The anti-LIGHT antibody comprises the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (b) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (c) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (d) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (e) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (f) SEQ ID NOs: 40, 41, 42, 43, 44, and 45; (g) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (h) the method of any one of items 1 and 2, comprising a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. (Item 19) The first anti-LIGHT antibody comprises the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (b) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (c) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (d) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (e) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (f) SEQ ID NOs: 40, 41, 42, 43, 44, and 45; (g) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (h) a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57; The method of item 4, wherein the second anti-LIGHT antibody comprises a heavy chain and a light chain that together comprise any one of the sets of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of (a) to (h) above, or SEQ ID NOs: 2, 3, 4, 5, 6, and 7. (Item 20) the anti-LIGHT antibody administered to the subject comprises the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 2, 3, 4, 5, 6, and 7; (b) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (c) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (d) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (e) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (f) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (g) SEQ ID NOs: 40, 41, 42, 43, 44, and 45, (h) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (i) The method according to any one of items 3 and 5 to 17, comprising a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. (Item 21) 2. The method of any one of the preceding claims, wherein the antibody comprises the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of any one of antibodies 1C02, 13H04, 31A10, 1C06, 98C07, 18E04, 42A02, 29C09, 14B09, 117C06, 114F05, or 62C01 described in WO2015 / 107331. (Item 22) 22. The method of any one of items 2 to 21, wherein the condition associated with elevated free LIGHT is a coronavirus infection. (Item 23) 23. The method of claim 22, wherein the condition associated with elevated free LIGHT is a COVID-19 infection. (Item 24) 24. The method of claim 23, wherein the coronavirus infection is a MERS-CoV or SARS-CoV infection. (Item 25) 25. The method of any one of items 2 to 24, wherein the condition associated with elevated free LIGHT is Crohn's disease or an inflammatory condition associated with Crohn's disease. (Item 26) The method of any one of the preceding items, wherein the anti-LIGHT antibody administered comprises heavy and light chains comprising the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, and 7, respectively. (Item 27) The method of any one of the preceding items, wherein a single dose of about 16 mg / kg of the anti-LIGHT antibody is administered. (Item 28) The method of any one of the preceding items, wherein the subject has been receiving or is currently receiving an anti-COVID-19 therapy, optionally wherein the therapy is a corticosteroid, hydroxychloroquine, and / or remdesivir. (Item 29) 29. The method according to item 28, wherein the dose of corticosteroid is considered a high dose. (Item 30) The method of any one of the preceding items, wherein the subject is a human. (Item 31) The method of any one of the preceding items, wherein the subject has a respiratory disease, optionally caused by a coronavirus infection. (Item 32) The method of any one of the preceding items, wherein the subject has pneumonia. (Item 33) The method of any one of the preceding items, wherein the subject has acute lung injury (ALI). (Item 34) The method of any one of the preceding items, wherein the subject has acute respiratory distress syndrome (ARDS). (Item 35) The method of any one of the preceding items, wherein the subject has a mild coronavirus infection. (Item 36) The method of any one of the preceding items, wherein the subject has a moderate coronavirus infection. (Item 37) The method of any one of the preceding items, wherein the subject has a severe coronavirus infection. (Item 38) The method of any one of the preceding items, wherein the subject is in early infection (Stage I) of a coronavirus infection. (Item 39) The method of any one of the preceding items, wherein the subject is in the pulmonary stage (stage II) of coronavirus infection. (Item 40) 2. The method of any one of the preceding items, wherein the subject is in the hyperinflammatory stage (stage III) of coronavirus infection. (Item 41) The method of any one of the preceding items, wherein the subject is a pediatric subject. (Item 42) The method of any one of the preceding items, wherein the subject is an adult. (Item 43) A kit for use in the method according to any one of items 1 to 3, 5 to 18, and 20 to 42, comprising an anti-LIGHT antibody and a reagent for carrying out the method. (Item 44) 20. A kit for use in the method of any one of items 4 and 19, comprising a first anti-LIGHT antibody and a second LIGHT antibody, wherein the first and second antibodies are different, and reagents for carrying out the method. (Item 45) 44. The kit of item 43, further comprising a solid phase to which the anti-LIGHT antibody is attached. (Item 46) 45. The kit of item 44, further comprising a solid phase to which the first anti-LIGHT antibody is attached. (Item 47) 45. The kit according to item 43 or 44, further comprising a solid phase to which free LIGHT from the biological sample is bound. (Item 48) 1. A method for determining the amount of free / unbound tumor necrosis factor superfamily member 14 (TNFSF14 or LIGHT) in a sample suspected of containing free LIGHT from a subject, comprising: (a) contacting the sample with a capture molecule for free LIGHT that specifically binds to free LIGHT but not to bound LIGHT; (b) incubating the sample to allow the capture molecules to bind to free LIGHT; (c) detecting binding of free LIGHT to said capture molecule to determine the amount of free LIGHT in said sample. (Item 49) The capture molecule is an antibody, and optionally the antibody binds to the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (b) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (c) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (d) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (e) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (f) SEQ ID NOs: 40, 41, 42, 43, 44, and 45; (g) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (h) the method of claim 48, comprising an anti-LIGHT antibody comprising a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. (Item 50) 50. The method according to item 48 or 49, wherein the capture molecule specifically binds to free LIGHT but not to the LIGHT / DcR3 complex, or the LIGHT / HVEM complex, or the LIGHT / LTβR complex. (Item 51) 51. The method of any one of items 48 to 50, wherein the capture molecule specifically binds to free LIGHT at or near the site where LIGHT binds to DcR3. (Item 52) 52. The method of claim 51, wherein the capture molecule specifically binds to free LIGHT at the site where LIGHT binds to DcR3. (Item 53) 53. The method according to any one of items 48 to 52, wherein a detection molecule is provided, said detection molecule binding to LIGHT at a site different from the site at which said capture molecule binds. (Item 54) 54. The method of any one of items 48 to 53, further comprising comparing the amount of free LIGHT and total LIGHT in the sample. (Item 55) 55. The method according to any one of items 48 to 54, wherein the capture molecule is an antibody. (Item 56) 56. The method according to any one of Items 48 to 55, wherein the capture molecule is an antibody selected from a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a single-chain antibody, a bispecific or bifunctional antibody, a simian antibody, a human antibody, and a humanized antibody. (Item 57) 57. The method according to any one of items 48 to 56, wherein the capture antibody is a monoclonal antibody. (Item 58) 58. The method according to any one of items 48 to 57, wherein the capture antibody is bound to a support (e.g., a nanoparticle in the Simoa platform). (Item 59) 59. The method according to any one of items 48 to 58, wherein the capture antibody is Enzo ALX-804-841-C100. (Item 60) 60. The method according to any one of items 48 to 59, wherein the detection molecule is an antibody. (Item 61) 61. The method according to any one of items 48 to 60, wherein the detection molecule is a monoclonal antibody. (Item 62) 62. The method of any one of items 48 to 61, wherein the capture antibody is Enzo ALX-804-841-C100 and the detection antibody is ProSci RF16062. (Item 63) 63. The method according to any one of items 48 to 62, wherein the sample is serum, plasma, saliva, or stool. (Item 64) 64. The method according to any one of items 48 to 63, wherein the sample is a serum sample. (Item 65) 1. A method of treating Crohn's disease or an inflammatory condition associated with Crohn's disease, comprising administering to a subject in need thereof an anti-LIGHT antibody, wherein the anti-LIGHT antibody has the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 2, 3, 4, 5, 6, and 7; (b) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (c) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (d) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (e) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (f) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (g) SEQ ID NOs: 40, 41, 42, 43, 44, and 45, (h) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (i) the heavy chain and the light chain together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57. (Item 66) 66. The method of paragraph 25 or 65, wherein a dose of 1.0 mg / kg of the anti-LIGHT antibody is administered every 14 days. (Item 67) 66. The method of paragraph 25 or 65, wherein a dose of 3.0 mg / kg of the anti-LIGHT antibody is administered every 14 days. (Item 68) 68. The method according to any one of items 65 to 67, wherein the subject is a human. (Item 69) 69. The method according to any one of items 65 to 68, wherein the subject is an adult. (Item 70) 70. The method of any one of items 65 to 69, wherein the subject has failed treatment with an approved therapeutic dose of an anti-TNFα monoclonal antibody therapy, either by failing to respond initially or by failing to respond initially to induction followed by failure to respond subsequently. (Item 71) 71. The method of any one of items 65-70, wherein administration of the anti-LIGHT antibody reduces the subject's CDAI score. (Item 72) 72. The method of any one of paragraphs 65-71, wherein administration of the anti-LIGHT antibody reduces the subject's SES-CD score. (Item 73) 73. The method of any one of paragraphs 65-72, wherein administration of the anti-LIGHT antibody increases the subject's IBD-Q score. (Item 74) 43. The method of any one of items 3 to 24 and 26 to 42, wherein administration of the anti-LIGHT antibody reduces serum free LIGHT levels in the subject by 85% or more. (Item 75) 75. The method of paragraph 74, wherein the decrease in serum free LIGHT levels occurs less than 5 days after administration of the anti-LIGHT antibody. (Item 76) 75. The method of paragraph 74, wherein the decrease in serum free LIGHT levels occurs about 1 day after administration of the anti-LIGHT antibody. (Item 77) 77. The method of any one of items 3-24, 26-42, and 74-76, wherein administration of the anti-LIGHT antibody reduces the risk of death in the subject by 50% or more 60 days after administration. (Item 78) 77. The method of any one of items 3-24, 26-42, and 74-76, wherein administration of the anti-LIGHT antibody reduces the risk of death in the subject by 50% or more 28 days after administration. (Item 79) 80. The method according to any one of items 3 to 24, 26 to 42, and 74 to 78, wherein the subject is 60 years of age or older. (Item 80) 80. The method of paragraph 79, wherein administration of the anti-LIGHT antibody reduces the subject's length of hospital stay as compared to subjects receiving standard medical treatment. (Item 81) The method of any one of paragraphs 3-24, 26-42, and 74-80, wherein administration of the anti-LIGHT antibody reduces the risk of respiratory failure in the subject. (Item 82) 82. The method of any one of items 3-42, 65-73, and 77-81, wherein administration of the anti-LIGHT antibody reduces serum free LIGHT levels in the subject. (Item 83) Use of an anti-LIGHT antibody in the manufacture of a medicament for treating a condition associated with elevated free LIGHT. (Item 84) A composition comprising an anti-LIGHT antibody for use as a medicament in the treatment of a condition associated with elevated free LIGHT. (Item 85) A composition comprising an anti-LIGHT antibody for use in treating a condition associated with elevated free LIGHT. (Item 86) the condition associated with elevated free LIGHT being a. inflammation, optionally wherein the inflammation is hyperinflammation; b. Immune dysregulation leading to multisystem organ failure, c. Acute lung injury (ALI), optionally wherein the ALI is associated with a bacterial or viral infection, including a coronavirus infection; d. Acute respiratory distress syndrome (ARDS), optionally wherein the ARDS is associated with a bacterial or viral infection, including a coronavirus infection; e. Cytokine storm driving tissue damage and vascular permeability; f. post-infectious pulmonary fibrosis, g. pneumonia, optionally wherein the pneumonia is associated with a bacterial or viral infection, including a coronavirus infection; h. Crohn's disease or an inflammatory condition associated with Crohn's disease; or i. COVID-19 infection. (Item 87) The anti-LIGHT antibody comprises the following set of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 amino acid sequences: (a) SEQ ID NOs: 2, 3, 4, 5, 6, and 7; (b) SEQ ID NOs: 10, 11, 12, 13, 14, and 15; (c) SEQ ID NOs: 16, 17, 18, 19, 20, and 21; (d) SEQ ID NOs: 22, 23, 24, 25, 26, and 27; (e) SEQ ID NOs: 28, 29, 30, 31, 32, and 33; (f) SEQ ID NOs: 34, 35, 36, 37, 38, and 39; (g) SEQ ID NOs: 40, 41, 42, 43, 44, and 45, (h) SEQ ID NOs: 46, 47, 48, 49, 50, and 51, and (i) The use or composition for use according to any one of items 83 to 86, comprising a heavy chain and a light chain that together comprise one of SEQ ID NOs: 52, 53, 54, 55, 56, and 57.

[0029] definition For purposes of the present invention, "a" or "an" entity refers to one or more of that entity, e.g., "a cDNA" refers to one or more cDNAs or at least one cDNA. Thus, the terms "a" or "an," "one or more," and "at least one" can be used interchangeably herein. It is also noted that the terms "comprising," "including," and "having" can be used interchangeably. Furthermore, a compound "selected from the group consisting of" refers to one or more of the compounds in the accompanying list, including mixtures (i.e., combinations) of two or more compounds. In accordance with the present invention, an "isolated" or "biologically pure" molecule is a compound that has been removed from its natural environment. Thus, the terms "isolated" and "biologically pure" do not necessarily reflect the extent to which a compound has been purified. An isolated compound of the present invention can be obtained from its natural source, can be produced using laboratory synthesis techniques, or can be produced by any such chemical synthesis route.

[0030] "Coronavirus", "corona respiratory virus", or "CoV" are used interchangeably herein and refer to viruses belonging to the Coronaviridae family. Coronaviruses are enveloped, positive-sense RNA viruses of approximately 31 Kb, making them the largest RNA viruses known. Coronaviruses infect a variety of host species, including humans and several other vertebrates. These viruses cause primarily respiratory and enteric infections and induce a wide range of clinical symptoms. In general, coronaviruses can be classified into low pathogenic CoVs, including human CoVs (hCoVs), and highly pathogenic CoVs, such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV). Low pathogenic hCoVs infect the upper respiratory tract and cause seasonal mild to moderate cold-like respiratory illness in healthy individuals. In contrast, highly pathogenic hCoV (pathogenic hCoV) infects the lower respiratory tract and causes severe pneumonia, which can sometimes cause fatal acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), resulting in high morbidity and mortality. SARS-CoV2 is a type of coronavirus. Coronavirus infection as used herein includes any of the above when it relates to coronavirus. "COVID-19 infection" as used herein can also refer to a condition or disease caused by SARS-CoV2.

[0031] "Acute lung injury" or "ALI" herein refers to acute lung disease with bilateral pulmonary infiltrates on chest radiography consistent with the presence of edema and no clinical evidence of left atrial hypertension or a pulmonary artery occlusion pressure of 18 mmHg or less (if measured). In addition, the ratio of arterial oxygen to fraction of inspired oxygen (PaO2 / FiO2) should be 300 mmHg or less, regardless of the level of positive end-expiratory pressure (PEEP).

[0032] "Acute respiratory distress syndrome" or "ARDS" herein refers to the most severe form of ALI, defined by an arterial oxygen to inspired oxygen ratio of 200 mmHg or less. Although the term ARDS is often used informally synonymously with ALI, by strict criteria, ARDS should be reserved for the most severe form of the disease.

[0033] As used herein, "LIGHT" or "TNFSF14" refers to a specific member protein of the tumor necrosis factor superfamily that is expressed by activated T cells, monocytes-macrophages, and additional types of antigen-presenting cells. "LIGHT" is a receptor that is homologous to lymphotoxin, exhibits inducible expression, and is expressed on T lymphocytes. H Competes with HSV glycoprotein D for binding to VEM (herpesvirus entry mediator) L ymphotoxin,exhibits I nducible expression and competes with HSV G lycoprotein D for binding to HVEM(herpesvirus entry mediator), a receptor expressed on T It is an acronym for "immunoglobulin (IgG) lymphocytes."

[0034] "Free LIGHT" or "free (active) LIGHT" herein refers to the unbound form of LIGHT (e.g., LIGHT bound to DcR3), which is the active form of LIGHT. In humans, free LIGHT is neutralized (inactivated) by DcR3, a unique soluble member of the TNFR superfamily that binds to LIGHT with high affinity and inhibits its interaction with two TNF receptors, HVEM and LTβR. "Bound LIGHT" and the like refers to LIGHT bound to a natural ligand, optionally the natural ligand being HVEM, LTβR, or DcR3. "Total LIGHT" and the like refers to the total amount of free LIGHT and bound LIGHT.

[0035] "Elevated free LIGHT" as used herein refers to a level of free LIGHT detected in a subject that is higher than a normal control. A normal control can be determined by a person skilled in the art as applicable to a particular situation. In some cases, a normal control is an industry standard agreed upon by a person skilled in the art as a typical level or range of levels of an individual who does not have a LIGHT-associated condition. In some cases, a normal control is a reference level of LIGHT from the same individual taken at a certain time point, and whether a subject has elevated LIGHT is determined based on a sample from the same individual taken at a different, typically later, time point.

[0036] The term "antibody" herein is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity. As used herein, the term refers to a molecule that comprises at least complementarity determining region (CDR)1, CDR2, and CDR3 of a heavy chain, and at least CDR1, CDR2, and CDR3 of a light chain, and the molecule is capable of binding to an antigen. The term antibody includes Fv, single chain Fv (scFv), Fab, Fab', and (Fab') 2 The term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, human antibodies, and antibodies of various species such as mouse, cynomolgus monkey, etc.

[0037] The term "heavy chain" refers to a polypeptide comprising at least a heavy chain variable region, with or without a leader sequence. In some embodiments, a heavy chain includes at least a portion of a heavy chain constant region. The term "full-length heavy chain" refers to a polypeptide comprising a heavy chain variable region and a heavy chain constant region, with or without a leader sequence.

[0038] The term "heavy chain variable region" refers to the region of a heavy chain comprising heavy chain complementarity determining region (CDR)1, framework region (FR)2, CDR2, FR3, and CDR3. In some embodiments, the heavy chain variable region also comprises at least a portion of FR1 and / or at least a portion of FR4. In some embodiments, heavy chain CDR1 corresponds to Kabat residues 31-35, heavy chain CDR2 corresponds to Kabat residues 50-65, and heavy chain CDR3 corresponds to Kabat residues 95-102. See, e.g., Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, NIH, Bethesda, Md.).

[0039] The term "light chain" refers to a polypeptide comprising at least a light chain variable region, with or without a leader sequence. In some embodiments, the light chain comprises at least a portion of a light chain constant region. The term "full-length light chain" refers to a polypeptide comprising a light chain variable region and a light chain constant region, with or without a leader sequence. The term "light chain variable region" refers to a region comprising light chain CDR1, FR2, HVR2, FR3, and HVR3. In some embodiments, the light chain variable region also comprises FR1 and / or FR4. In some embodiments, light chain CDR1 corresponds to Kabat residues 24-34, light chain CDR2 corresponds to Kabat residues 50-56, and light chain CDR3 corresponds to Kabat residues 89-97. See, e.g., Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, NIH, Bethesda, Md.).

[0040] "Chimeric antibody" refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, and the remainder of the heavy and / or light chain is derived from a different source or species. In some embodiments, a chimeric antibody refers to an antibody that comprises at least one variable region from a first species (mouse, rat, cynomolgus monkey, etc.) and at least one constant region from a second species (human, cynomolgus monkey, etc.). In some embodiments, a chimeric antibody comprises at least one mouse variable region and at least one human constant region. In some embodiments, a chimeric antibody comprises at least one cynomolgus monkey variable region and at least one human constant region. In some embodiments, all of the variable regions of the chimeric antibody are from a first species and all of the constant regions of the chimeric antibody are from a second species.

[0041] "Humanized antibody" refers to an antibody in which at least one amino acid in a framework region of a non-human variable region is replaced with the corresponding amino acid from a human variable region. In some embodiments, a humanized antibody comprises at least one human constant region or a fragment thereof. In some embodiments, a humanized antibody is an antibody that is a Fab, scFv, (Fab') 2 And so on.

[0042] As used herein, "human antibody" refers to antibodies produced in humans, antibodies produced in non-human animals that contain human immunoglobulin genes, such as the XenoMouse®, and antibodies selected using in vitro methods, such as phage display, where the antibody repertoire is based on human immunoglobulin sequences.

[0043] The term "leader sequence" refers to a sequence of amino acid residues located at the N-terminus of a polypeptide that facilitates secretion of the polypeptide from a mammalian cell. Leader sequences may be cleaved upon export of the polypeptide from a mammalian cell to form the mature protein. Leader sequences may be natural or synthetic, and they may be heterologous or homologous to the protein to which they are attached.

[0044] With respect to peptide, polypeptide, or antibody sequences, "percent (%) amino acid sequence identity" and "homology" are defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in a variety of ways that are within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms necessary to achieve maximum alignment over the full length of the sequences being compared.

[0045] The term "inhibition" or "inhibiting" refers to the reduction or cessation of any event (such as protein ligand binding), or the reduction or cessation of any phenotypic characteristic, or the reduction or cessation of the incidence, extent, or likelihood of that characteristic. "Reducing" or "inhibiting" is the reduction, reduction, or cessation of an activity, function, and / or amount compared to a reference. Inhibition or reduction need not be complete. For example, in certain embodiments, "reducing" or "inhibiting" refers to the ability to cause an overall reduction of 20% or more. In another embodiment, "reducing" or "inhibiting" refers to the ability to cause an overall reduction of 50% or more. In yet another embodiment, "reducing" or "inhibiting" refers to the ability to cause an overall reduction of 75%, 85%, 90%, 95%, or more.

[0046] "Sample" or "subject sample" or "biological sample" generally refers to a sample that can be tested for a particular molecule. Samples can include, but are not limited to, cells, bodily fluids, including blood, serum, plasma, urine, saliva, feces, tears, pleural fluid, and the like.

[0047] The terms "agent" and "test compound" are used interchangeably herein to refer to a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract obtained from biological materials such as bacteria, plants, fungi, or animal (especially mammalian) cells or tissues. Biological macromolecules include siRNAs, shRNAs, antisense oligonucleotides, peptides, peptide / DNA complexes, and any nucleic acid-based molecule that exhibits the ability to modulate the activity of the SNP-containing nucleic acids or their encoded proteins described herein. Agents are evaluated for potential biological activity by inclusion in screening assays described below.

[0048] A "subject" can be a mammal. In any of the embodiments involving a subject, the subject can be a human. In any of the embodiments involving a subject, the subject can be a cow, a pig, a monkey, a sheep, a dog, a cat, a fish, or a poultry.

[0049] A "pediatric" subject herein is a human under the age of 18, while an "adult" subject is 18 or older.

[0050] "Treatment" or "treating" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in which the disorder is to be prevented. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stable (i.e., not worsening) state of disease, delay or slowing of disease progression, improvement or palliation of the disease state, and remission (partial or total), whether detectable or not. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0051] The term "effective amount" or "therapeutically effective amount" refers to an amount of a drug effective for treating a disease or disorder in a subject, e.g., to partially or completely alleviate one or more symptoms. In some embodiments, an effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0052] Identification of the biomarker LIGHT LIGHT (TNFSF14) is a key regulatory cytokine that functions as a critical factor in orchestrating the cytokine storm and lung failure associated with pathogen-borne infections, including viral infections, including coronaviruses (e.g., COVID-19), and bacterial infections.

[0053] In some embodiments, a method is provided for detecting free (active) LIGHT in a human subject. In some embodiments, a biological sample (e.g., serum) of the subject is analyzed for free LIGHT. In some embodiments, the results provide a basis for understanding whether an anti-LIGHT therapy can be provided and effective. For example, with elevated levels of free LIGHT (e.g., levels of free LIGHT above that required, such as using a normal control), the subject can be diagnosed as having a condition associated with elevated free LIGHT and / or considered a suitable candidate for treatment with an anti-LIGHT antibody. In some embodiments, the anti-LIGHT antibody is an antibody that neutralizes LIGHT. In some embodiments, a method is provided for detecting free (active) LIGHT in a biological sample (e.g., serum) of the subject, the results of which provide a basis for understanding whether an anti-LIGHT therapy can be provided and effective. In some embodiments, detection of free LIGHT above that of a normal control indicates that an anti-LIGHT therapy can be provided and effective.

[0054] In some embodiments, the condition associated with elevated free LIGHT for which the subject may be diagnosed is Crohn's disease or an inflammatory condition associated with Crohn's disease. In some embodiments, the condition associated with elevated free LIGHT for which the subject may be diagnosed is a coronavirus infection. In some embodiments, the coronavirus infection is a moderate or severe coronavirus infection. In some embodiments, the condition associated with elevated free LIGHT includes any one or more of inflammation, optionally the inflammation is hyperinflammation, immune dysregulation causing multisystem organ failure, acute lung injury (ALI), optionally the ALI is associated with a coronavirus infection, bacterial or viral infection including acute respiratory distress syndrome (ARDS), optionally the ARDS is associated with a coronavirus infection, cytokine storm driving tissue damage and vascular permeability, post-infection pulmonary fibrosis, and pneumonia, optionally the pneumonia is associated with a bacterial or viral infection including a corona infection. In some embodiments, the condition associated with elevated free LIGHT is a mild, moderate, or severe coronavirus infection, optionally the coronavirus infection is a COVID-19 infection. In some embodiments, the COVID-19 infection is associated with ALI or ARDS in the subject. In some embodiments, the COVID-19 infection is associated with a cytokine storm that drives tissue damage and vascular permeability in the lungs and pulmonary fibrosis following infection. In some embodiments, the coronavirus infection is MERS-CoV, SARS-CoV, or SARS-CoV2 / COVID-19.

[0055] In some embodiments, a method is provided for diagnosing a condition associated with elevated free LIGHT in a subject, where the level of free (active) LIGHT in a biological sample is detected. If the level is above a normal control, the subject is diagnosed as having a condition associated with elevated free LIGHT. In some embodiments, the condition associated with elevated free LIGHT detected is Crohn's disease or an inflammatory condition associated with Crohn's disease. In some embodiments, the condition associated with elevated free LIGHT detected is a viral infection. In some embodiments, the condition associated with elevated free LIGHT detected is a coronavirus infection. In some embodiments, the condition associated with elevated free LIGHT detected is a moderate or severe coronavirus infection. In some embodiments, the condition associated with elevated free LIGHT detected is a mild, moderate, or severe COVID-19 infection. In some embodiments, the COVID-19 infection is associated with ALI or ARDS in the subject. In some embodiments, the coronavirus infection is MERS-CoV or SARS-CoV.

[0056] In some embodiments, methods for detecting free LIGHT in a biological sample from a subject may be performed using a biological sample that includes blood, urine, serum, plasma, feces, or gastric lavage fluid samples, or cell samples such as white blood cells or mononuclear cells.

[0057] In some embodiments, a method for detecting free (active) LIGHT in a subject includes: (a) contacting a biological sample with at least one anti-LIGHT antibody; (b) incubating the biological sample to allow the anti-LIGHT antibody to bind to free LIGHT; (c) determining the presence of a complex formed between the anti-LIGHT antibody and free LIGHT in the biological sample.

[0058] The method can further include the step of diagnosing the subject as having a condition associated with elevated free LIGHT, and / or administering an anti-LIGHT antibody.

[0059] Various methods known in the art can be used to detect specific antibody-antigen binding. Exemplary immunoassays that can be performed include fluorescence polarization immunoassay (FPIA), fluorescence immunoassay (FIA), enzyme immunoassay (EIA), turbidimetric inhibition immunoassay (NIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA), competitive assays, and sandwich assays.

[0060] Indicator moieties, or label groups, can be attached to the subject antibodies and are selected to meet the needs of the various uses of the method, which are often dictated by the availability of assay equipment and compatible immunoassay procedures. Suitable labels include, but are not limited to, radionuclides (e.g., 125I, 131I, 35S, 3H, or 32P), enzymes (e.g., alkaline phosphatase, horseradish peroxidase, luciferase, or β-galactosidase), fluorescent moieties or proteins (e.g., fluorescein, rhodamine, phycoerythrin, GFP, or BFP), or luminescent moieties (e.g., Qdot™ nanoparticles, supplied by Quantum Dot Corporation, Palo Alto, Calif.).

[0061] General techniques to be used in performing the various immunoassays noted above are known to those of skill in the art.

[0062] ELISA assays are generally known to those skilled in the art and can be designed to determine serum LIGHT levels. In an exemplary embodiment, blood is collected and serum is isolated. If a kit is not available, ELISA can be developed using a plate pre-coated with a capture antibody specific to the LIGHT to be measured. The plate is incubated at room temperature for a predetermined time and then washed. An enzyme-anti-LIGHT antibody conjugate is added and incubated. Unbound antibody conjugate is removed and the plate is washed, followed by the addition of a color-developing substrate solution that reacts with the enzyme. The plate is read in a suitable plate reader at an absorbance characteristic of the enzyme and substrate used.

[0063] The competitive method compares the competitive binding of an antigen in a sample to the monoclonal antibody of the present invention with a known amount of labeled antigen. To perform an immunological assay based on the competitive method, a sample containing an unknown amount of target antigen is added to a solid substrate on which the monoclonal antibody of the present invention is physically or chemically coated by a known means, and the reaction is allowed to proceed. At the same time, a predetermined amount of pre-labeled target antigen is added, and the reaction is allowed to proceed. After incubation, the solid substrate is washed, and the activity of the labeling agent bound to the solid substrate is measured.

[0064] In the sandwich method, the target antigen in the sample is sandwiched between an immobilized monoclonal antibody and a labeled monoclonal antibody, a labeled substrate such as an enzyme is added, and the color change of the substrate is detected to thereby detect the presence of the antigen. To perform an immunological assay based on the sandwich method, for example, a sample containing an unknown amount of the target antigen is added to a solid substrate on which the monoclonal antibody of the present invention is physically or chemically coated by a known means, and the reaction is allowed to proceed. Then, the labeled monoclonal antibody of the present invention is added, and the reaction is allowed to proceed. After incubation, the solid substrate is washed, and the activity of the labeling agent bound to the solid substrate is measured.

[0065] In some embodiments, the first antibody is used for diagnosis and the second antibody is used as a therapeutic agent. In some embodiments, the first antibody and the second antibody are different. In some embodiments, the first antibody and the second antibody can both bind to the antigen simultaneously by binding to distinct epitopes.

[0066] Methods of treatment with anti-LIGHT antibodies The present invention provides methods of treating subjects with elevated free LIGHT, including subjects with conditions associated with elevated free LIGHT, with an anti-LIGHT antibody. In some embodiments, the anti-LIGHT antibody is an antibody that neutralizes LIGHT. In some embodiments, the condition associated with elevated free LIGHT is a coronavirus infection, including COVID-19. In some embodiments, the condition associated with elevated free LIGHT is Crohn's disease or an inflammatory condition associated with Crohn's disease. Treatment can be performed with or without a diagnostic test to detect elevated free LIGHT in a sample from the subject.

[0067] In some embodiments, a biological sample from a subject is first tested for the presence and levels of free LIGHT in a threshold step before the subject is treated. In such embodiments, the treatment method comprises contacting a biological sample from the subject with at least one first anti-LIGHT antibody, incubating the biological sample to allow the anti-LIGHT antibody to bind to free LIGHT, determining the presence of a complex formed between the anti-LIGHT antibody and free LIGHT in the biological sample, and finally, based on a positive result of the detection step and findings of elevated free LIGHT, administering to the subject an effective amount of a second anti-LIGHT antibody, which is different from the first and second antibodies.

[0068] In some embodiments, subjects are treated without a threshold testing step. In such cases, it may be predetermined that the subject will benefit from anti-LIGHT therapy or that an anti-LIGHT antibody is administered prophylactically. In such embodiments, the method of treatment comprises administering an effective amount of an anti-LIGHT antibody to a subject having a condition associated with elevated free LIGHT.

[0069] In some embodiments of the methods of treatment, the condition associated with elevated free LIGHT is Crohn's disease or an inflammatory condition associated with Crohn's disease.

[0070] In some embodiments of the methods of treatment, the condition associated with elevated free LIGHT is a coronavirus infection. In some embodiments, the coronavirus infection is a COVID-19 infection. In some embodiments, the subject has a respiratory disease, optionally caused by a virus, bacteria, or fungus. In some embodiments, the subject has a respiratory disease caused by a coronavirus infection. In some embodiments, the subject has a respiratory disease caused by COVID-19. In some embodiments, the subject has pneumonia. In some embodiments, the subject has acute lung injury (ALI). In some embodiments, the subject has acute respiratory distress syndrome (ARDS). In some embodiments, the pneumonia is associated with a coronavirus infection. In some embodiments, the ALI or ARDS is associated with a coronavirus infection. In some embodiments, the pneumonia is associated with COVID-19. In some embodiments, the subject has acute lung injury (ALI) associated with COVID-19. In some embodiments, the subject has acute respiratory distress syndrome (ARDS) associated with COVID-19. In some embodiments, the subject has a mild coronavirus infection. In some embodiments, the subject has a moderate coronavirus infection. In some embodiments, the subject has a severe coronavirus infection. In some embodiments, a method of treating severe COVID-19 pneumonia is provided, comprising administering an anti-LIGHT antibody to a subject in need of such treatment. In some embodiments, a method of treating acute inflammatory disease associated with COVID-19 pneumonia is provided, comprising administering an anti-LIGHT antibody to a subject in need of such treatment. In some embodiments, a method of treating respiratory failure associated with COVID-19 pneumonia is provided, comprising administering an anti-LIGHT antibody to a subject in need of such treatment. In some embodiments, a method of treating cytokine storm is provided, comprising administering an anti-LIGHT antibody to a subject in need of such treatment.In some embodiments, methods are provided for treating a dysregulated hyperimmune response (sometimes referred to as a "cytokine storm") comprising administering an anti-LIGHT antibody to a subject in need of such treatment. In some embodiments, methods are provided for treating acute respiratory distress syndrome (ARDS) comprising administering an anti-LIGHT antibody to a subject in need of such treatment.

[0071] In some embodiments, administration of anti-LIGHT antibodies suppresses T cell activation. In some embodiments, administration of anti-LIGHT antibodies suppresses increased expression of cytokines (e.g., cytokine storm). In some embodiments, administration of anti-LIGHT antibodies suppresses increased expression of cytokines (e.g., cytokine storm) caused by viral and / or bacterial infections, e.g., from coronavirus infection. In some embodiments, administration of anti-LIGHT antibodies prevents or treats cytokine storm caused by viral and / or bacterial infections, such as coronavirus infection. In some embodiments, cytokine storm can drive tissue injury and vascular permeability in the lungs. Cytokine storm can result in ARDS and ALI associated with coronavirus (e.g., COVID-19) infection. In some embodiments, administration of anti-LIGHT antibodies optionally prevents or treats post-infection pulmonary fibrosis associated with coronavirus infection. In some embodiments, administration of anti-LIGHT antibodies reduces the risk of mortality or morbidity in a subject. In some embodiments, administration of anti-LIGHT antibodies prevents progression to ARDS in a subject with pneumonia associated with coronavirus infection (e.g., COVID-19 infection). In some embodiments, administration of an anti-LIGHT antibody prevents the progression of ALI associated with a coronavirus infection, including (e.g., COVID-19 infection), to ARDS. In some embodiments, administration of an anti-LIGHT antibody prevents or treats ARDS. In some embodiments, administration of an anti-LIGHT antibody prevents the need for mechanical ventilation / intubation in a subject.

[0072] The therapeutic method of the present invention may be carried out via conventional routes of administration, including, but not limited to, oral, buccal, sublingual, ocular, topical, parenteral, rectal, intracisternal, intravaginal, intraperitoneal, intravesical, topical (e.g., powder, ointment, or drops), or nasal. The term "parenteral" includes subcutaneous, intravenous, intramuscular, or injection. In certain embodiments, it may be appropriate to administer the agent by continuous infusion or as a subcutaneous injection every day, every other day or every few days, or once a week, or once every few weeks, or once a month, or once every few months, or at intervals within the range defined by any two of the aforementioned intervals.

[0073] In some embodiments, the anti-LIGHT antibody is administered to a subject already receiving another therapy. For subjects with COVID-19, the other therapy can be any therapy approved or tested to treat or ameliorate symptoms of COVID-19. Such therapies include, but are not limited to, remdesivir, corticosteroids, and hydroxychloroquine. In some embodiments, the other therapy continues (in its normal course) during treatment with the anti-LIGHT antibody. In some embodiments, the other therapy is discontinued during treatment with the anti-LIGHT antibody. In some embodiments, the subject has COVID-19 and is receiving a high dose of a corticosteroid and an anti-LIGHT antibody. In some embodiments, subjects receiving the combination of high dose corticosteroids and an anti-LIGHT antibody have a better outcome than those not receiving the combination.

[0074] In some embodiments, the dose of anti-LIGHT antibody is about 16 mg / kg with a maximum dose of 1,200 mg. In some embodiments, the dose is a single dose. In some embodiments, the dose is more than a single dose.

[0075] In some embodiments, administration of an anti-LIGHT antibody reduces serum free LIGHT levels in a subject by 85% or more, for example, compared to the free LIGHT levels in the subject prior to administration of the anti-LIGHT antibody, or compared to a subject not administered the anti-LIGHT antibody. In some embodiments, the 85% or more reduction in serum free LIGHT levels in a subject occurs less than 5 days or less than 1 day after administration of the anti-LIGHT antibody. In some embodiments, an anti-LIGHT antibody administered to a subject reduces the subject's risk of death by 50% or more 60 days after administration. In some embodiments, an anti-LIGHT antibody administered to a subject reduces the subject's risk of death by 50% or more 28 days after administration. In some embodiments, a subject is 60 years of age or older. In some embodiments, an anti-LIGHT antibody administered to a subject reduces the subject's length of hospitalization compared to a subject receiving standard medical treatment. In some embodiments, an anti-LIGHT antibody administered to a subject reduces the subject's risk of respiratory failure.

[0076] In some embodiments, the anti-LIGHT antibody is administered at a dose of about 1.0 mg / kg to about 3.0 mg / kg. In some embodiments, the anti-LIGHT antibody is administered at a dose of about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, or about 3.0 mg / kg. In some embodiments, the anti-LIGHT antibody is administered daily, every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, every week, every 2 weeks, every 3 weeks, or every 4 weeks. In some embodiments, the anti-LIGHT antibody is administered at a dose of about 1.0 mg / kg to about 3.0 mg / kg every 14 days. In some embodiments, the anti-LIGHT antibody is administered as a dose of 1.0 mg / kg every 14 days. In some embodiments, the anti-LIGHT antibody is administered as a dose of 3.0 mg / kg every 14 days.

[0077] In some embodiments, an anti-LIGHT antibody is administered to a subject who has failed treatment with an approved therapeutic dose of an anti-TNFα monoclonal antibody therapy, either by failing to initially respond or by failing to initially respond to induction with a subsequent failure to respond.

[0078] Treatment of Crohn's disease The primary clinical target in CD treatment is the resolution of symptoms. (Shi and Ng, The state of the art on treatment of Crohn's disease, J. Gastroenterol., 2018: 53; 989-998). The standard index for assessing symptoms is the Crohn's Disease Activity Index (CDAI), which includes eight variables: number of liquid stools, severity of abdominal pain, general health status, occurrence of extraintestinal symptoms, need for antidiarrheal medications, presence of abdominal masses, hematocrit, and weight. (Shi and Ng 2018). Symptom control does not appear to significantly alter the natural course of the disease. (Shi and Ng 2018).

[0079] Mucosal healing is becoming another target in clinical practice. The Simple Endoscopic Score in Crohn's Disease (SES-CD) is one of the most common endoscopic scoring systems for CD. SES-CD is scored based on four endoscopic variables in the same five segments: presence and size of ulcers, extent of ulcerated surface, extent of affected surface, and presence and type of strictures. An SES-CD score of less than 2 is considered endoscopic remission. At least a 50% reduction from baseline in the SES-CD score is used as the definition of endoscopic response. Although a universal definition for mucosal healing is currently not set, the absence of ulcers on ileocolonoscopy has been adopted as the endoscopic endpoint in CD. (Shi and Ng 2018).

[0080] Patient-reported outcomes are measurements elicited directly from patients about any aspect of their health status and can be treatment endpoints for CD. Several scales have been used to assess patients' perspective of their disease, including the Inflammatory Bowel Disease Questionnaire (IBD-Q) (Shi and Ng 2018).

[0081] In some embodiments, administration of an anti-LIGHT antibody reduces the subject's CDAI score, e.g., compared to the subject's CDAI score before administration of the anti-LIGHT antibody, or compared to a subject not administered the anti-LIGHT antibody. In some embodiments, administration of an anti-LIGHT antibody reduces the subject's SES-CD score, e.g., compared to the subject's SES-CD score before administration of the anti-LIGHT antibody, or compared to a subject not administered the anti-LIGHT antibody. In some embodiments, administration of an anti-LIGHT antibody results in the subject's SES-CD score of less than 2. In some embodiments, administration of an anti-LIGHT antibody increases the subject's IBD-Q score, e.g., compared to the subject's IBD-Q score before administration of the anti-LIGHT antibody, or compared to a subject not administered the anti-LIGHT antibody. In some embodiments, administration of an anti-LIGHT antibody results in the subject's IBD-Q score of 170 or greater. In some embodiments, administration of an anti-LIGHT antibody results in an increase in the subject's IBD-Q score of at least 16 points. In some embodiments, administration of an anti-LIGHT antibody results in an increase in the subject's IBD-Q score of at least 32 points.

[0082] Stages of COVID-19 disease progression The stages of COVID-19 disease progression are shown in Figure 1 in Siddiqi, HK, et al. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 39(5), 405-407(2020). The disease can be broadly divided into three stages: early infection, pulmonary stage, and hyperinflammatory stage. Stage I is the viral response stage, stage III is the host inflammatory response stage, and stage II is a combination of the two. As patients progress from the early stage (stage I) to the pulmonary stage (stage II) where pulmonary symptoms appear, the host inflammatory response is manifested. It is at this point that in some patients, dysregulation of the inflammatory response occurs. This dysregulation of the inflammatory response may be accompanied by elevated free LIGHT levels in biological fluids such as serum. This stage, the pulmonary stage, is the optimal stage to administer anti-LIGHT antibodies to correct this dysregulation and avoid the cytokine storm and progression to ARDS that occurs in the hyperinflammatory stage (stage III).

[0083] Patients in stage I of COVID-19 are considered to have mild disease, patients in stage II of COVID-19 are considered to have mild to moderate disease, and patients in stage III of COVID-19 are considered to have severe disease.

[0084] In some embodiments, anti-LIGHT antibodies are administered to subjects with mild coronavirus (e.g., COVID-19). In some embodiments, anti-LIGHT antibodies are administered during the early infection stage of coronavirus. In some embodiments, anti-LIGHT antibodies are administered during stage I of coronavirus. In some embodiments, anti-LIGHT antibodies are administered while a subject in need thereof has mild constitutional symptoms, fever >99.6°F, dry cough, diarrhea, or headache. In some embodiments, a subject in need thereof has lymphopenia, increased prothrombin time, increased D-dimer, and LDH (mild). In some embodiments, administration of anti-LIGHT antibodies treats stage I of coronavirus. In some embodiments, administration of anti-LIGHT antibodies prevents progression of coronavirus to stage II. Staging refers to Figure 1 of Siddiqi, HK et al. (2020), which is incorporated herein in its entirety.

[0085] In some embodiments, the anti-LIGHT antibody of the method is administered to a subject with moderate coronavirus (e.g., COVID-19). In some embodiments, the anti-LIGHT antibody is administered during the pulmonary stage of coronavirus. In some embodiments, the anti-LIGHT antibody is administered during stage II of coronavirus. In some embodiments of the invention, the anti-LIGHT antibody is administered during stage IIA or stage IIB of coronavirus. In some embodiments, the anti-LIGHT antibody is administered while the subject in need thereof exhibits shortness of breath or hypoxia. In some embodiments, the anti-LIGHT antibody is administered while the subject in need thereof meets clinical criteria for ALI. In some embodiments, the subject in need thereof has abnormal chest imaging, transaminitis, or low to normal procalcitonin. In some embodiments, the patient is not undergoing mechanical ventilation / intubation. In some embodiments, administration of the anti-LIGHT antibody treats stage II of coronavirus. In some embodiments, administration of the anti-LIGHT antibody prevents progression of coronavirus to stage III.

[0086] In some embodiments, anti-LIGHT antibodies are administered to subjects with severe coronavirus (e.g., COVID-19). In some embodiments, anti-LIGHT antibodies are administered during the hyperinflammatory stage of coronavirus. In some embodiments, anti-LIGHT antibodies are administered during stage III of coronavirus. In some embodiments, anti-LIGHT antibodies are administered while a subject in need thereof has ARDS, systemic inflammatory response syndrome (SIRS) / shock, or heart failure. SIRS is a complex immune response to an insult characterized by widespread inflammation in the body. Both infectious and non-infectious causes of SIRS have been identified. In some embodiments, the patient is undergoing mechanical ventilation / intubation. In some embodiments, administration of anti-LIGHT antibodies treats stage III of coronavirus.

[0087] Anti-LIGHT antibody In some embodiments, anti-LIGHT antibodies are utilized for both detection / diagnostic and therapeutic purposes and in the assays described herein. The anti-LIGHT antibody used for detection or diagnostic purposes is different from the antibody used for therapeutic purposes (even in the same subject).

[0088] Anti-LIGHT antibodies useful for therapeutic purposes may comprise the CDR sequences of the E1, E13, E63, F19, or F23 antibodies provided in WO2008 / 027338, and US8,058,402(B2), US8,461,307(B2), and US8,974,787(B2), each of which is incorporated herein by reference. Anti-LIGHT antibodies useful for detection / diagnostic purposes are not the same as those used for therapeutic purposes.

[0089] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 2, 3, and 4, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 5, 6, and 7, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 2, 3, and 4, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 5, 6, and 7, respectively.

[0090] In some embodiments, an anti-LIGHT antibody comprises a heavy chain variable region sequence that comprises SEQ ID NO:8 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:8. In some embodiments, an anti-LIGHT antibody comprises a light chain variable region sequence that comprises SEQ ID NO:9 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:9. In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises SEQ ID NO:8 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:8. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises SEQ ID NO:9 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:9. In some embodiments, an anti-LIGHT antibody comprises both a heavy chain that comprises SEQ ID NO:8 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:8, and a light chain that comprises SEQ ID NO:9 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:9.

[0091] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 10, 11, and 12, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 13, 14, and 15, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 10, 11, and 12, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 13, 14, and 15, respectively.

[0092] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 16, 17, and 18, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 19, 20, and 21, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 16, 17, and 18, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 19, 20, and 21, respectively.

[0093] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 22, 23, and 24, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 25, 26, and 27, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 22, 23, and 24, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 25, 26, and 27, respectively.

[0094] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 28, 29, and 30, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 31, 32, and 33, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 28, 29, and 30, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 31, 32, and 33, respectively.

[0095] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 34, 35, and 36, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 37, 38, and 39, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 34, 35, and 36, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 37, 38, and 39, respectively.

[0096] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 40, 41, and 42, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 43, 44, and 45, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 40, 41, and 42, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 43, 44, and 45, respectively.

[0097] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 46, 47, and 48, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 49, 50, and 51, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 46, 47, and 48, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 49, 50, and 51, respectively.

[0098] In some embodiments, an anti-LIGHT antibody may comprise the CDR sequences of the antibodies described in US2013 / 0323240 and US8,524,869(B2), which are incorporated herein by reference. For example, in some embodiments, an anti-LIGHT antibody comprises a heavy chain comprising three CDR sequences comprising each of SEQ ID NOs: 52, 53, and 54, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain comprising three CDR sequences comprising each of SEQ ID NOs: 55, 56, and 57, respectively. In some embodiments, an antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 52, 53, and 54, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 55, 56, and 57, respectively.

[0099] In some embodiments, an anti-LIGHT antibody comprises a heavy chain variable region sequence that comprises SEQ ID NO:58 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:58. In some embodiments, an anti-LIGHT antibody comprises a light chain variable region sequence that comprises SEQ ID NO:59 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:59. In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises SEQ ID NO:58 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:58. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises SEQ ID NO:59 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:59. In some embodiments, an anti-LIGHT antibody comprises both a heavy chain that comprises SEQ ID NO:58 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:58, and a light chain that comprises SEQ ID NO:59 or is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to SEQ ID NO:59.

[0100] In some embodiments, the anti-LIGHT antibody is selected from the group consisting of the following sets of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences set forth in the sequence listing from US2013 / 0323240: SEQ ID NOs: 18, 19, 20, and SEQ ID NOs: 38, 41, 42 of US2013 / 0323240; SEQ ID NOs: 18, 19, 21, and SEQ ID NOs: 39, 41, 42 of US2013 / 0323240; SEQ ID NOs: 18, 19, 22, and SEQ ID NOs: 40, 41, 42 of US2013 / 0323240; The heavy and light chains may together comprise one of: SEQ ID NOs: 23, 24, 25, and SEQ ID NOs: 43, 44, 45 of US2013 / 0323240; SEQ ID NOs: 26, 27, 28, and SEQ ID NOs: 46, 47, 48 of US2013 / 0323240; SEQ ID NOs: 29, 30, 31, and SEQ ID NOs: 49, 50, 51 of US2013 / 0323240; SEQ ID NOs: 32, 33, 34, and SEQ ID NOs: 52, 53, 54 of US2013 / 0323240; SEQ ID NOs: 35, 36, 37, and SEQ ID NOs: 55, 50, 51 of US2013 / 0323240.

[0101] In some embodiments, an anti-LIGHT antibody comprises the CDR sequences of antibodies 18E04, 98C07, 1C02, 1C06, 13H04, 31A10, 98C07, 42A02, 29C02, 14B09, 117C06, 114F05, and 62C01, described in WO2015 / 107331, which is incorporated by reference herein.

[0102] For example, in some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 60, 61, and 62, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 63, 64, and 65, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 60, 61, and 62, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 63, 64, and 65, respectively.

[0103] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 66, 67, and 68, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 69, 70, and 71, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 66, 67, and 68, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 69, 70, and 71, respectively.

[0104] In some embodiments, an anti-LIGHT antibody comprises a heavy chain that comprises three CDR sequences comprising each of SEQ ID NOs: 72, 73, and 74, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain that comprises three CDR sequences comprising each of SEQ ID NOs: 75, 76, and 77, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 72, 73, and 74, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 75, 76, and 77, respectively.

[0105] In some embodiments, an anti-LIGHT antibody comprises a heavy chain comprising three CDR sequences comprising each of SEQ ID NOs: 78, 79, and 80, respectively. In some embodiments, an anti-LIGHT antibody comprises a light chain comprising three CDR sequences comprising each of SEQ ID NOs: 81, 82, and 83, respectively. In some embodiments, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR sequences comprising each of SEQ ID NOs: 78, 79, and 80, respectively, and the light chain comprises three CDR sequences comprising each of SEQ ID NOs: 81, 82, and 83, respectively.

[0106] Kits and Products Any of the foregoing methods can be implemented via a kit for detection of free LIGHT and / or diagnosis and / or treatment of conditions associated with elevated free LIGHT, including viral and / or bacterial infections, such as coronaviruses, including COVID-19. The kit can include an antibody, one or more non-naturally occurring detectable labels, markers, or reporters, a pharma- ceutically acceptable carrier, a physiologically acceptable carrier, instructions for use, a container, a container for administration, an assay substrate, or any combination thereof.

[0107] In some embodiments, the kits are for use in methods to detect free LIGHT (as opposed to total or bound LIGHT) in a biological sample.

[0108] In some embodiments, the kit is for use in a method of detecting free LIGHT in a biological sample from a subject having, or suspected of having, a coronavirus infection, ALI, ARDS, or pulmonary fibrosis.

[0109] In some embodiments, the kit is for use in a method of detecting free LIGHT in a biological sample from a subject having or suspected of having Crohn's disease or an inflammatory condition associated with Crohn's disease.

[0110] In some embodiments, the kit is for use in a method of detecting elevated free LIGHT in a biological sample from a subject, optionally where the subject is suspected of having a coronavirus infection, and for treating the subject after diagnosis by administering an effective amount of an anti-LIGHT antibody.

[0111] In some embodiments, a kit for use in one of the above methods is suitable for use in a subject with mild, moderate, or severe Crohn's disease, or a mild, moderate, or severe inflammatory condition associated with Crohn's disease.

[0112] In some embodiments, the kit for use in one of the above methods is suitable for a subject having a mild, moderate, or severe coronavirus infection. In some embodiments, the mild, moderate, or severe coronavirus infection is a COVID-19 infection. In some embodiments, the coronavirus (including COVID-19) infection is associated with a respiratory disease. In some embodiments, the coronavirus (including COVID-19) infection is associated with ALI or ARDS.

[0113] In some embodiments, kits for use in methods of detection and / or treatment include a solid phase to which an anti-LIGHT antibody reagent is bound, hi some embodiments, kits for use in methods of detection and / or treatment include a solid phase to which free LIGHT from a biological sample will be bound.

[0114] The solid phases used in the kits of the present invention include, but are not limited to, microplates, magnetic particles, filter paper for immunochromatography, polymers such as polystyrene, glass beads, glass filters, and other insoluble carriers. In one embodiment, a solid substrate comprising many compartments or regions has at least one compartment coated with an antibody of the present invention.

[0115] The kits of the invention may also include additional components to the diagnostic anti-LIGHT antibody, including, but not limited to, enzymes for labeling and substrates therefor, radioisotopes, light reflecting substances, fluorescent substances, coloring substances, buffer solutions, and plates, as well as those mentioned above.

[0116] Free LIGHT detection assay Disclosed is an assay, which is a method for detecting and measuring free LIGHT in a sample suspected of containing free LIGHT from a subject. Such a method may use an antibody pair for sandwich immunoassay, in which free LIGHT from a sample is captured by a capture antibody coating, such as paramagnetic beads, and a detection antibody further binds to the captured free LIGHT. Then, a label enzyme conjugate, such as streptavidin-β-galactosidase (SβG), is added and binds to the detection antibody. Finally, an enzyme substrate is added to obtain a fluorescence intensity that can be correlated with the presence and amount of free LIGHT in the sample.

[0117] In some embodiments, a sample suspected of containing free LIGHT is contacted with a capture molecule for free LIGHT that specifically binds to free LIGHT but not to bound LIGHT, and incubated to allow the capture molecule to bind to the free LIGHT. Such embodiments further involve detecting binding of free LIGHT to the capture molecule and determining the amount of free LIGHT in the sample. The capture molecule can be, but need not be, an antibody. In some embodiments, bound LIGHT refers to LIGHT bound to a complex. In some embodiments, bound LIGHT is LIGHT bound to a complex with DcR3. In some embodiments, bound LIGHT is LIGHT that is neutralized or inactivated by DcR3. In some embodiments, bound LIGHT is LIGHT bound to either of its TNF receptors, HVEM and LTβR. In some embodiments, complex-bound LIGHT includes LIGHT bound to DcR3 or to an anti-LIGHT antibody.

[0118] In some embodiments, the capture molecule specifically binds to free LIGHT but not to the LIGHT / DcR3 complex. In some embodiments, the capture molecule specifically binds to free LIGHT at or near the site where free LIGHT binds to DcR3, such that, for example, LIGHT cannot bind to the capture molecule and DcR3 simultaneously. In some embodiments, the capture molecule specifically binds to free LIGHT at the site where LIGHT binds to DcR3. In some embodiments, the capture molecule specifically binds to free LIGHT at or near the site where free LIGHT binds to either of its TNF receptors, HVEM and LTβR. In some embodiments, the capture molecule specifically binds to free LIGHT at the site where free LIGHT binds to either of its TNF receptors, HVEM and LTβR.

[0119] In some embodiments of the method for detecting and measuring free LIGHT in a sample suspected of containing free LIGHT from a subject, the sample is contacted with a capture molecule as well as a detection molecule. Such embodiments further involve incubating the sample to allow the capture molecule and detection molecule to bind to the free LIGHT. Such embodiments further involve detecting binding of free LIGHT to the capture molecule and determining the amount of free LIGHT in the sample. In some embodiments, binding of free LIGHT to the detection molecule is also detected. In some embodiments, the detection molecule binds to a different site of free LIGHT than the capture molecule.

[0120] In some embodiments of the methods for detecting and measuring free LIGHT in a sample suspected of containing free LIGHT from a subject, the methods further involve comparing the amount of free LIGHT to the amount of total LIGHT in the sample.

[0121] In some embodiments, the capture molecule is an antibody. In some embodiments, the capture molecule is an antibody selected from a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a single chain antibody, a bispecific or bieffective antibody, a simianized antibody, a human antibody, and a humanized antibody. In some embodiments, the capture antibody is a monoclonal antibody. In some embodiments, the capture antibody is bound to a support (e.g., nanoparticles in the Simoa platform). In some embodiments, the capture antibody is ProSci RF16062.

[0122] In some embodiments, the detection molecule is an antibody. In some embodiments, the detection molecule is a monoclonal antibody. In some embodiments, the capture antibody is ProSci RF16062. In some embodiments, the capture antibody is Enzo ALX-804-841-C100. In some embodiments, the detection antibody is DCABH-13797. In some embodiments, the detection antibody is ProSci RF16062. In some embodiments, the capture antibody is ProSci RF16062 and the detection antibody is DCABH-13797. In some embodiments, the capture antibody is Enzo ALX-804-841-C100 and the detection antibody is ProSci RF16062.

[0123] In some embodiments, the sample is serum, plasma, saliva, or feces, hi some embodiments, the sample is a serum sample.

[0124] Example 1 A study was conducted in which serum from subjects with acute COVID-19 infection was examined to determine the levels of free LIGHT and other cytokines / inflammatory markers during the acute phase of the disease. Differences in LIGHT levels and other inflammatory markers were determined between healthy controls and subjects with mild to severe disease due to ALI / ARDS. Subjects with severe COVID-19 infection were expected to have higher levels of serum free LIGHT and other inflammatory markers compared to healthy controls or subjects with mild or moderate coronavirus infection without ARDS, and furthermore, these markers could be useful in identifying subjects who may benefit from treatment with anti-LIGHT therapy. Given the role of LIGHT in mediating immune responses, particularly its role in inflammatory cell infiltration and T cell activation, these subjects were expected to benefit from anti-LIGHT antibody therapy. Thus, the assay results were expected to provide guidance to clinicians as to which therapeutic agent is appropriate.

[0125] The study included 30 healthy controls, 28 intubated subjects with severe COVID-19 infection, and 20 non-ventilated subjects with mild to moderate COVID-19 infection. Blood was drawn from subjects at a single time point. The free LIGHT assay described in Example 4 herein was used to determine the presence and levels of free (active) LIGHT in serum, and in intubated patients, the determination was made at the time of intubation.

[0126] Free LIGHT was significantly elevated (p<0.0001) in COVID-19 subjects (N=47) compared to healthy controls (N=30). See FIG. 6.

[0127] Free LIGHT was also significantly elevated (p<0.0001) in serum of non-ventilated COVID-19 patients (N=20) and intubated COVID-19 patients (N=27) compared to healthy controls (N=30). See FIG.

[0128] Additional evidence suggests that the highest free LIGHT levels are observed in patients requiring ventilator support, particularly those over 60 years of age, and that elevated free LIGHT levels are associated with fatal outcomes in these patients, with a statistically significant association between higher serum LIGHT levels and mortality in patients over 60 years of age (p=0.0209). See Figure 8. The observed mortality rate was higher in patients over 60 years of age (82%) compared to those <60 years of age (32%).

[0129] Example 2 A randomized, double-blind, placebo-controlled, multicenter, Phase 2 clinical trial evaluating the efficacy and safety of anti-LIGHT antibodies in adults with COVID-19 pneumonia and acute lung injury was conducted according to the methods described in Example 2. The anti-LIGHT antibody has a VH of SEQ ID NO:8, and a VL of SEQ ID NO:9.

[0130] Example 2.1 - Study Objectives and Endpoints The primary objective of the study is to evaluate the efficacy of anti-LIGHT monoclonal antibodies compared to placebo in addition to standard medical care for the prevention of ARDS in adults with COVID-19 pneumonia and acute lung injury. The human anti-LIGHT monoclonal antibodies administered contain heavy and light chains that together comprise the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3 amino acid sequences: SEQ ID NOs: 2, 3, 4, 5, 6, and 7.

[0131] Secondary objectives of the trial are to evaluate the safety and tolerability of anti-LIGHT monoclonal antibody compared to placebo in addition to standard medical care in adults with COVID-19 pneumonia and acute lung injury, and to evaluate the effect of anti-LIGHT monoclonal antibody compared to placebo in addition to standard medical care on mortality in adults with COVID-19 pneumonia and acute lung injury.

[0132] Exploratory objectives are to evaluate the effect of anti-LIGHT monoclonal antibody compared with placebo, in addition to standard of care, on viral load in adults with COVID-19 pneumonia and acute lung injury, and to evaluate the PK, pharmacodynamics (PD), and immunogenicity of anti-LIGHT monoclonal antibody in adults with COVID-19 pneumonia and acute lung injury.

[0133] The primary endpoint of the study is the proportion of subjects surviving and free of respiratory failure over 28 days. Respiratory failure is defined based on resource utilization including one of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via augmented nasal cannula at a flow rate >20 L / min with a fraction of oxygen delivered of ≥0.5), noninvasive positive pressure ventilation, or extracorporeal membrane oxygenation (ECMO).

[0134] Secondary study endpoints were 1-month mortality defined as the proportion of subjects alive at day 28 / early termination (ET), partial pressure of arterial oxygen / fraction of inspired oxygen (PaO2 / FiO2) ratio, time on invasive mechanical ventilation, duration of mechanical ventilatory support, intensive care unit (ICU) time on study, length of hospital stay, time to return to room air with resting pulse oximeter >93%, peak PaO2 / FiO2 ratio, partial pressure of oxygen (PO2), change in Sequential Organ Failure Assessment (SOFA) score, change in body temperature, and adverse event (AE) monitoring and safety laboratory determinations.

[0135] Exploratory endpoints of the study include measurement of viral load, LIGHT levels and inflammatory biomarker patterns (InflammationMAP) in nasopharyngeal aspirates, plasma concentrations of anti-LIGHT monoclonal antibodies over time, and anti-drug antibodies (ADA).

[0136] Example 2.2 - Study Design The study is designed to determine the efficacy and safety of anti-LIGHT monoclonal antibody compared to standard of care plus placebo, administered SC to subjects with COVID-19 pneumonia and acute lung injury. The primary objective of the study is to evaluate the efficacy of anti-LIGHT monoclonal antibody in preventing ARDS in adults with COVID-19 pneumonia and acute lung injury. The efficacy of anti-LIGHT monoclonal antibody will be determined by measuring PaO2 / FiO2, days of respiratory failure survived, days free of mechanical ventilation survived, ICU and hospital stay, return to room air or baseline oxygen requirement, SOFA score, body temperature, viral load in nasopharyngeal aspirate, time to invasive mechanical ventilation, and duration of mechanical ventilation support. These are routinely used and accepted methods to assess respiratory function. The study will also evaluate 1-month mortality apart from other parameters.

[0137] The trials will be conducted at approximately 10 testing facilities in the United States.

[0138] 83 patients will be enrolled in the study. A screening log of study candidates will be maintained at each study site.

[0139] Inclusion criteria Subjects will be randomized into the study if they meet the following requirements: 1. Subject / legally authorized representative (LAR) understands and is able to provide written informed consent and assent (if applicable) to participate in this study. 2. Subjects are ≥ 18 years of age at the time of informed consent and assent (if applicable). 3. Subject is male or non-pregnant, non-lactating female and, if of childbearing potential, agrees to comply with applicable contraceptive requirements if discharged prior to completing the study. 4. Subject will be diagnosed with COVID-19 infection through an approved testing method. 5. Subject is admitted to the hospital with a clinical diagnosis of pneumonia with acute lung injury defined as bilateral radiographic diffuse infiltrates with PaO2 / FiO2 >100 and <300. 6. Subject's resting oxygen saturation on ambient air, if available, is <93%.

[0140] Exclusion criteria The presence of any of the following criteria will exclude a subject from the study: 1. The subject is intubated. 2. Subject is taking immunomodulatory or anti-rejection medications. The use of corticosteroids as part of standard medical care in severe COVID-19 patients is permitted if clinically indicated and in consultation with the medical monitor. 3. Subject has received an immune-modulating biologic within 60 days prior to baseline. 4. Subject is in septic shock, defined as persistent hypotension requiring vascular pressure to maintain a mean arterial pressure (MAP) of 65 mmHg or greater and a serum lactate level greater than 2 mmol / L (18 mg / dL) despite adequate volume resuscitation. 5. Subject has ALT / AST > 5 x ULN or creatinine > 2.5 mg / dl 6. Subject has <500 neutrophils / ml 7. Subject has <50,000 platelets / ml 8. Subject has known hypersensitivity to any of the components of the anti-LIGHT monoclonal antibody. 9. Subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit.

[0141] Screening failure Subjects missing the inclusion and / or exclusion criteria will not be rescreened for the study.

[0142] Early subject withdrawal All subjects are advised that they are free to withdraw from participation in this study at any time, regardless of reason, without prejudice. Investigators are instructed to make all reasonable attempts to retain subjects in the study, but if a subject withdraws consent to participate, the subject must withdraw from the study.

[0143] The sponsor reserves the right to request subject withdrawal due to protocol deviations or other reasons.

[0144] The investigator also has the right to withdraw a subject from the study at any time for any reason. If a subject withdraws before completing the study, the subject shall be followed up as indicated in the assessment schedule (Table 1). The reason for withdrawal shall be determined by the investigator and recorded in the subject's medical record and on the case report form (CRF). If a subject withdraws for more than one reason, each reason shall be recorded in the source document and the most clinically relevant reason shall be entered on the CRF.

[0145] Possible reasons for discontinuation include, but are not limited to: Adverse events Significant protocol deviations Subject withdrawal from study evaluation Subject withdrawal from investigational drug ● Unknown to follow-up ● Other. If Other is selected, the investigator is requested to specify the reason on the CRF.

[0146] Subject replacement criteria Subjects who withdraw or discontinue from the study may be replaced. [Table 1] Abbreviations: ADA = anti-drug antibodies, EC = electrocardiogram, ET = early termination, Inflammat ionMAP = inflammatory biomarker pattern; LIGHT = lymphotoxin-like, exhibits inducible expression, and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed by T lymphocytes; PK = pharmacokinetics. 1. Day 28 will be conducted as a follow-up call for subjects who discontinue from the study and for subjects who are discharged prior to the Day 28 visit. In addition, a Day 28 / ET visit procedure will be conducted if a subject discontinues or is discharged from the study prior to Day 28. No further visits will be required except for the Day 28 and Day 60 follow-up calls. 2. A safety follow-up call will be conducted approximately 59 days (± 7 days) after study drug administration. 3. Concomitant medications will be collected throughout the study period. 4. Adverse events will be collected throughout the study. 5. Samples will be collected prior to study drug administration. 6. Samples are collected 24 hours (± 2 hours) after Day 1 dosing. 7. ECGs will be collected daily when the subject is not being evaluated by cardiac monitoring. 8. ADA samples will be collected on days 8, 14, and 28 / ET. In addition, samples will be collected when immunologically related adverse events are reported (e.g., skin reactions, lupus-like syndrome, thrombocytopenia of unknown etiology). 9. If the facility is not capable of performing a quantitative test to obtain viral load, viral load samples collected on Days 1 and 5 are not required to be collected. 10. For women of potential childbearing potential: Subjects will not be considered of childbearing potential if they are postmenopausal (spontaneous amenorrhea for 12 consecutive months and ≥ 51 years of age) and / or surgically sterilized (having undergone one of the following surgical procedures: hysterectomy, bilateral salpingectomy, bilateral salpingectomy, or bilateral salpingectomy) and at least 6 weeks post-sterilization. [Table 2]

[0147] Example 2.3 - Treatment Investigational drug identity, dose, and mode of administration Anti-LIGHT monoclonal antibody is the investigational drug used in this study. It will be supplied in vials. Placebo will be sourced locally and provided as volume-matched saline for injection. Anti-LIGHT monoclonal antibody or placebo will be administered by SC injection into the abdomen within a zone 4-10 cm from the umbilicus, with rotation of injection site based on the number of syringes used. Anti-LIGHT monoclonal antibody or placebo will be administered at baseline (day 1). Anti-LIGHT monoclonal antibody will be administered at a 16 mg / kg dose (maximum dose 1200 mg).

[0148] Labelling and Packaging All packaging and labeling activities will be performed by the sponsor or designee in accordance with Good Manufacturing Practice and Good Clinical Practice (GCP) regulations. The investigational product will be shipped to the study site by the sponsor or designee. Labeling will be in the local language and dependent on local regulations.

[0149] Treatment given Eligible subjects will receive standard of care plus anti-LIGHT monoclonal antibody or placebo on day 1. Standard of care will be maintained throughout the study and may include off-label use of other drugs, devices, or interventions used to treat COVID-19.

[0150] Distribution and storage Anti-LIGHT monoclonal antibody supplied by the sponsor will be used exclusively in this clinical trial as directed by the protocol. Placebo will be sourced locally and provided as volume-matched saline for injection. The investigator is responsible for dispensing the study drug according to the dosing scheme and for ensuring proper storage of the study drug.

[0151] The unblinded pharmacist acknowledges receipt of the investigational product by his or her signature. A copy of this receipt is kept by the unblinded pharmacist and another copy is kept by the sponsor and / or designee. Until the investigational product is dispensed to the subject, it is stored at 2°C to 8°C (35.6°F to 46.4°F) and protected from light. The investigator or other authorized person (e.g., pharmacist) is responsible for storing the investigational product provided by the sponsor in a secure and safe place in accordance with local regulations, labeling specifications, and facility policies and procedures.

[0152] Control of storage conditions of the investigational product provided by the sponsor, in particular temperature control (e.g., refrigeration) and daily temperature monitoring, as well as in-use stability information and instructions for handling the investigational product, should be controlled in accordance with regulations provided by the sponsor.

[0153] Blinded and open-label treatment assignment This is a double-blind study. All subjects, investigators, and study personnel involved in the conduct of the study, including data management, will be blinded to treatment assignment, except for the following individuals: a specific unblinded statistician at the contract research organization (CRO) who will have access to the randomization code, and a specific unblinded pharmacist at the hospital who will have access to the randomization code to prepare the investigational drug.

[0154] The unblinded pharmacist and unblinded statistician will not participate in the study or data analysis other than prior to unblinding of the study.

[0155] Treatment unblinding is not recommended if knowing the treatment assignment would not materially change the planned management of the medical emergency. Unblinding is permitted for medical emergencies that require immediate knowledge of the subject's treatment assignment. Whenever possible, unblinding should be discussed with the sponsor's medical monitor. In an emergency unblinding, the investigator will contact the unblinding pharmacist. If the investigator cannot discuss treatment unblinding in advance, he or she must notify the sponsor's medical monitor of the unblinding event as soon as possible without revealing the subject's treatment assignment. The investigator or designee will record the date and reason for study discontinuation in the appropriate eCRF for that subject. In all non-urgent cases, the investigator will discuss the event with the sponsor's medical monitor prior to unblinding the subject's treatment assignment.

[0156] If the treatment assignment is unblinded for an individual subject, the investigator will be informed of that subject's treatment assignment without unblinding the treatment assignments of the remaining subjects in the study. The investigator will make this decision after consulting with the Sponsor's medical monitor.

[0157] Dose Selection for the Study The 16 mg / kg dose (maximum dose of 1200 mg) is chosen in an effort to maximize the ability to achieve LIGHT blockade while ensuring patient safety. In a robust toxicology program, the anti-LIGHT monoclonal antibody was administered at doses as high as 100 mg / kg and well tolerated in monkeys, with a NOAEL of 60 mg / kg. In human dosing, the anti-LIGHT monoclonal antibody was safe and well tolerated at single escalating doses up to 1200 mg in healthy volunteers. There were no clinically significant adverse events or changes in ECG parameters or clinical laboratory values ​​that occurred during treatment. A safety review committee analyzed data from individual subjects and across all subjects treated routinely to evaluate any safety signals with dosing.

[0158] Dose adjustment criteria No dose adjustments are permitted.

[0159] Investigational Drug Management Record Records showing receipt, distribution, or other disposition of the investigational product will be maintained by the unblinded pharmacist, including dates, lot identifiers, doses, volumes administered to each subject, and the identification of the subject receiving the investigational product (subject number and initials). The investigator will not supply the investigational product to anyone other than the person named as the co-investigator on the US Food and Drug Administration (FDA) Form FDA1572 and designated study personnel, and the subjects in this study. The investigator will not dispense the investigational product from any study location other than that listed on the FDA1572 form. If any of the investigational product is not distributed, lost, stolen, spilled, unusable, or received in damaged containers, that information should be documented and reported to the sponsor and appropriate regulatory agencies as appropriate.

[0160] Upon completion of the study, unused investigational product may be left in its original packaging for final disposal by the sponsor or in accordance with the site's standard operating procedures. All partially used investigational product and all empty packaging (e.g., vials) may be retained for final disposal by the sponsor or returned to the sponsor's designee for destruction, or in accordance with the site's standard operating procedures.

[0161] Permitted and Prohibited Therapies All non-study therapies, including but not limited to over-the-counter and non-pharmacological treatments received within 7 days prior to baseline and through the end of the study, will be recorded on the appropriate electronic case report form (eCRF) page.

[0162] Pretreatment Prior treatment includes any treatment received within 7 days of the first dose of study drug. Prior treatment information will be recorded on the appropriate eCRF page.

[0163] Combination therapy Concomitant therapy refers to any therapy administered between the date of first administration of study drug and the end of the follow-up period. Concomitant therapy information will be recorded on the appropriate CRF page.

[0164] Permitted Therapies Medications deemed necessary for the subject's welfare will be administered at the discretion of the Investigator. In the event that a site has a situation requiring further clarification, the Sponsor's Medical Monitor may be contacted.

[0165] Acceptable contraceptive methods are implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or a vasectomy partner.

[0166] Prohibition therapy Subjects cannot have received any immunomodulatory biologics within 60 days prior to the baseline visit, and cannot have received any live attenuated vaccines such as varicella zoster, oral polio, or rubella within 3 months prior to the baseline visit. New initiation of test compounds may be prohibited during the study, except for corticosteroids, which may be allowed to be administered as part of standard of care in severe COVID-19 patients if clinically indicated and in consultation with the medical monitor. Use of immunomodulatory or anti-rejection medications may be prohibited.

[0167] Treatment after the end of the study Subjects will be treated according to standard clinical practice throughout the study.

[0168] Example 2.4 - Test Procedure Subjects / LARs will provide written informed consent and assent (if applicable) before any study-related procedures are initiated.

[0169] Refer to the Schedule of Events (Tables 1 and 2) for timing of evaluations and procedures throughout the study. Procedures listed in Table 2 will be considered standard of care and will be performed in accordance with institutional practice unless otherwise defined. Throughout the study, study personnel will make every reasonable effort to follow the timing of evaluations and procedures in the Schedule of Events for each subject.

[0170] Test period Anti-LIGHT monoclonal antibody and placebo treatments were administered on day 1, and the study duration was 60 days.

[0171] Efficacy evaluation Efficacy response will be assessed at the time points described in the evaluation schedule (Tables 1 and 2) by the following procedures: arterial blood gas (ABG) test to measure PaO2 / FiO2, pulse oximetry, SOFA score measurement (SOFA score is a simple and objective tool that calculates both the number and severity of organ dysfunction in six organ systems: respiratory, coagulation, hepatic, cardiovascular, renal, and neurological systems [Table 3], the score can measure individual or collective organ dysfunction (Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction / failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710]), body temperature, viral load in nasopharyngeal aspirate. Apart from these tests, the time to invasive ventilation and the duration of mechanical ventilation support will also be recorded. [Table 3]

[0172] Safety assessment Safety and tolerability assessments included evaluation of the frequency and severity of AEs, and changes in clinical laboratory values, vital signs, ECG recordings, and physical examination findings.

[0173] Laboratory tests performed Samples for C-reactive protein will be collected at the time points specified in the assessment schedule (Table 1). All other testing samples, except for PK, LIGHT, and InflammationMAP samples, are considered standard of care and may be performed according to institutional practice.

[0174] The specimens are analyzed in the hospital laboratory according to their collection and processing requirements.

[0175] Blood collection volume The blood collection volumes for this study are shown in Table 4. [Table 4]

[0176] Anti-LIGHT monoclonal antibody concentrations, pharmacokinetics, and anti-drug antibody evaluation Pharmacokinetic and ADA assessments will be calculated from the plasma concentrations of anti-LIGHT monoclonal antibodies.

[0177] Specimen Handling Requirements Transmission of infectious agents can occur through contact with contaminated needles and blood or blood products. Therefore, appropriate blood and body fluid precautions should be used by all laboratory personnel involved in blood collection and specimen handling in both clinic and laboratory settings. Refer to the latest recommendations of the appropriate authorities.

[0178] In addition to proper handling of subject samples, there are specific regulations regarding the shipping of biological / pathogen samples. Procedures and regulations regarding the packaging and shipping of infectious samples are outlined in the facility and / or testing laboratory manual. The investigator is responsible for ensuring that all study samples shipped to another location are properly packaged and shipped in accordance with applicable regulations.

[0179] Evaluation of laboratory values Normal ranges of values ​​for the test evaluations in this study are provided by the local laboratories of each hospital. They are considered reference ranges determined at that particular facility.

[0180] If a laboratory value is outside the reference range, it is not necessarily clinically relevant. The investigator may evaluate the out-of-range value and record his or her assessment of clinical relevance in the subject's source documentation.

[0181] Any laboratory values ​​that, in the opinion of the investigator, are clinically relevant or indicate pathological changes during or after the end of treatment should be discussed with the medical monitor and, if appropriate, reported and followed up as AEs.

[0182] All measurements described in this section are accepted standard methods.

[0183] Clinical examination: blood pressure, pulse rate, respiratory rate, temperature, height, and weight Blood pressure, pulse rate, respiratory rate, temperature, height, and weight are considered standard of care and will be taken in accordance with site practice. Additional blood pressure and pulse rate measurements may be taken as determined by the investigator to ensure adequate monitoring of subject safety and accurate recording of vital signs. Any changes from baseline that are deemed clinically significant by the investigator will be recorded as an AE.

[0184] Clinical Test: Electrocardiogram Standard 12-lead ECGs are considered standard of care and will be performed daily for those not being evaluated by cardiac monitors. They will be performed according to site practice unless otherwise defined in Table 2. All ECG recordings will be identified with subject number, subject initials, date, and time of recording, and copies will be included with the subject's source documentation. All ECGs will be performed using equipment supplied by the investigational site.

[0185] Electronic ECG tracings will be analyzed according to site procedures. In addition, the investigator's assessment of the ECG tracing as normal or abnormal will be documented, and if abnormal, their determination of whether the abnormality is clinically significant or not may be noted on the tracing.

[0186] Any ECG values ​​that, in the opinion of the investigator, indicate clinically relevant or pathological changes during or after the end of treatment, in consultation with the sponsor's medical monitor, will be reported and tracked as AEs.

[0187] Clinical Test: Physical Examination A complete physical examination is considered standard of care and will be performed per institutional practice unless otherwise defined in Table 2. Clinically significant physical examination findings will be reported and tracked as AEs.

[0188] Clinical Tests: Adverse Events The Investigator is responsible for the detection and documentation of events that meet the aforementioned criteria and definitions of AEs or SAEs. Any clinically relevant observations made during the hospitalization will be considered an AE.

[0189] Pharmacokinetic and immunogenicity analysis Blood samples for PK analysis will be collected at random time points on Day 2, 24 hours (± 2 hours) after dosing, and on Days 8, 14, and 28. Blood samples for ADA analysis will be collected at random time points on Days 8, 14, and 28. In addition, samples will be collected when immunologically related adverse events are reported. Samples will be processed to plasma. The time of the PK sample will be recorded in the eCRF. A total of 1.0 mL of plasma per PK and ADA sample will be collected from each subject to measure plasma concentrations of anti-LIGHT monoclonal antibody and ADA. Pharmacokinetic and ADA samples should be processed according to the methods and instructions described in the Laboratory Manual and Guidance. Pharmacokinetic and ADA plasma sample analyses will be performed by laboratories defined in the Laboratory Manual and Guidance according to their standard operating procedures (SOPs) using validated enzyme-linked immunosorbent assays (ELISAs). Details of the assays and analyses are described in the Method Validation and Bioanalytical Information.

[0190] Pharmacodynamics Blood samples will be collected for exploratory analyses, including but not limited to LIGHT levels and InflammationMAP as specified in Table 1. Exploratory biomarker analyses will be performed in laboratories as specified in the laboratory manual and guidance.

[0191] Example 2.5 - Adverse Events Adverse event collection An AE is defined as any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product, not necessarily causally related to the product. Thus, an AE can be any untoward, unintended sign (including new, clinically significant abnormal laboratory findings), symptom, or disease that is time-related to the product, whether or not related to the product. An AE is considered treatment-emergent if it occurs after the first dose of investigational drug and within 30 days of the subject's last dose of investigational drug.

[0192] All AEs will be collected from the time informed consent is signed through the end of the study (Day 60). This includes events that occur whether or not study drug is administered. When possible, record a diagnosis rather than a list of symptoms. If a diagnosis has not yet been made, list each symptom individually. All AEs will be captured on the appropriate AE page in the eCRF and source documents. In addition to adverse AEs, capture off-label unexpected benefits in source documents and the AE eCRF.

[0193] All AEs will be followed until closure (subject's health status has returned to their baseline state or all variables have returned to normal) regardless of whether the subject is still in the study. Closure indicates that the outcome has been reached, stabilization has been achieved (the Investigator does not expect any further improvement or worsening of the event), or the event has been explained in another way. Where appropriate, medical tests and investigations will be performed to allow for documenting the resolution of the event.

[0194] Severity of the adverse event The severity of the AE is recorded over the course of the event, including the start and stop dates of each change in severity. Events that change in severity are captured as new events. Worsening of a pretreatment event after starting study drug is recorded as a new AE. For example, if a subject experiences mild intermittent headaches before receiving study drug, however, the headache intensity increases to moderate after the first dose of study drug, a new AE of moderate intermittent headache is recorded in the source document and eCRF.

[0195] Medical assessment of the clinical severity of AEs is determined using definitions outlined in the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 (published on November 27, 2017 by the US Department of Health and Human Services, National Institutes of Health, National Cancer Institute). Grade 1 is defined as mild, asymptomatic or mild symptoms, or clinical or diagnostic observation only, or no intervention indicated. Grade 2 is defined as moderate, or minimal, local or noninvasive intervention indicated, or limiting age-appropriate instrumental activities of daily living (ADLs). Grade 3 is defined as severe or medically significant but not immediately life-threatening, or hospitalization or prolonged hospital stay indicated, or disabling, or limiting self-care ADLs. Grade 4 is defined as life-threatening consequences, or urgent intervention indicated. Grade 5 is defined as death related to the AE.

[0196] The above referenced CTCAE document may be consulted for a complete explanation of CTCAE terminology and measures and self-management ADLs. Severity is a classification of intensity and SAEs are AEs that meet serious criteria.

[0197] Related Categories The investigator will assess each AE for a relationship to the investigational drug. The investigator will determine whether, in his or her medical judgment, there is a reasonable possibility that the event could be caused by the investigational drug. If there is no good reason to suggest a relationship, the AE may be classified as "unrelated."

[0198] Otherwise, the AE will be classified according to the following guidelines: Causality assessment may be documented in the source document and eCRF (Table 5). [Table 5]

[0199] Outcome at last observation Outcome at last observation will be classified as recovered / resolved, recovered / resolved with sequelae, recovering / resolving, not recovered / not resolved, fatal, or unknown.

[0200] Reporting of serious adverse events Initial and follow-up SAE reports are completed by the Investigator or designee and sent to the CRO within 24 hours of initial knowledge of the SAE. The Investigator or designee completes, signs, and dates the appropriate SAE form and verifies accuracy of the information against corresponding source documentation. This information is sent to the CRO Pharmacovigilance Department.

[0201] Definition of serious adverse events An SAE is defined as any untoward medical occurrence, at any dose, that results in death, is life-threatening, requires hospitalization or an extension of an existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly, or is a significant medical event, whether or not considered related to the investigational drug.

[0202] Please note that the term "life-threatening" in the definition of "serious" refers to an event in which the subject was at risk of death at the time of the event, not an event that could have hypothetically caused death if it had been more severe.

[0203] Please note that the term "patient hospitalization" is defined as a 24-hour or overnight stay in a hospital. Voluntary hospitalization to treat a condition present prior to exposure to the test drug, or hospitalization for diagnostic evaluation of an AE, does not qualify the condition or event as an SAE. Additionally, an overnight stay in a hospital due solely to transportation, organizational, or accommodation issues and without a medical context need not be considered an SAE.

[0204] Please note that the term "congenital anomaly" refers to an infant who is an SAE born to a mother exposed to the investigational drug during pregnancy, however, a newly diagnosed pregnancy in a subject receiving an investigational drug is not considered an SAE unless the investigational drug is suspected to have interacted with a contraceptive method to result in the pregnancy.

[0205] It is noted that medical and scientific judgment may be used in determining whether it is appropriate to consider other serious circumstances, such as significant medical events that are not immediately life-threatening or that do not result in death or hospitalization but may endanger the subject or may have intervention required to prevent one of the other outcomes listed in the definition above. Examples of such events are allergic bronchospasm, blood disorders or convulsions that do not result in hospitalization, or intensive care in the emergency room or at home in the development of drug addiction or abuse.

[0206] Time frame for collecting serious adverse events All SAEs, regardless of study relatedness, will be collected from the time the subject / LAR signs the informed consent and assent form [if applicable] until last subject contact. The investigator or designee must promptly report all SAEs to the CRO within 24 hours of first becoming aware of the event.

[0207] Any SAEs detected by the investigator at any interval after completing the study, regardless of study relatedness, will be reported to the CRO within 24 hours of first knowledge of the event.

[0208] Date of onset and resolution of serious adverse events The onset date of an SAE is defined as the date the event meets the severe criteria. The resolution date is the date the event no longer meets the severe criteria, the symptoms resolve, or the event is considered chronic. In the case of hospitalization, the dates of admission and discharge are considered the onset and resolution dates of the SAE, respectively.

[0209] Any sign or symptom experienced by the subject after signing the informed consent form and assent form (if applicable), or up to the date of onset of the SAE, or after the date of resolution of the SAE will be recorded as an AE.

[0210] Fatal outcome Fatal will be selected as an outcome only when an AE results in death. If more than one AE may be associated with the subject's death, the outcome of death must be presented for each such AE.

[0211] Any AE resulting in the death of a subject will be checked as fatal as the outcome and the date of death will be recorded as the date of resolution. AEs resulting in death should be reported within 24 hours as SAEs if not already reported as such. In the event of subject death, data should be collected on whether death occurred after discontinuation of treatment and, if so, the reason for discontinuation of treatment.

[0212] For other AEs that were ongoing at the time of death and did not contribute to the subject's death, the outcome should be considered as not resolved and a resolution date was not recorded.

[0213] Adverse events of special interest No events were identified as AEs of particular interest from the studies to date.

[0214] Adverse drug reactions observed in anti-LIGHT monoclonal antibody preclinical observations include injection site reactions.

[0215] Observed reactions with other biologics include a potential increase in infections (including opportunistic infections such as tuberculosis), hypersensitivity reactions (including anaphylaxis), immunogenicity, malignancies, and immune disorders.

[0216] Any new infections that occur during the study must be obtained, regardless of the infectious agent (i.e., viral or non-viral). In addition, the site of infection and the source of cultures (bronchoalveolar lavage, tracheal aspirate, sputum, blood, urine, etc.) must be obtained.

[0217] pregnancy All women of childbearing potential participating in this study will be counseled about the need to practice adequate contraception and the importance of avoiding pregnancy while participating in the study. Women will be instructed to contact the investigator or study staff immediately if pregnancy occurs or is suspected.

[0218] Pregnancy testing will be performed at baseline in women of childbearing potential. Women who are found to be pregnant at baseline will be excluded from the study and will be considered a screening failure. Any women who are found to be pregnant after dosing will be required to discontinue the study and an end-of-study evaluation visit will be performed as soon as possible after learning of the pregnancy.

[0219] The Investigator will report pregnancies of any female (study participant or female partner of a male study participant) who becomes pregnant during study drug treatment or within 60 days of randomization or receiving study drug. Pregnancies will be reported to the CRO within 24 hours of learning of the pregnancy using the Pregnancy Data Collection Form via fax and email address similar to the SAE report. The Investigator will contact the designated individual notified of the SAE and record any information related to the pregnancy on the In Utero Exposure Form / other designated form provided by the Sponsor or designee.

[0220] The Investigator will also be responsible for following the pregnancy until delivery or termination. These findings will be reported on the Pregnancy Data Collection Form and forwarded to a designated individual. An event will meet the criteria for an SAE only if it results in spontaneous abortion or congenital anomaly.

[0221] Anaphylaxis Any AEs representative of anaphylactic reactions were classified using the definitions provided in Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: Summary Report-Second National Institute of Allergy and Infectious Disease / Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol 2006;117(2):391-97 and are shown in Table 6. [Table 6]

[0222] Example 2.6 - Statistics Sample size determination A total of 83 subjects will be randomized in a 1:1 ratio to one of two treatment groups (standard medical care plus anti-LIGHT monoclonal antibody or placebo). One subject will drop out, leaving 82 subjects. This sample size of 82 subjects provides greater than 80% power to detect a difference of 0.25 (25%) in the proportion of subjects alive and free of respiratory failure using a chi-square exact test at a one-sided significance level of 0.05. This calculation estimates that the proportion alive and free of respiratory failure is 0.60 in the placebo group and 0.85 in the anti-LIGHT monoclonal antibody group.

[0223] Analysis population This study has several populations of interest. The Randomized Analysis Set includes all subjects randomized in the study. Subjects are classified according to their randomized treatment group. The Randomized Analysis Set is used for all disposition, protocol deviation, and demographic and other baseline characteristic analyses. The Safety Analysis Set includes all subjects randomized in the study who receive at least one dose of study drug. Subjects are classified according to their actual treatment group. The Safety Analysis Set is used for all exposure and safety analyses. The Total Analysis Set includes all subjects who receive at least one dose of study drug and have a baseline and at least one post-baseline efficacy assessment. Subjects are classified according to their randomized treatment group. The Total Analysis Set is used for all efficacy and pharmacodynamic analyses. The PK Analysis Set includes all subjects who receive at least one dose of study drug and have a measurable plasma sample after at least one dose. Subjects are classified according to their actual treatment group. The PK Analysis Set is used for all PK analyses.

[0224] statistical analysis All efficacy and safety variables will be summarized using descriptive statistics. For continuous data, descriptive statistics will include number of subjects (n), mean, standard deviation (SD), median, minimum, and maximum. Summary of change from baseline variables will include only subjects with both baseline values ​​and corresponding values ​​at the time points of interest. For categorical data, descriptive statistics will include frequencies and percentages.

[0225] A listing of all test data collected will be provided.

[0226] The disposition of all subjects randomized in the study will be summarized by treatment group and completion / withdrawal status. Subjects withdrawing early from the study will be summarized by treatment group and reason for withdrawal. The number of subjects in each analysis set will be summarized by treatment group.

[0227] All subject data will be reviewed for the occurrence of protocol deviations. Prior to database lock, all protocol deviations will be reviewed and classified for their potential to affect study outcomes. Protocol deviations will be summarized by treatment group.

[0228] Demographic and other baseline characteristics will be summarized by treatment group using descriptive statistics.

[0229] All prior and concomitant medications will be coded using the WHO Drug Dictionary. Prior and concomitant medications will be summarized by treatment group using descriptive statistics.

[0230] Exposure to study drug will be summarized by treatment group using descriptive statistics.

[0231] Safety analyses will be performed using data from the safety analysis set. Safety variables included TEAEs, clinical laboratory values, vital signs, and ECG results. No formal inferential analyses will be performed for any safety variables unless otherwise noted.

[0232] The verbatim terms of adverse events are listed in the Medical Dictionary Events were coded using the Medication for Regulatory Activities (MedDRA) Index. The overall incidence of subjects with at least one AE was summarized by treatment group. The incidence of TEAEs was summarized by treatment group, system organ class (SOC), and preferred preferred term (PT). Each subject was counted only once per SOC and preferred term. AEs were considered treatment-emergent if they occurred after the first dose of study drug and within 30 days after the subject's last dose of study drug.

[0233] For all continuous test variables, descriptive statistics of all reported values ​​and changes from baseline will be summarized by treatment group and time point.

[0234] For all continuous vital sign and ECG variables, descriptive statistics of all reported values ​​and changes from baseline will be summarized by treatment group and time point. In addition, the frequency and proportion of subjects with abnormal ECG findings will be summarized.

[0235] The proportion of subjects alive and free of respiratory failure with 90% confidence intervals is then presented. In addition, the proportion of subjects alive and free of respiratory failure in the anti-LIGHT monoclonal antibody group is compared to the placebo group using a chi-square test or similar method. Other dichotomous efficacy variables are analyzed similarly. All efficacy variables are summarized using descriptive statistics.

[0236] For all PK variables, descriptive statistics will be presented by collection time point (if applicable) using the PK analysis set. Descriptive statistics for plasma concentrations include n, the number of subjects with concentrations below the level of quantification (BLQ), mean, SD, coefficient of variation, median, minimum, and maximum. For narrative summaries, plasma concentrations reported as BLQ are set to zero.

[0237] For all PD variables, descriptive statistics will be presented by treatment group and time point.

[0238] For all immunogenicity variables, descriptive statistics will be presented by treatment group and time point.

[0239] Example 3 Specific results of tests performed according to the methods described in Example 2 herein are presented in Example 3.

[0240] Screening included identifying patients with COVID-19-associated pneumonia and mild to moderate ARD. Patients (n=83) who met these criteria were then randomized 1:1 to receive standard medical care + anti-LIGHT monoclonal antibody or standard medical care + placebo. One of the 83 patients withdrew informed consent. A total of 82 patients received either standard medical care + anti-LIGHT monoclonal antibody or standard medical care + placebo. Full analyses of secondary endpoints and safety were completed for these patients. An intention-to-treat analysis for the primary endpoint was completed for the group of 62 patients who did not have high-flow O2 or positive pressure O2 at 28-day follow-up.

[0241] More than 90% of patients in this study received corticosteroids and more than 60% received remdesivir. Patient demographics were as follows in Table 7: [Table 7-1] [Table 7-2]

[0242] The study showed robust improvement in the primary endpoint (proportion of patients surviving and free of respiratory failure over the 28-day study period) in COVID-19 patients with ARDS treated with a single dose of anti-LIGHT monoclonal antibody (n=62) at 16 mg / kg (up to 1,200 mg) compared to placebo, as shown in Figure 10. A prespecified subpopulation of patients aged 60 years or older showed similar improvement in the primary endpoint (n=34), with efficacy being highest in this subpopulation, the population most vulnerable to severe complications and death from COVID-19 infection. Patients treated with anti-LIGHT monoclonal antibody in this subpopulation also had shorter hospital stays compared to patients treated with placebo.

[0243] In addition, 62 patients were included in the intention-to-treat (ITT) analysis of the primary endpoint because of the protocol allowing patients to receive high-flow oxygen before randomization.At the date of data availability, there was a numerical mortality benefit in favor of the anti-LIGHT monoclonal antibody, with four patient deaths on active drug and nine deaths on placebo.

[0244] A single dose of anti-LIGHT monoclonal antibody reduced mortality by approximately 50% in the study, observed at both 28 and 60 days. 28-day mortality was substantially reduced in patients treated with anti-LIGHT monoclonal antibody (3 patients) versus placebo (6 patients). 28-day mortality was 7.7% in patients treated with anti-LIGHT monoclonal antibody and 14.3% in patients treated with placebo. 60-day mortality was 10.8% in patients treated with anti-LIGHT monoclonal antibody and 22.5% in patients treated with placebo.

[0245] >90% of patients in the trial received corticosteroids and >65% received remdesivir, therefore, anti-LIGHT monoclonal antibody demonstrated statistically significant efficacy above corticosteroids and standard of care in COVID-19 ARDS.

[0246] Anti-LIGHT monoclonal antibodies dramatically and rapidly reduced serum free LIGHT levels in these patients (approximately 85% reduction in free LIGHT in 1 day). Referring to FIG. 9, squares are subjects treated with placebo and circles are subjects treated with anti-LIGHT monoclonal antibodies. Table 8 shows LIGHT levels over time (n, mean, SD, min, and max) for patients in the study who received placebo, and Table 9 shows LIGHT levels over time (n, mean, SD, min, and max) for patients in the study who received anti-LIGHT monoclonal antibodies. [Table 8] [Table 9]

[0247] Table 10 shows IL-6 levels over time (n, mean, SD, min, and max) for patients in the study who received placebo, and Table 11 shows IL-6 levels over time (n, mean, SD, min, and max) for patients in the study who received anti-LIGHT monoclonal antibody. [Table 10] [Table 11]

[0248] The anti-LIGHT monoclonal antibody was safe and well tolerated, with no apparent differences in immunosuppression or other SAEs between the anti-LIGHT monoclonal antibody and placebo. Specifically, the anti-LIGHT monoclonal antibody was well tolerated at a single dose of 16 mg / kg, there were no serious adverse events attributable to the anti-LIGHT monoclonal antibody, the majority of AEs were judged to be mild or moderate, and there was no evidence of an increase in infections or adverse events related to immunosuppression (see Table 12 below). [Table 12]

[0249] Example 4 Free LIGHT detection assay Capturing free LIGHT using candidate pairs Free LIGHT was detected and measured with high sensitivity using the Simoa™ Ultrasensitive Assay (Myriad RBM), using Quanterix's automated immunoassay platform: Simoa HD-1 Analyzer and single molecule array (Simoa) technology. All incubations are performed at room temperature inside the Simoa HD-1 Analyzer. Capture antibody-conjugated paramagnetic beads were incubated with standards, samples, or controls, and biotinylated detection antibodies. The beads were then washed and incubated with streptavidin-β-galactosidase (SβG). After a final wash, the beads were added to a Simoa Disc with the enzyme substrate resorufin β-galactopyranoside (RGP). The fluorescent signal is compared to a standard curve, and the amount of LIGHT release is determined for each sample. After pairwise screening of anti-LIGHT antibodies for the sandwich immunoassay, the assay was performed with one candidate pair (capture antibody: Enzo ALX-804-841-C100, detection antibody: ProSci RF16062; specific epitopes not detailed for these antibodies) and tested for linearity and specificity.

[0250] Linearity is a measure of the acceptable sample dilution of the analyte and is measured by the ability to obtain results proportional to the analyte concentration in the sample upon serial dilution. It was shown that samples diluted 2x, 4x, 5x, 10x, 20x, 40x, and 80x maintained linearity. Linearity performed at 1:10, 1:20, and 1:40 is shown in Figure 1. Linearity performed at 1:10, 1:20, 1:40, and 1:80 is shown in Figure 2.

[0251] Free LIGHT detection antibody vs. DCR3 interference DcR3 interference was tested with the candidate pair Enzo ALX-804-841-C100-ProSci RF16062 (capture-detection). Diluents containing free LIGHT were used, rather than native free LIGHT in serum or plasma samples. DcR3 spike concentrations were 10,000ng / ml and 11 lower series concentrations. Signal inhibition values ​​were calculated as the signal reduction (mean fluorescence intensity (MFI)) of the Enzo / ProSci pair, as shown in Figure 3. DcR3 shows 96.3% signal inhibition (=(9938-361) / 9938) for the candidate pair. This demonstrated that the epitope of free LIGHT for the tested pair overlaps with the epitope of free LIGHT for DcR3. Thus, this indicates that the candidate pair binds to free LIGHT.

[0252] Free LIGHT detection antibody vs. DcR3 interference comparison Spiking and recovery experiments were performed to evaluate DcR3 (10 μg / mL) interference in the candidate pair Enzo ALX-804-841-C100-ProSci RF16062 (capture-detection). Serum and plasma samples containing native free LIGHT were incubated with (spiked) and without (unspiked) 150 pg / mL free LIGHT (LIGHT standard recombinant antigen). The spiked and unspiked samples were then incubated with DcR3.

[0253] Based on the MFI data, the % recovery signal was calculated compared to the control without interference, as shown in Figure 4A. The % recovery signal with interference is divided by the signal of the control. Signal inhibition values ​​were calculated for serum 1 without supplementation (having the most significant reduction). In the set shown in Figure 4A, 78% represents a reduction in signal, related to (100%-% recovery). That is, the DcR3 recovery rate of serum 1 is 22%, representing a 78% reduction in signal. In addition, in the sample group spiked with LIGHT (150 pg / ml) (lower panel), sample serum 1 shows 92% inhibition (8% recovery).

[0254] Another dataset from the same experiment but using ProSci RF16062-LSBio LS-C133566-100 (capture-detection) is shown in Figure 4B.

[0255] Graphs characterizing DcR3 interference using recovery of each candidate pair in native free LIGHT and spiked free LIGHT samples are shown in FIG. 4C. Candidate pair Enzo ALX-804-841-C100-ProSci RF16062 (capture-detection) was identified as a native free LIGHT binder because it competed with DcR3 and anti-LIGHT antibodies with a degree of competition of over 60%. For this pair, serum was the preferred sample to detect free LIGHT compared to plasma. Sensitivity has not yet been fully characterized, but it suggests that the sample can be diluted 10-fold, lowering the background. In contrast, the relatively little DcR3 interference by % recovery signal for candidate pair ProSci RF16062-LSBio LS-C133566-100 (capture-detection) indicates that the pair does not bind native free LIGHT effectively, and yet both candidate pairs bound to the non-native LIGHT standard recombinant antigen to approximately the same extent.

[0256] Assay Validation The free LIGHT assay using the free LIGHT binding agent pair is tested for assay validation parameters of minimum detectable dose, lower limit of quantification, upper limit of quantification, dynamic range, precision, spike recovery, linearity, matrix interference, freeze-thaw stability, and short-term analyte stability and meets the acceptance criteria for the parameters listed above to reproducibly quantify free LIGHT levels in serum / plasma samples.

[0257] Antibody competition was performed to assess whether any non-specific binding occurred. Serum and plasma samples were incubated with and without 50 μg / mL capture antibody for 35 minutes at room temperature and then analyzed on a Quanterix HD-1 instrument. Recovery was calculated as the capture antibody treated (competition) sample concentration versus the untreated (control) sample concentration. The % recoveries were all 0%, well within the acceptance criteria of ≦20%.

[0258] Example 5 Free LIGHT levels in Crohn's disease samples FIG. 5 shows free LIGHT levels in serum samples from 89 Crohn's disease (CD) subjects selected and grouped according to disease duration. 89 subjects and 10 healthy controls (gender and age matched) were measured using the free LIGHT assay described herein using the candidate antibody pairs. After excluding outliers, 62 samples and 7 controls were analyzed. Crohn's disease subjects showed significantly higher serum free LIGHT levels (527.93 pg / ml, mean in subjects 0-1 month from disease) than healthy controls (40.43 pg / ml, P<0.0021). Free LIGHT serum levels also correlate with disease program. This suggests that free LIGHT represents a potential target for the treatment of CD and that the free LIGHT assay can serve as a companion diagnostic for anti-LIGHT therapy.

[0259] Example 6 This is an escalating dose, open-label, signal detection study to evaluate the safety, tolerability, and short-term efficacy of an anti-LIGHT monoclonal antibody in adults with moderate to severe active Crohn's disease who have failed prior treatment with an anti-TNFα agent, with or without loss-of-function mutations in decoy receptor 3 (DcR3). The anti-LIGHT antibody has a VH of SEQ ID NO:8, and a VL of SEQ ID NO:9.

[0260] Example 6.1 - Study Objectives and Endpoints The primary objective of this study is to evaluate the safety and tolerability of anti-LIGHT monoclonal antibody administered by SQ injection in adults with moderately to severely active CD who have failed prior treatment with an anti-tumor necrosis factor alpha (anti-TNFα) agent.

[0261] The secondary objectives of this study are to estimate the plasma concentrations of anti-LIGHT monoclonal antibody administered by SQ injection in adults with moderately to severely active CD and to evaluate the response to treatment with anti-LIGHT monoclonal antibody administered by SQ injection in adults with moderately to severely active CD.

[0262] Example 6.2 - Study Design This is a phase 1b, multicenter, open-label, dose-escalation, signal-finding study evaluating the safety, tolerability, PK, and short-term efficacy of anti-LIGHT monoclonal antibody in adults with moderately to severely active CD who have failed previous anti-TNFα treatment.

[0263] Four subjects with Crohn's disease who meet all eligibility criteria will be enrolled into each of two dose cohorts: The first cohort will receive anti-LIGHT monoclonal antibody 1.0 mg / kg SQ every 14 days (q14).

[0264] Dose escalation will proceed after the first cohort is completed and a decision to proceed to the second cohort is made based on review of cumulative safety, tolerability, pharmacokinetic, and efficacy data by a Data Monitoring Committee. The estimated dose escalation for the second cohort is 3.0 mg / kg SQ q14 days, if permitted by review of safety data.

[0265] Each subject's participation includes a screening period and, if necessary, a 12-week washout period in subjects who are receiving biologic therapy or have been receiving biologic therapy within 12 weeks of the screening visit. For subjects who require a washout period, there is an optional 1-14 days between the screening visit and the start of the washout period, if necessary. Only subjects who do not have detectable biologic levels after an 8-week washout period, except for subjects who require a washout period of the biologic certolizumab pegol (Cimzia), may enter the study after confirmation of undetectable levels; all other subjects (including those who received certolizumab pegol [Cimzia]) are required to complete the full washout period of 12 weeks. The washout period includes the period from the last dose received prior to the screening visit. Subjects who do not require a washout period of the biologic may enter the study after review and confirmation of eligibility at screening. Screening is followed by an 8-week open-label treatment period and a safety follow-up visit approximately 4 weeks after the last dose. The maximum study duration is 26 weeks.

[0266] Study visits will occur at screening and on days 0, 7, 14, 21, 28, 35, 42, 49, and 56. A safety follow-up visit will occur on day 84. The assessment schedule is shown in Table 13. [Table 13-1] [Table 13-2] [Table 13-3] [Table 13-4] [Table 13-5]

[0267] Test period The study will include a screening period, an open-label treatment period, and a safety follow-up visit. The 1.0 mg / kg dose cohort will complete the study period described below, to be determined after review of safety data.

[0268] Screening Period During the screening period (Week -14 to Day 0), all subjects will be assessed for eligibility to participate in the study. At Visit 1, subjects will sign an informed consent form before any study-related procedures or assessments are performed.

[0269] Demographic information will be obtained along with treatment history including CD diagnosis information, CD-related procedures / surgeries, and medication history. Any pre-existing conditions reported at the screening visit will be recorded on the electronic case report form (eCRF) and current medications will also be recorded on the eCRF. Prior CD therapy (lifetime recall) will be recorded on the eCRF with the date reflecting prior use. All safety assessments will be performed including physical examination (including weight measurement), vital signs (blood pressure, pulse, respiratory rate, temperature), 12-lead ECG, laboratory tests, fecal samples, and urine analysis. A urine drug screen (as appropriate) will be performed on all subjects, as well as tuberculosis (TB) testing defined as either a purified protein derivative (PPD) skin test or QuantiFERON-TB Gold (QFT) blood test, and chest x-ray if required per protocol. A serum β-human chorionic gonadotropin (β-hCG) test will be performed on women of potential childbearing potential. A CDAI and Inflammatory Bowel Disease Questionnaire (IBD-Q) will be performed. Subjects will undergo endoscopy with biopsy and histology during the screening period. Subjects will be provided with access to a study diary (electronic or hard copy) to record daily assessments of well-being, abdominal pain, and stool frequency, including loose and watery stools. The diary will be completed for a minimum of 7 days immediately prior to the start of open-label treatment, as described in Table 13. Subjects will record the frequency of loose or watery stools and assess overall abdominal pain daily. Finally, adverse events (AEs) will be monitored.

[0270] Subjects who are receiving biologic therapy or have received biologic therapy within 12 weeks of the screening visit but are eligible for study participation based on review of all screening assessments and results will begin a washout period for these medications. Except for subjects who require a washout of the biologic certolizumab pegol (Cimzia), blood tests will be performed on subjects who undergo an 8-week washout period after the last dose of biologic therapy to ensure that serum levels of any prior biologic therapy are below detection levels. If it is established that the levels of prior biologic therapy are undetectable, subjects will proceed to Visit 2. If test results indicate that prior biologic therapy is detectable, subjects will be required to complete the full 12-week washout period before proceeding to Visit 2. For subjects receiving the biologic certolizumab pegol (Cimzia), a washout period of 12 weeks will be required.

[0271] Open-label treatment period Eligible subjects return to the clinic after the screening period (and washout period, if applicable) at Visit 2, Day 0 of the 8-week open-label treatment period. A physical examination including weight and vital sign assessment, clinical laboratory tests, urinalysis, and CDAI will be performed. A urine β-hCG test will be performed in women of childbearing potential. Any AEs and concomitant medications will be recorded. Blood will be drawn for PK, ADA, and exploratory analyses (including LIGHT, cytokines, RNA sequencing, and flow cytometry). Subjects will record daily assessments of their well-being, abdominal pain, and stool frequency, including loose, watery stools, in their study diary. Diary data will be reviewed for entries during each visit. Subjects will be reevaluated to determine if they meet all inclusion criteria and none of the exclusion criteria.

[0272] Eligible subjects will then be enrolled in the study and receive their first dose of anti-LIGHT monoclonal antibody in the clinic. Subjects will receive anti-LIGHT monoclonal antibody by SQ injection into the abdomen within a zone 4-10 cm from the umbilicus, with the injection site rotated with each subsequent dose. Doses of anti-LIGHT monoclonal antibody will be administered every 14 days (± 3 days) for 8 weeks. Subjects will be monitored for AEs during and for 60 minutes after administration of each dose.

[0273] Enrollment of subjects within cohorts is staggered by at least one day to assess any delayed adverse events.

[0274] Subjects return to the clinic every 14 days (± 3 days) (Visits 4, 6, 8, and 10) after the first anti-LIGHT monoclonal antibody dose for safety, PK, and efficacy assessments and to receive the next dose of study drug, as shown in Table 13. Additional weekly visits occur between dosing visits (Visits 3, 5, 7, and 9) when blood is drawn for PK analyses, subjects are provided with access to a study diary (electronic or hardcopy) for diary data collection, and AEs and concomitant medication use are recorded.

[0275] Prior to enrolling subjects in the second dose cohort, all subjects in the first cohort will complete their participation in the study and safety data from those subjects will be reviewed by the Data Monitoring Committee. A recommendation will be provided by the DMC and a decision will be made by the sponsor as to whether the subject can be enrolled in the next dose cohort.

[0276] Safety Follow-up Visit Approximately 28 days after the final dose, subjects will have a safety follow-up visit. The safety follow-up visit will be conducted in the clinic with the subject. Any AEs occurring after the subject's last anti-LIGHT monoclonal antibody dose will be recorded, along with any concomitant medication use.

[0277] Safety Data Review The Investigator will review all available safety data collected at participating sites on a weekly basis and communicate any safety concerns to the Sponsor's Medical Monitor, who will review all relevant safety findings with the Investigator and DMC, coordinating as necessary.

[0278] Particular attention will be paid to adverse drug reactions observed in anti-LIGHT monoclonal antibody preclinical studies, as well as other common adverse reactions exhibited with other biologic therapies, including injection site reactions in anti-LIGHT monoclonal antibodies during preclinical observations. Particular attention will be paid to adverse reactions observed with other biologic therapies, including the potential for increased infections, including opportunistic infections (e.g., tuberculosis), hypersensitivity reactions (including anaphylaxis), immunogenicity, malignancies, immune disorders, and CD exacerbations.

[0279] Data Monitoring Committee An external, independent Data Monitoring Committee (DMC) consisting of physicians, scientists, and biostatisticians will periodically review the study data throughout the study, including meetings after the completion of each cohort and ad hoc meetings to evaluate individual exacerbations of Crohn's disease meeting Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or greater. The role of the DMC is to protect the interests of study subjects and those further into the study by reviewing the accumulating safety, tolerability, pharmacokinetic, and efficacy data. The DMC meeting schedule may be adjusted based on recommendations made by the DMC, the growing volume of safety data, and other practical considerations. Data provided to the DMC may not be monitored and is not considered "complete" until the database is locked at the end of the study.

[0280] Possible outcomes of a DMC review may include one of the following recommendations: the trial may continue, the trial may continue with modifications, and the trial should be terminated.

[0281] The recommendations of the Data Monitoring Committee will be documented in meeting minutes that will include, at a minimum, the following: a list of meeting participants, a summary of the data reviewed during the meeting, and a summary of the DMC recommendations regarding further dose cohorts, including any concerns raised.

[0282] The sponsor is responsible for the decision to continue, modify, or terminate the study. A copy of the DMC meeting recommendation and sponsor's decision will be sent to the study site prior to administration of the next subject dose or start of the next cohort.

[0283] Stopping criteria for individual subjects The following individual subject stopping criteria will be used during the study and will be evaluated beginning after dosing at Visit 2. An individual subject will be stopped from the study if he or she develops any of the following CTCAE Grade 3 or greater: injection site reaction; opportunistic infection (i.e., tuberculosis); hypersensitivity reaction (e.g., allergic reaction, anaphylaxis, or cytokine release syndrome); malignancy; decreased white blood cell count; decreased neutrophil count; decreased platelet count; colonic or ileal bleeding; colonic, ileal, or small bowel obstruction; colonic, ileal, or small bowel perforation; and colonic, ileal, or small bowel stenosis.

[0284] Subjects should also be stopped if their liver enzymes are ALT or AST >8xULN; ALT or AST >5xULN for more than 2 consecutive weeks; or ALT or AST >3xULN, with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and / or eosinophilia (>5%). Note that subjects who show ALT or AST >3xULN without the appearance of any of the above symptoms are required to repeat the test within 48-72 hours to confirm the abnormality and determine the direction (increase or decrease) from the initial value. If Hy's Law is detected (i.e., ALT or AST >3xULN and total bilirubin >2xULN, and no other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C, pre-existing or acute liver disease, or another drug that could cause the observed injury), the subject will be stopped.

[0285] Test Stopping Criteria The following study stopping criteria will be used during the study. The study will be stopped if two or more subjects develop the same CTCAE grade 3 or if one subject develops the following CTCAE grade 4: injection site reaction, opportunistic infection (i.e., tuberculosis), hypersensitivity reaction (e.g., allergic reaction, anaphylaxis, or cytokine release syndrome), malignancy, decreased white blood cell count, decreased neutrophil count, or decreased thrombocytopenia. The study will be stopped if two individual subjects develop any of the following hepatotoxicity: ALT or AST >8×ULN; ALT or AST >5×ULN for 2 or more consecutive weeks; or ALT or AST >3×ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and / or eosinophilia (>5%).

[0286] If a single subject is found to fulfill Hy's Law (i.e., ALT or AST > 3xULN and total bilirubin > 2xULN, and no other reason can be found to explain the combination of elevated AT and TBL, such as viral hepatitis A, B, or C, pre-existing or acute liver disease, or another drug capable of causing the observed injury), the study will be stopped.

[0287] Individual reports of worsening Crohn's disease CTCAE grade 3 or greater, such as colonic or ileal bleeding; colonic, ileal, or small bowel obstruction; colonic, ileal, or small bowel perforation; or colonic, ileal, or small bowel stenosis, will be reviewed by the DMC on the first available day after the report and a decision will be made whether to modify or stop the study.

[0288] Test Design Rationale This is the second study in which anti-LIGHT monoclonal antibody is administered to human subjects and the first in subjects with treatment-resistant CD. The study is a pilot study using a dose-escalation design to characterize the safety and tolerability of two different doses of anti-LIGHT monoclonal antibody (1.0 mg / kg and 3.0 mg / kg) in the target population. The dose-escalation design allows for the evaluation of safety and tolerability in a small number of subjects before progressing to the next dose level. Open-label administration of anti-LIGHT monoclonal antibody to all enrolled subjects minimizes the number of subjects undergoing study procedures. Inclusion of PK blood sampling and efficacy assessments allowed for preliminary evaluation of plasma levels and efficacy, respectively.

[0289] No specific hypotheses will be tested in this pilot study. All data will be summarized using descriptive statistics as appropriate.

[0290] Number of subjects For a maximum of eight subjects, four subjects will be enrolled in each of the two planned dose cohorts. Subjects who leave the study early will be allowed to be replaced prior to the third dose.

[0291] Treatment Allocation Subjects in the first cohort will be assigned to a 1.0 mg / kg dose of anti-LIGHT monoclonal antibody. Subjects will be assigned to the second dose cohort following DMC review of safety data from the first cohort, provided that no study stopping criteria are met.

[0292] Subject Inclusion Criteria Subjects who meet all of the following inclusion criteria are eligible to enroll in the study. 1. Subjects must be fluent in English and provide written informed consent for this study. 2. Subjects are male or female, ≥18 to ≤75 years of age. 3. Subject has a documented diagnosis of CD by endoscopy / colonoscopy and histological confirmation. 4. Subject has moderate to severe active CD as evidenced by a Simple Endoscopy Study of Crohn's Disease (SES-CD) score of ≧7 and histological confirmation. 5. Subject has failed treatment with an approved therapeutic dose of anti-TNFα monoclonal antibody therapy, as defined below, either by lack of initial response (primary non-responder) or by initial response to induction followed by no subsequent response (secondary non-responder). 6. Subject is allowed to receive concomitant treatment with oral corticosteroids and / or azathioprine or 6-mercaptopurine (6-MP) or methotrexate (MTX). 7. Subject agrees to be genotyped at the DcR3 locus.

[0293] A primary non-responder is defined as a subject in whom treatment with infliximab, adalimumab, or certolizumab pegol produced an inadequate initial response. Details of inadequate initial response symptoms occur ≧2 weeks after the last dose of induction therapy. The algorithm for defining an inadequate initial response is provided below. Subjects classified as primary non-responders meet both parts of the algorithm. Required documentation includes the date and dose of failed induction therapy and details of the lack of response in terms of disease activity recorded by the treating clinician.

[0294] The following algorithm is used for inadequate initial response to current or prior therapy with infliximab, adalimumab, or certolizumab pegol. Subjects have received induction doses of either infliximab (2 or 3 doses of ≥ 5 mg / kg), adalimumab (160 mg dose followed by ≥ 80 mg dose, or 80 mg dose followed by ≥ 40 mg dose), or certolizumab pegol (2 or 3 doses of ≥ 400 mg), and subjects have not initially responded to these induction doses as documented by the presence of at least one of the following signs or symptoms associated with Crohn's disease activity: lack of improvement or worsening of stool frequency; lack of improvement or worsening of daily abdominal pain; onset, lack of improvement, or worsening of fever associated with Crohn's disease; recurrent draining from a previous non-draining fistula or onset of a new draining fistula; lack of improvement or worsening of rectal bleeding; or initiation or increase of an anti-diarrheal medication.

[0295] A secondary non-responder is defined as a subject whose treatment with infliximab, adalimumab, or certolizumab pegol produced an initial response without subsequent response. Details of the lack of response occur >2 weeks after the last dose of maintenance therapy. The algorithm for defining the lack of response is described below. Subjects classified as secondary non-responders meet both parts of the algorithm. Documentation required includes the initial response and subsequent lack of response, including induction and maintenance dates and doses, details on disease activity recorded by the treating clinician. Below is the algorithm for lack of response to prior therapy with infliximab, adalimumab, or certolizumab pegol. Subjects responded to induction therapy at the doses above and received at least two maintenance doses of infliximab (>5 mg / kg), adalimumab (at doses >40 mg, or if failed as a pediatric dose of >20 mg), or certolizumab pegol (>400 mg) and failed to respond to these maintenance doses as documented by the presence of at least one of the following signs or symptoms associated with Crohn's disease activity: worsening stool frequency; worsening daily abdominal pain; development or worsening of Crohn's disease-associated fever; recurrent draining from a previous non-draining fistula or development of a new draining fistula, worsening rectal bleeding; or initiation or increase in an anti-diarrheal medication.

[0296] Subject Exclusion Criteria Subjects who meet any of the following exclusion criteria are not eligible to enroll in the study. 1. Subject has a diagnosis of ulcerative colitis (UC) or indeterminate colitis. 2. Subject is unable or unwilling to tolerate study procedures, including endoscopy and biopsy, during the study. 3. Subject has signs or symptoms of bowel obstruction with small bowel imaging supporting obstruction. 4. Subject has short bowel syndrome as determined by the investigator. 5. Subject has a currently functioning colostomy or ileostomy. 6.Subject has had a surgical bowel resection within the past 6 months prior to screening or is scheduled to have any resection during the study period. 7. Clinical suspicion of intra-abdominal abscess present in the opinion of the investigator. 8. Subject has concurrent intestinal metaplasia or a history of intestinal metaplasia within the 5 years prior to screening. 9. Subject has known, active C. difficile infection and / or a positive test for C. difficile infection. 10. Subject has a history or current diagnosis of any cancer other than cancer that has been cured by surgical resection (e.g., non-melanoma skin cancer). 11. Subject has a history of a lymphoproliferative disorder, including lymphoma, or signs and symptoms suggestive of a lymphoproliferative disease at any time. 12. Subject has a history of active TB infection, has active TB infection, or has a positive TB test at screening. 13. Subject has known concurrent viral hepatitis, or acquired immune deficiency syndrome (AIDS) or known human immunodeficiency virus (HIV) infection. 14. Subject has been treated with natalizumab (TYSABRI®). 15. Subject has not completed the primary vaccination series (specifically Hepatitis B, Chickenpox, Measles / Mumps / Rubella) and immunity is not documented by blood titers. 16. Subject received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit. 17. Subject has the following abnormal screening test results: clinically significant ECG abnormalities; aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin >ULN; hemoglobin <10g / dL; absolute neutrophil count <1500 cells / mm 3 or estimated glomerular filtration rate <60 mL / min / 1.73 m 2 , . 18. Subject has abnormal vital signs during Screening (Visit 1) or prior to enrollment at the Baseline visit (Visit 2). 19. Subject is a pregnant or nursing mother. 20. Subject is sexually active and not on effective contraception. 21. Subject has a history of substance abuse that may preclude participation in a clinical trial. 22. Subject has current or recent history (within 6 months prior to screening) of significant and severe renal, hepatic, hematological, gastrointestinal (excluding CD or conditions outlined above), endocrine, pulmonary, cardiac, or neurological disease. 23. The subject has any other clinically significant mental or physical illness or infection that, in the opinion of the Investigator, may confound the results of the study, or participation may pose additional risk to the subject, or which may prevent or delay the subject from completing the study. 24. The investigator has any concerns about the subject's safety, compliance, or suitability for participation in the trial.

[0297] Screening failure Subjects who do not meet the inclusion and / or exclusion criteria may be rescreened for the study with prior approval of the Sponsor's Medical Monitor. In the event of a rescreening, the initial screening visit will be entered into the eCRF as a Screening Visit (Visit 1) and the repeat assessment will be entered into the eCRF as an unscheduled visit.

[0298] Subject Withdrawal Criteria All subjects are advised that they are free to withdraw from participation in this study at any time, regardless of reason, without prejudice. The Investigator will make all reasonable attempts to keep the subject in the study, but if the subject withdraws consent to participate, the subject will be withdrawn from the study. For subjects who do not attend a scheduled visit, the Investigator will attempt to contact the subject by phone or other means to rule out the possibility that an AE is the cause of withdrawal. If it is the cause, the AE will be documented, reported, and followed up.

[0299] The sponsor reserves the right to request that a subject withdraw due to protocol violations or other reasons.

[0300] The Investigator also has the right to withdraw a subject from the study at any time because of lack of treatment effect that is intolerable or other unacceptable to the subject, because of a concomitant illness that is an intolerable or unacceptable AE, because of meeting the individual subject stopping criteria, for non-compliance with study procedures, for administrative reasons, or to protect the best interests of the subject in the Investigator's opinion.

[0301] If a subject withdraws before completing the study, the reason for withdrawal and discontinuation date will be recorded on the appropriate eCRF. If possible and reasonable, assessments performed at the completion of the open-label treatment period (i.e., Visit 10) will be performed at the time of early termination.

[0302] Subjects who withdraw before receiving the third dose of study drug may be replaced, if possible.

[0303] All samples will be retained in accordance with applicable rules and regulations. Blood and biopsy samples will be stored and used for further analyses related to this study. Saliva samples have been authorized for use for purposes related to this study. Samples will be given a unique code that does not contain any information indicating the subject's name. Remaining DNA samples will be stored for future biomarker testing.

[0304] Example 6.3 - Treatment of Subjects Explanation of the investigational drug Subjects in each dose cohort will receive the investigational drug as a single SQ injection into the abdomen within a zone 4-10 cm from the umbilicus, with the injection site rotating with each subsequent dose. Doses of anti-LIGHT monoclonal antibody will be administered on days 0, 14, 28, and 42. After day 0, injections will occur within ±3 days of scheduled 14-day intervals.

[0305] Subjects in the first dose cohort will receive 1.0 mg / kg of anti-LIGHT monoclonal antibody for a full 8-week open-label treatment period. Data from this cohort will be reviewed after all subjects have completed the treatment period and its associated assessments, but before the second cohort is enrolled. It is expected that there will be at least 2 weeks between a subject's last visit and review of cumulative safety, tolerability, pharmacokinetic, and efficacy data.

[0306] Eligible subjects in the second dose cohort will receive 3.0 mg / kg of anti-LIGHT monoclonal antibody for a full 8-week open-label treatment period. Data from the second cohort will be reviewed after all subjects have completed the treatment period and its associated evaluations.

[0307] Any quality problems noted in connection with the receipt or use of investigational products provided by the sponsor (defects in condition, packaging, appearance, documentation, labeling, expiration date, etc.) will be promptly communicated to the sponsor, who will conduct an investigation.

[0308] Potential defects in the quality of the investigational product provided by the sponsor may result in the initiation of a recall procedure by the sponsor, in which case the investigator is responsible for promptly responding to any request by the sponsor to retrieve the investigational product and eliminate the potential hazard.

[0309] Permitted and Prohibited Therapies All lifetime prior CD therapies and concomitant medications used (including over-the-counter medications and herbal supplements) will be recorded in source documents and appropriate eCRFs.

[0310] Permitted Therapies Subjects are permitted to receive concomitant treatment with oral corticosteroids and / or azathioprine, 6-MP, or MTX. Subjects are not permitted to increase the dose of these medications during the study. If a dose increase of permitted concomitant therapy is required, subjects will be discontinued from the study utilizing an Early Termination Visit procedure. Concomitant treatment with oral corticosteroids and / or azathioprine, 6-MP, or MTX is defined as follows: Oral corticosteroids - a prednisone dose not to exceed 40 mg / day with a stable dose for at least 2 weeks prior to baseline; Azathioprine or 6-MP - an azathioprine dose of at least 2 mg / kg / day or a 6-MP dose of 1 to 1.5 mg / kg / day rounded to the nearest available tablet formulation for at least 8 weeks prior to baseline with a stable dose for at least 4 weeks prior to baseline, or the dose highest tolerated by the subject in the opinion of the investigator; or an MTX dose of 25 mg / week during the study, either SQ, IM, or orally, for at least 8 weeks prior to baseline with a stable dose for at least 4 weeks prior to baseline.

[0311] Doses of these therapies will be allowed to be reduced during the study, but all doses will be within the combinations and dose ranges specified above. These changes will be recorded in the Concomitant Medications eCRF.

[0312] For subjects taking corticosteroids at study enrollment, weaning during the study will be performed according to the following rules: corticosteroid dose >20 mg and a maximum tapering rate of 10 mg per week; 10 to <20 mg and a maximum tapering rate of 5 mg per week; or <10 mg and a maximum tapering rate of 2.5 mg per week. Subjects will be withdrawn from study participation if deviations from permitted concomitant therapy combinations, dose ranges, or weaning schedules are necessary.

[0313] Prohibited Therapies Concomitant biologic therapy during the study is prohibited and includes use of anakinra (KINERET®, Amgen), abatacept (ORENCIA®, Bristol-Myers Squibb), or tocilizumab (ACTEMRA®, Genentech). A washout period of up to 12 weeks is required for all biologic therapy received within 12 weeks of the screening visit prior to study enrollment (Visit 2) and after confirmation of eligibility from the screening procedure performed at Visit 1. Prior treatment with natalizumab (TYSABRI®, Biogen) will exclude subjects from participation.

[0314] Vaccination with live or attenuated virus within 3 months prior to screening and at any time during the study is prohibited.

[0315] Contraception Sexually active study participants agree to use effective contraception during the study and for a defined period after completion of the study visit. Approved methods require a double barrier according to the following algorithm: condom + intrauterine device or condom + hormonal contraceptive. When subjects are sterilized, sterilization procedures are required to be completed ≥ 3 months prior to the study screening visit.

[0316] Sexually active male participants will be required to use one of the dual barrier contraceptive methods listed above during the study and for 3 months following the completion of the study visit. Sexually active female participants will be required to use one of the dual barrier contraceptive methods listed above during the study and for 1 month following the completion of the study visit.

[0317] Male subjects also agree not to donate sperm during the study and for up to three months after the end-of-study visit.

[0318] Study participants who are abstinent at the time of study entry agree to use the approved methods described in this section if they become sexually active during the study.

[0319] Treatment Compliance Treatment with anti-LIGHT monoclonal antibody will be administered by study center personnel under direct medical supervision and appropriate records will be made in the source data by the investigator or his / her designee. The investigator or designee will record administration information on the appropriate eCRF page. It is the investigator's responsibility to ensure that accurate records of administration of investigational product are maintained.

[0320] Randomization and blinding All subjects will receive the anti-LIGHT monoclonal antibody in an open-label fashion.

[0321] Treatment after the end of the study Upon successful enrollment, and subsequent completion or early termination of the study, each subject will be treated according to standard clinical practice. To assist subjects in transitioning out of the clinical trial, aftercare medical expenses, including co-payments and out-of-pocket medical / treatment-related costs, will be covered in the sum of $5,000.00 and may be used for up to a full six months following study termination. Aftercare payments will be administered by a third-party vendor contracted by the Sponsor.

[0322] Example 6.4 - Investigational Drug Materials and Control Investigational Drug Anti-LIGHT monoclonal antibody is the investigational drug used in this study. The dosage form is administered in a 150 mg / mL solution. The unit dose is 1.0 mg / kg or 3.0 mg / kg. The route of administration is SQ injection into the abdomen within the zone 4-10 cm from the umbilicus, and the injection site is rotated for each subsequent dose. It is in a colorless to slightly yellowish brown solution. It is manufactured by the Sanofi-Aventis group.

[0323] Packaging All packaging and labeling activities will be performed by the sponsor or designee in accordance with Good Manufacturing Practice and Good Clinical Practice (GCP) regulations. The investigational product will be shipped to the study site by the sponsor or designee. Labeling will be in the local language and will depend on local regulations.

[0324] display The vials and cartons are labeled to meet applicable regulatory requirements.

[0325] The Investigator will retain all unused or partially used drug vials and all empty packaging for ultimate disposal by the local (Colombia and Israel sites) or sponsor (US sites). Syringes used for administration will be treated as biological waste and disposed of appropriately.

[0326] keep All investigational products will be stored at 2°C to 8°C and protected from light. The investigator or other authorized person (e.g., pharmacist) is responsible for ensuring that all investigational products provided by the sponsor are stored securely and in a safe place in accordance with local regulations, labeling specifications, and institutional policies and procedures.

[0327] Control of storage conditions of the investigational product provided by the sponsor, in particular temperature control (e.g., refrigeration) and daily temperature monitoring, as well as in-use stability information and instructions for handling the investigational product, will be controlled in accordance with regulations provided by the sponsor.

[0328] Administration Anti-LIGHT monoclonal antibody is administered by SQ injection into the abdomen within a zone 4-10 cm from the umbilicus, with the injection site rotated with each subsequent administration.

[0329] Accountability The investigator will maintain appropriate records showing receipt, administration, or other disposition of the investigational drug, including date, lot identifier, dose, volume administered to each subject, and identification of subjects receiving the investigational drug (subject number and initials). The investigator will not be permitted to supply the investigational drug to any other location or person other than the co-investigator on the FDA 1572 form, the designated study personnel, and the subjects in this study. The investigator will not be permitted to dispense the investigational drug from any study site other than those listed on the FDA 1572 form. If any of the investigational drug is not dispensed, lost, stolen, spilled, unusable, or received in damaged containers, this information will be documented and reported to the sponsor and appropriate regulatory authorities as appropriate.

[0330] Upon completion of the study, unused investigational product will be left in its original packaging for final disposal at the local (Colombian and Israeli sites) or sponsor (US sites). All partially used investigational product and all empty packaging (e.g., vials) will be retained for final disposal at the local (Colombian and Israeli sites) or sponsor (US sites) and returned to the sponsor's designee for destruction.

[0331] Handling and Disposal Reconciliation of the investigational product will be performed at the site by the investigator and monitoring team using a treatment log form and documented on a site inventory countersigned by the investigator and monitoring team.

[0332] After cross-approval by the sponsor, all used, partially used, and unused vials and all original packaging will be disposed of locally (Colombia and Israel sites) or by the sponsor (US sites), a process provided to the sites by the sponsor's designee.

[0333] Example 6.5 - Test Procedures and Evaluation Subjects will provide written informed consent, including discontinuation of prohibited concomitant medications, before any study-related procedures are initiated.

[0334] Refer to the Schedule of Assessments (see Table 13) for timing of assessments and procedures throughout the study. Throughout the study, study personnel will make every reasonable effort to follow the timing of assessments and procedures in the Schedule of Events for each subject. Visits conducted after the Visit 2 baseline visit will be scheduled for Visit 2 every 14 days ± 3 days to maintain open-label treatment and dosing for 56 days. If a subject misses a study visit for any reason, the visit will be rescheduled as soon as possible. The window for each study visit after Visit 2 is ± 3 days. Visit procedures will be performed in the order shown, but can be ordered to accommodate site-specific requirements.

[0335] Study period and visits: Screening (Visit 1, Week -14 to Day 0) Subjects will be screened within 14 weeks prior to enrollment in the study. The following procedures will occur at screening: 1. Obtain written informed consent 2. Review inclusion / exclusion criteria 3. Genotyping of the DcR3 gene 4. Collect demographic information 5. Record medical and medication history 6. Conduct a complete physical examination, including weight measurement 7. Collect vital signs, including systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature. 8. Performing a 12-lead ECG 9. Collect blood samples for laboratory testing 10. Administer the QuantiFERON-TB Gold (QFT) blood test or PPD skin test. If the subject has a PPD skin test ≥ 5mm, a confirmatory chest x-ray is required. 11. Collect a blood sample for β-hCG testing (women of childbearing potential only) 12. Collect fecal samples for C. difficile and fecal calprotectin analysis 13. Collect a urine sample for urinalysis 14. Collect urine samples for drug testing, if required 15. Conduct CDAI 16. Complete the IBD-Q questionnaire 17. Perform endoscopy with biopsy 18. Assess and record AEs and concomitant medications 19. Provide access to a patient diary (electronic or hard copy) to record abdominal pain, general well-being, and frequency of stools containing loose or watery stools (6 or 7 on the Bristol Stool Form Scale), as well as the severity of daily abdominal pain (scale of 0 to 10).

[0336] Note that stool samples can be obtained at any time during the visit. Subjects who do not meet the clinical laboratory enrollment requirements may be retested once as part of the screening period. Extension of the screening window to accommodate clinical laboratory retest windows (excluding endoscopy with biopsy) is permitted, but the total screening period, including endoscopy and drug holidays, should not exceed 16 weeks.

[0337] Study period and visits: Eligibility check / washout period (week -12 to day 0) Each subject will receive a phone call no later than Week -12 (i.e., 12 weeks prior to the planned start of treatment). This call will confirm the subject's continued eligibility. For subjects who do not require a washout period after review and confirmation of eligibility during this call, subjects will be instructed to begin recording their daily abdominal pain assessment, general well-being assessment, and stool frequency, including frequency of loose, watery stools, in their diary for at least 7 days immediately prior to Visit 2. Once completed, subjects will return >7 days after the initial phone call for Visit 2. Any changes in concomitant medication use and new-emerging AEs since the last assessment was recorded will be recorded.

[0338] For subjects who require a drug break, subjects will be asked to begin a drug break from their current biologic treatment, if eligible. Except for subjects who require a drug break from the biologic certolizumab pegol (Cimzia), blood tests will be performed on subjects undergoing a drug break 8 weeks after the last dose of biologic treatment to ensure that serum levels of any prior biologic treatment are below detection levels. If levels of prior biologic treatment are confirmed to be undetectable, subjects will be instructed to begin recording their daily abdominal pain assessment, general well-being assessment, and stool frequency, including frequency of loose watery stools, in their diary for at least 7 days immediately prior to dosing. Once completed, subjects will return >7 days after the drug break call for Visit 2. If study results indicate that prior biologic treatment is detectable, subjects will be required to complete the full 12-week drug break period. For subjects receiving the biologic certolizumab pegol (Cimzia), a 12-week drug break is required. Upon completion of the washout period, subjects will begin completing a daily diary and will have Visit 2 scheduled >7 days after the end of washout. The diary will be completed up until the time of the visit. Any changes in concomitant medication use and new-emerging AEs since the last assessment recorded will be recorded.

[0339] If a subject is ineligible, the subject may have had any changes in concomitant medications since the last recorded assessment and any newly occurring AEs and may be excluded from screening.

[0340] Study Periods and Visits: Open-label Treatment Period, Baseline Visit (Visit 2, Day 0) Prior to administration of the first dose of study drug on Day 0, the following procedures will be performed: 1. Review inclusion / exclusion criteria to determine continued eligibility or screening failure status. If the subject is still eligible for the study, the subsequent procedures will be performed. If the subject is ineligible, any changes in concomitant medication use and any newly occurring AEs since the last evaluation will be recorded and the subject will be removed from screening. 2. Conduct a complete physical examination, including measuring height and weight 3. Collect vital signs, including systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature. 4. Collect blood samples for laboratory testing 5. Collect Blood Samples for Plasma Anti-LIGHT Monoclonal Antibody Concentration and PK Analysis 6. Collect Blood Samples for Plasma ADA Analysis 7. Collect blood samples for exploratory analyses defined in Table 13 8. Collect a urine sample for urinalysis 9. Collect a urine specimen for urinary β-hCG testing (women of childbearing potential only) 10. Perform CDAI and IBD-Q 11. Check your journal entries 12. Assess and record concomitant medications and new emerging AEs since the last evaluation.

[0341] In addition, any ongoing AEs since the previous visit will be assessed and any changes in their status will be recorded.

[0342] After completing the assessments, subjects will receive anti-LIGHT monoclonal antibody by SQ injection into the abdomen within a zone 4-10 cm from the umbilicus, with the injection site rotated with each subsequent administration. Vital sign assessment will be performed within 60 minutes after administration.

[0343] After receiving the study drug, subjects will remain in the clinic for 60 minutes, during which time the following details will be recorded: 1. AEs occurring after administration 2. All concomitant medications administered after administration 3. Evaluate subject responses and available outcomes against individual stopping rule criteria.

[0344] Following completion of post-dose assessments, subjects will be allowed to leave the clinic.

[0345] Study Period and Visits: Open-Label Treatment Period, Visit 3 (Day 7 [± 3 days]) Subjects will return to the clinic on Day 7 (± 3 days), at which time the following procedures will be performed: 1. Collect Blood Samples for Plasma Anti-LIGHT Monoclonal Antibody Concentration and PK Analysis 2. Assess and record AEs and concomitant medications 3. Review your journal entries 4. Evaluate subject response and available outcomes against individual stopping rule criteria. In addition, any ongoing AEs since the previous visit were evaluated and any changes in their status were recorded.

[0346] Study period and visit: Visit 4 (Day 14 [± 3 days]) Subjects will return to the clinic on Day 14 (± 3 days), at which point the following procedures will be performed prior to dosing: 1. Conduct a brief physical examination, including weighing 2. Collect vital signs, including systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature. 3. Collect blood samples for laboratory testing 4. Collect Blood Samples for Plasma Anti-LIGHT Monoclonal Antibody Concentration, PK, and ADA Analysis 5. Conduct CDAI 6. Review your journal entries 7. Assess and record concomitant medication use and any new AEs since the last evaluation.

[0347] In addition, any ongoing AEs since the previous visit will be assessed and any changes in their status will be recorded.

[0348] After completing these assessments, subjects will receive anti-LIGHT monoclonal antibody by SQ injection into the abdomen within a zone 4-10 cm from the umbilicus, with the injection site rotated with each subsequent administration. Vital sign assessments will be performed within 60 min after administration.

[0349] After receiving the study drug, subjects will remain in the clinic for 60 minutes, during which time the following details will be recorded: 1. AEs occurring after administration 2. All concomitant medications administered after administration. Following completion of post-dose assessments, subjects will be allowed to leave the clinic.

[0350] Study period and visit: Visit 5 (Day 21 [± 3 days]) Subjects will return to the clinic on Day 21 (± 3 days), at which time the following procedures will be performed: 1. Collect Blood Samples for Plasma Anti-LIGHT Monoclonal Antibody Concentration and PK Analysis 2. Assess and record AEs and concomitant medications 3. Review your journal entries 4. Evaluate subject responses and available outcomes against each stopping rule criterion.

[0351] In addition, any ongoing AEs since the previous visit will be assessed and any changes in their status will be recorded.

[0352] Study period and visit: Visit 6 (Day 28 [± 3 days]) Subjects will return to the clinic on Day 28 (± 3 days), at which point the following will occur prior to dosing: 1. Perform a complete physical examination, including assessment of vital signs and weight 2. Collect vital signs, including systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature. 3. Perform a 12-lead ECG 4. Collect blood samples for laboratory testing 5. Collect Blood Samples for Plasma Anti-LIGHT Monoclonal Antibody Concentration, PK, and ADA Analysis 6. Collect blood samples for exploratory analyses defined in Table 13 7. Collect Feces for Fecal Calprotectin Analysis 8. Collect a urine sample for urinalysis 9. Collect a urine specimen for urinary β-hCG testing (women of childbearing potential only) 10. Conduct CDAI 11. Review your journal entries 12. Assess and record concomitant medication use and any new AEs since the last evaluation.

[0353] In addition, any ongoing AEs since the previous visit will be assessed and any changes in their status will be recorded.

[0354] After completing these assessments, subjects will receive anti-LIGHT monoclonal antibody by SQ injection into the abdomen within a zone 4-10 cm from the umbilicus, with the injection site rotated with each subsequent administration. Vital sign assessments will be performed within 60 min after administration.

[0355] After receiving the study drug, subjects will remain in the clinic for 60 minutes, during which time the following details will be recorded: 1. AEs occurring after administration 2. All concomitant medications taken after dosing. Note: Stool samples may be obtained at any time during the visit. 3. Evaluate subject responses and available outcomes against individual stopping rule criteria.

[0356] Following completion of post-dose assessments, subjects will be allowed to leave the clinic.

[0357] Study period and visit: Visit 7 (Day 35 [± 3 days]) Subjects will return to the clinic on Day 35 (± 3 days), at which time the following procedures will be performed: 1. Collect Blood Samples for Pharmacokinetic Analysis 2. Assess and record AEs and concomitant medications 3. Review your journal entries 4. Evaluate subject responses and available outcomes against each stopping rule criterion.

[0358] In addition, any ongoing AEs since the previous visit will be assessed and any changes in their status will be recorded.

[0359] Study period and visit: Visit 8 (Day 42 [± 3 days]) Subjects will return to the clinic on Day 42 (± 3 days), at which point the following procedures will be performed prior to dosing: 1. Conduct a brief physical examination, including weighing 2. Collect vital signs, including systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature. 3. Collect blood samples for laboratory testing 4. Collect Blood Samples for Plasma Anti-LIGHT Monoclonal Antibody Concentration and PK Analysis 5. Conduct CDAI 6. Review your journal entries 7. Assess and record AEs and concomitant medications

[0360] In addition, any ongoing AEs since the previous visit will be assessed and any changes in their status will be recorded.

[0361] After completing these assessments, subjects will receive anti-LIGHT monoclonal antibody by SQ injection into the abdomen within a zone 4-10 cm from the umbilicus, with the injection site rotated with each subsequent administration. Vital sign assessments will be performed within 60 min after administration.

[0362] Subjects will remain in the clinic for 60 minutes after administration of the study drug. During this time the following details will be recorded: 1. AEs occurring after administration 2. All concomitant medications administered after administration. 3. Evaluate subject responses and available outcomes against individual stopping rule criteria.

[0363] Following completion of post-dose assessments, subjects will be allowed to leave the clinic.

[0364] Study period and visit: Visit 9 (Day 42 [± 3 days]) Subjects will return to the clinic on Day 49 (± 3 days), at which time the following procedures will be performed: 1. Collect Blood Samples for Plasma Anti-LIGHT Monoclonal Antibody Concentration and PK Analysis 2. Assess and record AEs and concomitant medications 3. Check your journal entries

[0365] In addition, any ongoing AEs since the previous visit will be assessed and any changes in their status will be recorded.

[0366] Study period and visit: Visit 10 (Day 56 [± 3 days]) Subjects will return to the clinic on Day 56 (± 3 days), at which time the following procedures will be performed: 1. Conduct a complete physical examination, including measuring weight 2. Collect vital signs, including systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature. 3. Perform a 12-lead ECG 4. Collect blood samples for laboratory testing 5. Collect Blood Samples for Plasma Anti-LIGHT Monoclonal Antibody Concentration, PK, and ADA Analysis 6. Collect blood samples for exploratory analyses defined in Table 13 7. Collect Feces for Fecal Calprotectin Analysis 8. Collect a urine sample for urinalysis 9. Collect a urine specimen for urinary β-hCG testing (women of childbearing potential only) 10. Conduct CDAI 11. Review your journal entries 12. Complete the IBD-Q questionnaire 13.Perform endoscopy and biopsy 14. Assess and record AEs and concomitant medications 15. Evaluate subject responses and available outcomes against individual stopping rule criteria.

[0367] In addition, any ongoing AEs since the previous visit will be assessed and any changes in their status will be recorded.

[0368] Note that stool samples can be obtained at any time during the visit.

[0369] Early termination If a subject is withdrawn from the study for any reason, every effort will be made to ensure that all procedures and evaluations on Day 56 (Visit 10) are performed.

[0370] Study Period and Visits: Safety Follow-up, Visit 11 (Day 84 [± 3 days]) Subjects will return to the clinic at Visit 10 or 28 days (± 3 days) after the early termination visit for a safety follow-up visit, as appropriate. Subjects will have blood collected for plasma anti-LIGHT monoclonal antibody concentrations, PK, and ADA analysis. Any concomitant medications and new-emerging AEs since the last visit will be recorded. In addition, any ongoing AEs since the previous visit will be evaluated and any changes in their status will be recorded.

[0371] Test period The total study duration will be approximately 26 weeks (including up to 14 weeks of screening [including up to 12 weeks of washout if necessary], 56 days of open-label treatment, and a follow-up visit approximately 28 days after the last dose of study drug).

[0372] The planned sequence and maximum duration of the study periods are as follows: 1. Screening period: Approximately 14 weeks 2. Drug holiday, if applicable: up to 12 weeks from the subject's last dose of biologic treatment 3. Open-label treatment period: 56 days (doses administered q14 days starting on day 0) 4. Follow-up: 28 days after the last dose of study drug. The maximum study duration for each subject is approximately 26 weeks.

[0373] The maximum treatment duration for each subject will be approximately 56 days, with SQ injections beginning on day 0 and continuing every 14 (± 3) days until day 42.

[0374] Note: Extension of the screening window to accommodate clinical test repeat windows (excluding endoscopy with biopsy) is permitted but cannot exceed a total screening period of 16 weeks.

[0375] Safety assessment Safety assessments will include monitoring for AEs, clinical laboratory tests, vital sign measurements, physical examination (including weight measurement), and 12-lead ECG parameters. Demographic information and medical and treatment history will be obtained at the screening visit.

[0376] All safety assessments will be recorded in the appropriate eCRF.

[0377] Demographics / Medical History Demographic information, complete medical history (including surgical history), and medication history will be collected at the screening visit by appropriate site staff designated by the PI and will be reviewed and verified by a licensed physician, physician assistant, or nurse. Medical history will be reviewed and recorded and will include the following: Date of birth ●Gender Race and ethnicity Recent use of medications (30 days prior to enrolment for relevant indications other than Crohn's disease, and lifetime recall of all medications relevant for Crohn's disease) Past and ongoing treatment of CD (recalling the past year) CD-related surgical procedures and hospitalizations - Medical history of respiratory, circulatory, renal, digestive, hepatic, endocrine, hematological, neurological, psychiatric, and other diseases, and surgical treatment history

[0378] Vital signs Vital signs, including systolic and diastolic blood pressure, pulse, and respiratory rate, will be collected as indicated in the Assessment Schedule (see Table 13). Vital signs will be within the ranges listed below during screening (Visit 1) and prior to enrollment at Visit 2: ●Blood pressure: 80 / 50~140 / 90mm / Hg Respiratory rate: 8-20 breaths per minute Pulse rate: 50-120 beats per minute ●Body temperature: 97.8°F~99.1°F (36.5°C~37.3°C) / Average 98.6°F (37°C)

[0379] Vital signs will be taken pre-dose and post-dose at Visits 2, 4, 6, and 8. Pre-dose vital signs will be taken within 60 minutes prior to dosing. Post-dose vital signs will be taken at least 60 minutes after dosing and prior to discharge. Additional blood pressure and pulse rate measurements will optionally be taken as determined by the Investigator to ensure adequate monitoring of subject safety and accurate recording of vital signs. Any changes from baseline that are deemed clinically significant by the Investigator will be recorded as an AE.

[0380] The same blood pressure measurement method (auscultatory or oscillometric) will be used and documented throughout the study for all subjects. In addition, conditions for vital sign measurements will be controlled and as consistent as possible to minimize variability in readings. Measurements may be collected at a comfortable room temperature with little or no background noise, using the same (appropriately sized) cuff placed in the same position on the same arm. The cuff will have a bladder length that is 80% and a width that is at least 40% of the arm circumference (length to width ratio of 2:1).

[0381] Subjects are asked to remove all clothing covering the cuff placement site. Subjects cannot have exercised or consumed caffeine, alcohol, or nicotine within 30 minutes of collection. Subjects may sit comfortably with uncrossed legs, feet flat on the floor, back and arms supported, with the center of the cuff on the upper arm at right atrium height (midpoint of the sternum). Subjects are instructed to relax as much as possible for at least 5 minutes prior to collection. Subjects may remain motionless during this time and throughout the measurement.

[0382] The bladder is deflated (calibrated for manual by oscillometry or auscultation) at a rate of 2-3 mmHg / s (first and last audible sounds recorded as systolic and diastolic pressures) after at least 5 min of rest.

[0383] Use of automated devices to measure pulse is considered acceptable, but if done manually, pulse may be measured at the brachial / radial arteries for at least 30 seconds. Blood pressure and pulse may be obtained a short time before blood is drawn, when the timing of these measurements coincides with the blood draw.

[0384] Physical Examination A complete physical examination, including measurement of weight, will be performed by a licensed physician, physician assistant, or nurse practitioner at the screening visit and at Visits 2 (Day 0), 6 (Day 28), and 10 (Day 56). A brief physical examination, including measurement of weight, will be performed at Visit 4 (Day 14) and Visit 8 (Day 42) (see Table 13).

[0385] A complete physical examination includes a review of the following body systems: ● Overall appearance ●Skin Head, eyes, ears, nose, and throat ●Spine / cervical / thyroid Musculoskeletal ●Respiratory system Cardiovascular Nerves ● Abdomen (including liver and kidneys)

[0386] Any abnormalities or changes in intensity from baseline noted during review of body systems will be documented in the medical record and may be reported in the appropriate eCRF. Any new clinically significant abnormal findings reported after baseline testing should be considered an AE and recorded in the appropriate AE eCRF. In addition, resolution of any abnormal finding during the study, if clinically significant, will be recorded in the medical record and eCRF.

[0387] A brief physical examination will include, at a minimum, a review of the appearance, skin, head, eyes, ears, nose, and throat, abdomen, joints, and perianal area, with other systems reviewed as medically indicated. Weight measurements will also be collected.

[0388] Subjects were asked to remove their shoes before their weight (kg) was measured.

[0389] electro-cardiogram A standard 12-lead ECG will be performed by appropriate site staff designated by the PI as indicated in the Evaluation Schedule (see Table 13), and the results will be reviewed and verified by the PI or a qualified licensed physician designated by the PI.

[0390] A 12-lead ECG will be taken after the subject has been supine for approximately 5 minutes. All ECG recordings will be identified with the subject number, subject initials, date, and time of recording and will be included in the subject's study file.

[0391] Subjects will be asked to remove all clothing covering the lead placement site. Subjects cannot have exercised or consumed caffeine, alcohol, or nicotine within 30 minutes prior to collection.

[0392] In some cases, it may be appropriate to repeat an abnormal ECG to rule out improper lead placement as a contributing factor to the ECG abnormality. To achieve accurate ECG recordings, the leads are placed in the same position at each time point. One complete recording, including a 10-second rhythm strip, may be taken at each time point. This is immediately evaluated as a valid recording, and if not valid, it may be repeated. All collected ECGs are entered into the eCRF.

[0393] All ECGs will be performed using equipment supplied by the site. ECG recordings will be collected and copies will be provided to the Sponsor.

[0394] The following parameters will be recorded in the appropriate eCRF: heart rate, PR, respiratory rate (RR), QRS, and QT interval, as well as the corrected QT interval using both the Bazett (QTcB) and Fridericia (QTcF) formulas. The Investigator's assessment of the ECG tracing as normal or abnormal will be required to be documented, and if abnormal, their determination of whether the abnormality is clinically significant will be documented for the tracing and recorded in the eCRF.

[0395] Any ECG values ​​that, in the opinion of the investigator, indicate clinically relevant or pathological changes during or after completion of study drug will be discussed with the medical monitor and reported and tracked as AEs.

[0396] Lab Test Specimens for the following laboratory tests will be collected at the times specified in the Assessment Schedule (see Table 13). [Table 14-1] [Table 14-2]

[0397] Blood collection volume The sample blood volumes taken from each subject are shown in Table 15. [Table 15]

[0398] Tuberculosis (TB) Testing All subjects will be screened for tuberculosis at screening using the QuantiFERON-TB Gold (QFT) blood test or the tuberculin skin test (PPD skin test). If a subject's PPD tine skin test is ≥ 5 mm, a chest x-ray will be performed to rule out active or latent TB infection. Subjects will be excluded from the study if they have active or latent TB as documented by any of the following: - Positive QFT test result or positive PPD skin test reaction ≥ 10mm. • Chest x-ray unable to exclude active or latent pulmonary TB.

[0399] Decoy receptor 3 genotyping Two milliliters of saliva for genotyping are collected in a designated collection vehicle according to the manufacturer's instructions.

[0400] Deoxyribonucleic acid (DNA) is isolated from a saliva sample from each test subject and then evaluated for genetic mutations in TNFRSF6B, which encodes the protein DcR3, or mutations in at least one DcR3 network gene. All genotyping is performed in a CLIA-certified laboratory as specified in the laboratory manual and guidance. The remaining DNA sample is stored for future biomarker testing.

[0401] LIGHT, cytokine, RNA sequencing, and flow cytometry exploratory analyses Blood samples will be collected for exploratory analyses, including but not limited to LIGHT biomarkers, cytokines (e.g., IL-1 beta, IL-6, IL-8, TNF-alpha, and other exploratory cytokines), ribonucleic acid (RNA) sequencing, and flow cytometry of peripheral blood leukocytes at the visits identified in Table 13.

[0402] Prebiotics Testing An adequate washout period is necessary to avoid the possibility that effects related to treatment with the anti-LIGHT monoclonal antibody may be confounded by prior use of other biologics. To allow for a shorter washout period, available commercially available tests are utilized to identify serum concentrations of biologics. With the exception of Cimzia, blood tests are performed in subjects undergoing an 8-week washout period after the last dose of biologic treatment to ensure that serum levels of any prior biologic treatment are below detection levels. If serum concentrations of biologic treatment are undetectable (i.e., below quantification levels) according to the respective CLIA-validated commercially available test, the subject is considered to have completed the washout period and is permitted to proceed to Visit 2. If biologic treatment is detectable, the subject completes the full 12-week washout period before proceeding to Visit 2. A 12-week washout period is required in subjects receiving the biologic certolizumab pegol (Cimzia).

[0403] Specimen Handling Requirements Transmission of infectious agents can occur through contact with contaminated needles, blood or blood products, and / or laboratory specimens. Therefore, appropriate blood, body fluid, and specimen precautions may be used by all laboratory personnel involved in specimen collection and handling in both the clinic and laboratory. Refer to the latest recommendations of the appropriate authorities.

[0404] In addition to proper handling of subject samples, there are specific regulations regarding the shipping of biological samples. Procedures and regulations regarding the packaging and shipping of infectious samples are outlined in the study laboratory manual. The investigator is responsible for ensuring that all study samples to be transported to another location are properly packaged and shipped in accordance with applicable regulations.

[0405] Evaluation of laboratory values Normal ranges of values ​​for clinical safety laboratory evaluations will be provided by the responsible clinical laboratory and submitted to the sponsor prior to the initiation of the study. These will be considered as reference ranges against which clinical decisions will be made.

[0406] There are some exceptions when laboratory values ​​are outside the reference range, which are not necessarily clinically relevant. Investigators are required to evaluate out-of-range values ​​and record their assessment of their clinical relevance in the appropriate eCRF.

[0407] Any laboratory value that, in the opinion of the investigator, is clinically relevant or indicates a pathological change during or after the end of treatment, will be reported and tracked as an AE in discussion with the medical monitor.

[0408] Example 6.6 - Adverse Events Adverse event collection The Investigator is responsible for detecting and documenting events that meet the criteria and definitions of AEs or SAEs described below. At each visit, subjects will be given a period to spontaneously report any problems since their last visit or evaluation. At each visit, the Investigator will: ● "How are you feeling?" ● "Have you had any problems since your last visit?" ● Monitor, question, and / or evaluate any AEs using non-leading questions such as, "Have you taken any new medications since your last visit?".

[0409] Any clinically relevant observation made during each visit will be considered an AE.

[0410] Definition of adverse events, observation period, and recording of adverse events An AE is defined as any untoward medical occurrence in a clinical trial subject administered a medicinal product, not necessarily having a causal relationship to the product. Thus, an AE can be any untoward, unintended sign (including new, clinically significant abnormal laboratory findings), symptom, or disease that is temporally linked to the product, whether or not it is product-related.

[0411] All AEs will be collected from the time informed consent is signed through the final safety follow-up visit. This includes events occurring during the screening phase of the study whether or not the investigational product is administered. When possible, record a diagnosis rather than a list of symptoms. If no diagnosis is given, list each symptom individually. All AEs will be captured in the appropriate AE eCRF and source documentation. In addition to AEs, off-label unexpected benefits will also be captured in the source documentation and AE eCRF.

[0412] All AEs will be followed until closure (i.e., the subject's health status has returned to their baseline state or all variables have returned to normal), regardless of whether the subject is still in the study. Closure indicates that either outcome is achieved, stabilization is achieved (the Investigator does not expect any further improvement or worsening of the event), or the event is explained in another way. Medical tests and investigations will be performed, where appropriate, to allow for documenting the resolution of the event.

[0413] Severity of the adverse event The severity of the AE is recorded during the course of the event, including the start and stop dates of each change in severity. Events that change in severity are captured as new events. Worsening of a pretreatment event after initiation of study drug is recorded as a new AE. For example, if a subject experiences mild intermittent headache before receiving study drug and the headache intensity increases to moderate after the first dose of study drug, a new AE of moderate intermittent headache is recorded in the source document and eCRF.

[0414] Medical assessment of the clinical severity of AEs is determined using definitions outlined in the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (published May 28, 2009 by the US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, version 4.0.3 on June 14, 2010). Grade 1 is defined as mild, asymptomatic or mild symptoms, or clinical or diagnostic observation only, or no intervention indicated. Grade 2 is defined as moderate, or minimal, local or noninvasive intervention indicated, or limiting age-appropriate instrumental activities of daily living (ADLs). Grade 3 is defined as severe or medically significant but not immediately life-threatening, or hospitalization or prolonged hospital stay indicated, or disabling, or limiting self-care ADLs. Grade 4 is defined as life-threatening consequences, or urgent intervention indicated. Grade 5 is death related to an AE.

[0415] Severity is a classification of intensity, while SAEs are AEs that meet the serious criteria. The above referenced CTCAE documents may be consulted for a complete explanation of CTCAE terminology and measures and self-management ADLs.

[0416] Related Categories The Investigator will assess each AE for a relationship to the investigational drug. The Investigator will determine whether, in their medical judgment, there is a reasonable possibility that the event could have been caused by the investigational drug. If there is no good reason to suggest a relationship, the AE will be classified as "unrelated." Otherwise, the AE will be classified according to the following guidelines. The causality assessment will be documented in the source document and eCRF (Table 16). [Table 16]

[0417] Outcome at last observation The outcome of the AE at last observation will be classified as resolved / resolved, resolved / resolved with sequelae, resolving / resolving, not resolved / not resolved, fatal, or unknown.

[0418] Reporting of serious adverse events Initial and follow-up SAE reports may be completed by the investigator and sent to the sponsor and CRO within 24 hours of first learning of the SAE. The investigator completes, signs, and dates the appropriate SAE form and verifies the accuracy of the information against the corresponding source documentation. The source documentation is not sent with the SAE form. This SAE information (form) is sent to the CRO pharmacovigilance department and copied by email or fax to the sponsor's medical monitor.

[0419] Definition of serious adverse events An SAE is any untoward medical occurrence, at any dose, whether or not considered related to the investigational drug: that results in death, is life-threatening, requires hospitalization or extension of existing hospitalization, results in persistent or significant impairment / incapacity, is a congenital anomaly, or is a significant medical event.

[0420] Please note that the term "life-threatening" in the definition of "serious" refers to an event in which the subject was at risk of death at the time of the event, not an event that could have hypothetically caused death if it had been more severe.

[0421] Please note that patient hospitalization is defined as a 24-hour or overnight stay in a hospital. Elective hospitalization to treat a condition present prior to exposure to the study drug, or hospitalization for diagnostic evaluation of an AE, will not qualify the condition or event as an SAE. Additionally, an overnight stay in a hospital due solely to transportation, organizational, or accommodation issues and without a medical context need not be considered an SAE.

[0422] Note that a congenital anomaly in an infant born to a mother exposed to an investigational drug during pregnancy is an SAE, however, a newly diagnosed pregnancy in a subject who has been receiving an investigational drug is not considered an SAE unless the pregnancy is suspected to have resulted from an interaction of the investigational drug with a contraceptive method.

[0423] It is noted that medical and scientific judgment may be used in determining whether it is appropriate to consider other serious circumstances, such as significant medical events that may not be immediately life-threatening or result in death or hospitalization, but may endanger the subject or require intervention to prevent one of the other outcomes listed in the definition above. Examples of such events are allergic bronchospasm, blood disorders or convulsions that do not result in hospitalization, or intensive care in the emergency room or at home in the development of drug addiction or abuse.

[0424] Time frame for collecting serious adverse events All SAEs, regardless of study relatedness, will be collected from the time the subject signs the informed consent until the subject's last visit (clinic or telephone contact). The investigator or designee will promptly report all SAEs to the CRO and sponsor's medical monitor within 24 hours of first becoming aware of the event.

[0425] Any SAEs detected by the investigator at any interval after completion of the study, regardless of association with the IP, will be reported to the CRO and the Sponsor's medical monitor within 24 hours of first knowledge of the event.

[0426] Date of onset and resolution of serious adverse events The onset date of an SAE is defined as the date the event meets the severe criteria. The resolution date is the date the event no longer meets the severe criteria, the symptoms resolve, or the event is considered chronic. In the case of hospitalization, the dates of admission and discharge are considered the onset and resolution dates of the SAE, respectively.

[0427] Any sign or symptom experienced by the subject after signing the informed consent form or until the date of onset of the SAE or after the date of resolution of the SAE will be recorded as an AE.

[0428] Fatal outcome The "fatal" outcome may be selected only when an AE results in death. If more than one AE may be associated with the subject's death, a "fatal" outcome will be indicated for each such AE.

[0429] Any AE that resulted in the death of a subject was required to have "fatal" checked as the outcome, and the date of death was recorded as the date of resolution. Adverse events resulting in death may be reported as an SAE within 24 hours if not already reported as such.

[0430] For other AEs that were ongoing at the time of death and did not contribute to the subject's death, the outcome will be considered "not resolved" and a resolution date will not be recorded.

[0431] Adverse Events and Adverse Drug Reactions of Special Interest None of the studies to date have identified any events that could be considered adverse events of particular interest. Adverse drug reactions observed in anti-LIGHT monoclonal antibody preclinical studies include injection site reactions.

[0432] Adverse drug reactions with other biologics include potential increased infections (including opportunistic infections such as tuberculosis), hypersensitivity reactions (including anaphylaxis), immunogenicity, malignancies, immune disorders, or exacerbations of CD.

[0433] pregnancy All women of childbearing potential participating in this study will be counseled about the need to practice adequate contraception and the importance of avoiding pregnancy while participating in the study. Study participants will be instructed to contact the investigator or study staff immediately if pregnancy occurs or is suspected.

[0434] A pregnancy test will also be performed on all women of childbearing potential prior to administration of the study drug. Women who are found to be pregnant at the screening visit will be excluded from the study and will be considered a screening failure.

[0435] The Investigator will report the pregnancy of any female (study participant or female partner of a male study participant) who becomes pregnant during study drug treatment or within 7 days of discontinuing study drug. Pregnancy will be reported to the CRO within 24 hours of becoming aware. The Investigator will contact the designated individual to receive SAE notification and record the pregnancy related information on the designated form provided by the Sponsor or designee.

[0436] An Early Termination Visit evaluation will occur as soon as possible after learning of the pregnancy. The Investigator is also responsible for following the pregnancy until delivery or termination. These findings will be reported on the In Utero Exposure Form / other designated form and forwarded to a designated individual. An event will meet the criteria for an SAE only if it results in spontaneous abortion or congenital anomaly.

[0437] Example 6.7 - Abuse, Misuse, Overdose, and Medication Errors Abuse, misuse, overdose, or medication error involving an investigational medicinal product will be reported to the sponsor using the SAE reporting procedures, whether or not it results in an AE or SAE, as defined below. The 24-hour reporting period from the time it is first recognized does not apply to an abuse, misuse, overdose, or medication error event if the abuse, misuse, overdose, or medication error event does not result in an SAE. [Table 17-1] [Table 17-2]

[0438] Example 6.8 - Anti-LIGHT Monoclonal Antibody Concentrations, Pharmacokinetics, and Anti-Drug Antibody Assessment Pharmacokinetics will be calculated from plasma concentrations of anti-LIGHT monoclonal antibody.

[0439] Blood sample collection and analysis Blood samples will be collected within 60 minutes prior to administration of anti-LIGHT monoclonal antibody on Days 0, 14, 28, and 42 (Visits 2, 4, 6, and 8, respectively) and at any time on Days 7, 21, 35, 49, 56, and 84 (Visits 3, 5, 7, 9, 10, and 11) and processed to plasma. PK sample times will be recorded on the electronic CRF. A total of 1.0 mL of plasma (0.5 mL for PK and ADA samples) will be collected from each subject to measure plasma concentrations of anti-LIGHT monoclonal antibody or ADA samples. Pharmacokinetic and ADA samples will be processed according to methods and instructions described in the laboratory manual and guidance.

[0440] Pharmacokinetic and ADA plasma sample analysis will be performed using a validated enzyme-linked immunosorbent assay (ELISA) by a designated laboratory according to its SOPs.

[0441] Example 6.9 - Efficacy Assessment Crohn's Disease Activity Index The CDAI is completed by a licensed physician, physician assistant, or nurse practitioner at the times indicated on the assessment schedule (see Table 13). Facility personnel administering the CDAI calculate ideal weight according to ideal weight for men = (height in meters) 2 × 22.1 and ideal weight for women = (height in meters) 2 × 20.8 to derive individual and total scores.

[0442] Information regarding frequency of abdominal pain and loose watery stools will be obtained from subject diary information. Whenever possible, the same individual will compile the CDAI for a given subject throughout the study.

[0443] The CDAI was developed by the National Cooperative Crohn's Disease Study group and published in 1976 by Best et al. (1976) (Best et al., Development of a Crohn's disease activity index, National Cooperative Crohn's Disease Study, Gastroenterol., 1976:70;439-44) to determine which variables best predicted disease activity. A total of eight items were identified (abdominal pain, number of liquid stools, general health, extraintestinal complications, use of antidiarrheal medications, abdominal masses, hematocrit, and weight). Each item is scored based on an individual parameter criterion. Total CDAI scores can range from 0 to approximately 600, with higher scores indicating more active disease. The CDAI is the most frequently used efficacy scale in intervention trials in CD (Sostegni et al., Review: Crohn's disease: monitoring disease activity, Aliment Pharmacolo Ther., 2003:17(Suppl.2)11-17).

[0444] Endoscopy with biology and histology All subjects enrolled in the study will undergo endoscopy with biopsy at screening and again on Day 56 (Visit 10) or at early termination. Screening endoscopy will optionally be performed either as a standalone endoscopy for purposes of this protocol or as a clinically indicated endoscopy, provided that consent procedures for this clinical trial are completed prior to the endoscopy.

[0445] Endoscopic evaluation uses the SES-CD. The SES-CD is a simple, easy-to-use endoscopic scoring system developed specifically for CD. It evaluates four variables: ulcer size, percentage of ulcerated surface, percentage of surface affected, and presence of stenosis on a scale of 0 to 3 across four categories per variable (Daperno M, D'Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastroinest Endosc. 2004 Oct;60(4):505-12). Biopsies taken at screening are evaluated for histological confirmation of disease. Each subject has screening and visit 10 / ET biopsy samples retained for evaluation of exploratory parameters (which may include, but are not limited to, DcR3, LIGHT, HVEM, and LTβR), which may optionally occur after study completion.

[0446] Patient-reported assessment of health status, abdominal pain, and stool frequency All subjects enrolled in the study report through a diary (electronic or hard copy) their daily assessment of well-being, abdominal pain, and stool frequency, including loose and / or watery stools. Abdominal pain is rated on a scale of 0 to 3, with higher values ​​indicating greater pain severity. Stool frequency, including the number of loose and / or watery stools per day, corresponding to a score of 6 or 7 on the Bristol Fecal Scale, is recorded.

[0447] Loose stools are described as fluffy, ragged edges, and slimy stools. Watery stools are described as watery and devoid of solid matter (O'Donnell et al., Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate, Br. Med. J. 1990;300:439-40).

[0448] Quality of Life Assessment - Inflammatory Bowel Disease Questionnaire The IBD-Q is a 32-item questionnaire validated to measure quality of life in Crohn's disease. It assesses a range of bowel function, emotional state, general symptoms, and social functioning (Guyatt et al., A new measure of health status for clinical trials in inflammatory bowel disease, Gastroenterol., 1989:96;804-10). The IBD-Q is completed by all subjects at screening (Visit 1), pre-dose (Visit 2), and at the end or early termination of the open-label treatment period (Visit 10 / ET) (see Table 13).

[0449] Example 6.10 - Statistics Pharmacokinetic, efficacy, and quality of life data will be summarized using conventional descriptive statistics. Continuous variables will be summarized using N, mean, standard deviation, and range. Categorical variables will be summarized using frequencies and percentages.

[0450] No formal inferential analysis is planned.

[0451] The safety population includes all subjects who enroll in the study and receive any amount of investigational drug. The pharmacokinetic population includes all subjects who receive their assigned dose of anti-LIGHT monoclonal antibody and have anti-LIGHT monoclonal antibody plasma concentration data available. The efficacy population includes all subjects with baseline and at least one post-baseline efficacy score.

[0452] Efficacy analyses will focus on the efficacy population. Endpoint (e.g., CDAI, SES-CD, frequency of abdominal pain and loose / watery stools, and IBD-Q) outcomes will be summarized by visit for each cohort, both as raw scores and change from baseline. CDAI individual and total scores will be derived programmatically using data recorded from patient diaries, responses to CDAI questions, clinical tests, and physical examination results.

[0453] Quantitative endoscopy and biopsy results will also be summarized for both baseline and end-of-study visits.

[0454] Analysis of safety data will focus on the safety population.

[0455] Safety variables included treatment-emergent AEs (TEAEs), clinical laboratory results, vital sign measurements, ECG results, and physical examination findings.

[0456] Adverse events will be coded using the Medical Dictionary for Regulatory Affairs (MedDRA) version 20. TEAEs are defined as any AE with first onset or worsening in severity after the first dose of IP. TEAEs will be categorized by system organ class (SOC) and preferred term and summarized by the number of subjects reporting each event in each cohort and overall. Similar summaries will be generated for SAEs, AEs leading to discontinuation, and AEs at least possibly related to the study drug. The intensity of the AE and its relationship to the study drug will also be summarized with each SOC and preferred term.

[0457] For laboratory tests, a narrative summary of actual (absolute) values ​​and changes from baseline will be provided by cohort at each study visit. The number of subjects with laboratory values ​​below, within, or above normal range at each study visit will be tabulated for each laboratory test by cohort (shift table).

[0458] Vital signs (systolic and diastolic blood pressure, pulse, and respiratory rate) and ECG results will be summarized by visit and cohort using appropriate descriptive statistics. The number and percentage of subjects with abnormal ECG findings will be summarized by cohort at each study visit.

[0459] Data from this open-label study will be monitored on an ongoing basis.

[0460] This is the first use of an anti-LIGHT monoclonal antibody in the intended population of patients with CD resistant to anti-TNFα monoclonal antibodies. The sample size of the study was based on feasibility.

[0461] Example 7 Specific results of tests conducted according to the methods described in Example 6 herein are presented in Example 7.

[0462] Serum samples were obtained at three time points from two patients who completed anti-LIGHT antibody treatment in the study described in Example 6. Healthy adult donors (n=30 controls) had a mean pre-treatment free LIGHT level of 202 pg / mL. The first patient had an elevated pre-treatment plasma free LIGHT level of 455 pg / mL. After treatment with anti-LIGHT antibody (having VH of SEQ ID NO:8 and VL of SEQ ID NO:9) subcutaneously (SQ) every two weeks (q), the subject's plasma free LIGHT levels were found to be within the normal range, with free LIGHT levels of 15 and 24 pg / mL on days 28 and 56, respectively. The second patient had an elevated pre-treatment plasma free LIGHT level of 193 pg / mL. After treatment with anti-LIGHT antibody subcutaneously (SQ) every 2 weeks (q), subjects' plasma free LIGHT levels were found to be within the normal range, with free LIGHT levels of 42 and 29 pg / mL on days 28 and 56, respectively. These data indicate that even relatively low doses of anti-LIGHT antibody can reduce plasma free LIGHT levels in an outpatient setting, and that free LIGHT levels remain reduced.

[0463] Furthermore, the first patient's clinical improvement was shown to correlate with this decrease. The first patient's score for the Simple Endoscopic Score for Crohn's Disease (SES-CD) decreased with treatment. SES-CD score: 0-2 means remission, 3-6 means mild, 7-15 means moderate, and >15 means severe. The first patient's SES-CD score was 11 at screening and 4 at day 56.

[0464] Example 8 Using the free LIGHT assay described herein, LIGHT testing was performed on samples from ARDS patients and compared with healthy donor LIGHT levels.Preliminary data shows elevated LIGHT levels in the ARDS population compared with healthy donor levels.A box plot generated from this data is shown in Figure 11.

[0465] Table 18 below provides the sequences referred to in this application. [Table 18-1] [Table 18-2] [Table 18-3] [Table 18-4] [Table 18-5]

Claims

[Claim 1] The invention described in the specification.